

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number  
**WO 00/73469 A2**

- (51) International Patent Classification<sup>7</sup>: **C12N 15/54**, 9/12, 15/11, 5/12, C07K 16/40, A61K 38/00, G01N 33/68
- (74) Agents: **WARBURG, Richard, J.** et al.; Brobeck, Phleger & Harrison LLP, 12390 El Camino Real, San Diego, CA 92130 (US).
- (21) International Application Number: **PCT/US00/14842**
- (22) International Filing Date: **26 May 2000 (26.05.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**60/136,503** **28 May 1999 (28.05.1999)** **US**
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **SUGEN, INC.** [US/US]; 230 East Grand Avenue, South San Francisco, CA 94080 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **PLOWMAN, Gregory, D.** [US/US]; 4 Honeysuckle Lane, San Carlos, CA 94070 (US). **MARTINEZ, Ricardo** [US/US]; 984 Cartier Lane, Foster City, CA 94404 (US). **WHYTE, David** [US/US]; 2623 Barclay Way, Belmont, CA 94002 (US). **SUDERSANAM, Sucha** [US/US]; 20 Corte Patencio, Greenbrae, CA 94904 (US).
- Published:**  
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 00/73469 A2**

(54) Title: **PROTEIN KINASES**

(57) Abstract: The present invention relates to novel kinase polypeptides, nucleotide sequences encoding the novel kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions.

DESCRIPTION  
PROTEIN KINASES

FIELD OF THE INVENTION

5           The present invention relates to novel kinase polypeptides, nucleotide sequences encoding the novel kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions.

BACKGROUND OF THE INVENTION

10           The following description of the background of the invention is provided to aid in understanding the invention, but is not admitted to be or to describe prior art to the invention.

          Cellular signal transduction is a fundamental mechanism whereby external stimuli that regulate diverse cellular processes are relayed to the interior of cells. One of the key  
15           biochemical mechanisms of signal transduction involves the reversible phosphorylation of proteins, which enables regulation of the activity of mature proteins by altering their structure and function.

          Protein phosphorylation plays a pivotal role in biological signal transduction. Among the biological functions controlled by protein phosphorylation are the following:  
20           cell division; differentiation and death (apoptosis); cell motility and cytoskeletal structure; control of DNA replication, transcription, splicing and translation; protein translocation events from the endoplasmic reticulum and Golgi apparatus to the membrane and extracellular space; protein nuclear import and export; regulation of metabolic reactions, etc. Abnormal protein phosphorylation is widely recognized to be causally linked to the  
25           etiology of many diseases including cancer as well as immunologic, neuronal and metabolic disorders.

          The most common phospho-acceptor amino acid residues are serine, threonine and tyrosine. Phosphorylation in histidine has also been observed in bacteria. The presence of a phosphate moiety modulates protein function in multiple ways. A common mechanism  
30           includes changes in the catalytic properties ( $V_{\max}$  and  $K_m$ ) of an enzyme leading to its activation or inactivation. A second widely recognized mechanism involves promoting protein-protein interactions. An example of this is the tyrosine autophosphorylation of the

ligand-activated EGF receptor tyrosine kinase. This event triggers the high-affinity binding to the phosphotyrosine residue on the receptor's C-terminal intracellular domain to the SH2 motif of the adaptor molecule Grb2. Grb2 in turn binds through its SH3 motif to a second adaptor molecule, such as SHC. The formation of this ternary complex  
5 activates the signaling events that are responsible for the biological effects of EGF. Serine and threonine phosphorylation events have also been recently recognized to exert their biological function through protein-protein interaction events mediated by the high-affinity binding of phosphoserine and phosphothreonine to WW motifs present in a large variety of proteins (Lu, P.J. *et al.* (1999) *Science* 283:1325-1328). A third important  
10 outcome of protein phosphorylation is changes in the subcellular localization of the substrate. As an example, nuclear import and export events in a large diversity of proteins are regulated by protein phosphorylation (Drier E.A. *et al.* (1999) *Genes Dev* 13: 556-568).

Protein kinases are one of the largest families of eukaryotic proteins with several  
15 hundred known members. These proteins share a 250-300 amino acid domain that can be subdivided into 12 distinct subdomains that comprise the common catalytic core structure. These conserved protein motifs have recently been exploited using PCR-based and bioinformatic strategies leading to a significant expansion of the known kinases. Multiple  
20 alignment of the sequences in the catalytic domain of protein kinases and subsequent parsimony analysis permits their segregation into a dendrogram reflecting the relatedness of their catalytic domains (Fig. 1). In this manner, related kinases are clustered into distinct branches or subfamilies including: tyrosine kinases, cyclic-nucleotide-dependent kinases, calcium/calmodulin kinases, cyclin-dependent kinases and MAP-kinases, serine-threonine kinase receptors, and several other less defined subfamilies.

25 We have recently completed a systematic analysis of the protein kinases present in *C. elegans*, the multicellular organism whose entire DNA sequence has been determined. We identified 473 unique kinase profiles including 398 full-length conventional kinases, and 20 additional proteins that may function as atypical protein kinases. (Plowman G.D. *et al.* (1999), *Proc. Natl. Acad. Sci.* 96:13603-13610).

30 Using parsimony analysis, the protein kinases may be divided into 4 major groups: AGC, CAMK, CMGC and tyrosine kinases. In addition, there are a number of minor yet distinct families, including the STE and casein kinase 1, families related to worm- or

fungus-specific kinases, and a family designated "other" to represent several smaller families. In addition, we designate an "atypical" family to represent protein kinases whose catalytic domain has little or no primary sequence homology to conventional kinases, including the A6 kinases and PI3 kinases.

5           The AGC kinases are basic amino acid-directed enzymes that phosphorylate residues found proximal to Arg and Lys. Examples of this group are the cyclic nucleotide-dependent kinases, G protein kinases, NDR or DBF2 and the ribosomal S6 kinases.

          The CAMK group kinases are also basic amino acid-directed kinases. They include the Ca<sup>2+</sup>/calmodulin-regulated and AMP-dependent protein kinases, myosin light chain  
10          kinases, checkpoint 2 kinases (CHK2) and EMK-related protein kinases. The EMK family of STK are involved in the control of cell polarity, microtubule stability and cancer. One member of the EMK family, C-TAK1 has been reported to control entry into mitosis by activating Cdc25C which in turn dephosphorylates Cdc2.

          CMGC group kinases are "proline-directed" enzymes phosphorylating residues  
15          that exist in a proline-rich context. They include the cyclin-dependent kinases (CDKs), mitogen-activated kinases (MAPKs), GSK3s and CLKs. Most CMGC kinases have larger-than-average kinase domains owing to the presence of insertions within subdomains X and XI.

          The tyrosine kinase group encompass both cytoplasmic (i.e. src) as well as  
20          transmembrane receptor tyrosine kinases (i.e. EGF receptor). These kinases play a pivotal role in the signal transduction processes that mediate cell proliferation, differentiation and apoptosis.

          Group members that define smaller, yet distinct phylogenetic branches of conventional kinases include the elongation factor 2 kinases (EIFKs); homologues of the  
25          yeast sterile family kinases (STE) which refers to 3 classes of kinases which lie sequentially upstream of the MAPKs; mixed lineage kinases (MLKs); Lim-domain containing kinases (LIMKs); Calcium-calmodulin kinase kinases (CAMKK), dual-specific tyrosine kinases (DYRK), integrin receptor associated kinase (IRAK); testis-specific kinases (TSK); UNC-51 related kinases (UNC); several families that are close  
30          homologues to worm (C26C2.1, YQ09, ZC581.9, YFL033c, C24A1.3), Drosophila (SLOB), or yeast (YDOD\_sp, YGR262\_sc) kinases, and others that are "unique" and don't cluster into any obvious family.

### SUMMARY OF THE INVENTION

Through a search of the EST database for homologies to the conserved catalytic kinase domain of protein kinases, hundreds of mammalian members of known and previously unidentified protein kinase families and groups have been identified as part of the present invention. Multiple alignment and parsimony analysis of the catalytic domain reveals that approximately half of these protein kinases cluster into 10 known groups, with the other half perhaps defining novel groups. Classification in this manner has proven highly accurate not only in predicting motifs present in the remaining non-catalytic portion of each protein, but also in their regulation, substrates, and signaling pathways. The present invention includes the partial or complete sequence of new protein kinases, their classification, predicted or deduced protein structure, and a strategy for elucidating their biologic and therapeutic relevance.

Thus, a first aspect of the invention features an isolated, enriched, or purified nucleic acid molecule encoding a kinase polypeptide selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211,

SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216,  
SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221,  
SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226,  
SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231,  
5 SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236,  
SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241,  
and SEQ ID NO:242.

By "isolated" in reference to nucleic acid is meant a polymer of nucleotides  
conjugated to each other, including DNA and RNA, that is isolated from a natural source  
10 or that is synthesized. The isolated nucleic acid of the present invention is unique in the  
sense that it is not found in a pure or separated state in nature. Use of the term "isolated"  
indicates that a naturally occurring sequence has been removed from its normal cellular  
(*i.e.*, chromosomal) environment. Thus, the sequence may be in a cell-free solution or  
placed in a different cellular environment. The term does not imply that the sequence is  
15 the only nucleotide chain present, but that it is essentially free (about 90 - 95% pure at  
least) of non-nucleotide material naturally associated with it, and thus is distinguished  
from isolated chromosomes.

By the use of the term "enriched" in reference to nucleic acid is meant that the  
specific DNA or RNA sequence constitutes a significantly higher fraction (2 - 5 fold) of  
20 the total DNA or RNA present in the cells or solution of interest than in normal or  
diseased cells or in the cells from which the sequence was taken. This could be caused by  
a person by preferential reduction in the amount of other DNA or RNA present, or by a  
preferential increase in the amount of the specific DNA or RNA sequence, or by a  
combination of the two. However, it should be noted that enriched does not imply that  
25 there are no other DNA or RNA sequences present, just that the relative amount of the  
sequence of interest has been significantly increased. The term "significant" is used to  
indicate that the level of increase is useful to the person making such an increase, and  
generally means an increase relative to other nucleic acids of about at least 2 fold, more  
preferably at least 5 to 10 fold or even more. The term also does not imply that there is no  
30 DNA or RNA from other sources. The other source DNA may, for example, comprise  
DNA from a yeast or bacterial genome, or a cloning vector such as pUC19. This term  
distinguishes from naturally occurring events, such as viral infection, or tumor type

growths, in which the level of one mRNA may be naturally increased relative to other species of mRNA. That is, the term is meant to cover only those situations in which a person has intervened to elevate the proportion of the desired nucleic acid.

5 It is also advantageous for some purposes that a nucleotide sequence be in purified form. The term "purified" in reference to nucleic acid does not require absolute purity (such as a homogeneous preparation). Instead, it represents an indication that the sequence is relatively more pure than in the natural environment (compared to the natural level this level should be at least 2-5 fold greater, *e.g.*, in terms of mg/mL). Individual clones isolated from a cDNA library may be purified to electrophoretic homogeneity. The  
10 claimed DNA molecules obtained from these clones could be obtained directly from total DNA or from total RNA. The cDNA clones are not naturally occurring, but rather are preferably obtained via manipulation of a partially purified naturally occurring substance (messenger RNA). The construction of a cDNA library from mRNA involves the creation of a synthetic substance (cDNA) and pure individual cDNA clones can be isolated from  
15 the synthetic library by clonal selection of the cells carrying the cDNA library. Thus, the process which includes the construction of a cDNA library from mRNA and isolation of distinct cDNA clones yields an approximately  $10^6$ -fold purification of the native message. Thus, purification of at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated.

20 By a "kinase polypeptide" is meant 10 (preferably 20, more preferably 40, most preferably 75) or more contiguous amino acids set forth in an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133,  
25 SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158,  
30 SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173,

5 SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178,  
SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183,  
SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188,  
SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193,  
10 SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198,  
SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203,  
SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208,  
SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213,  
SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218,  
15 SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223,  
SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228,  
SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233,  
SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238,  
SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or functional  
20 derivatives thereof as described herein. For sequences for which the full-length sequence  
is not given, the remaining sequences can be determined using methods well-known to  
those in the art and are intended to be included in the invention. In certain aspects,  
polypeptides of 100, 200, 300 or more amino acids are preferred. The kinase polypeptide  
can be encoded by a full-length nucleic acid sequence or any portion of the full-length  
25 nucleic acid sequence, so long as a functional activity of the polypeptide is retained. By  
"functional" domain is meant any region of the polypeptide that may play a regulatory or  
catalytic role as predicted from amino acid sequence homology to other proteins or by the  
presence of amino acid sequences that may give rise to specific structural conformations  
(*i.e.*, coiled-coils). For some purposes, polypeptide domains are preferred, including, but  
not limited to, N-terminal, catalytic/kinase and C-terminal.

The amino acid sequence will be substantially similar to a sequence selected from  
the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID  
NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID  
NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID  
30 NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID  
NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID  
NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID

NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID  
NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID  
NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID  
NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID  
5 NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID  
NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID  
NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID  
NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID  
NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID  
10 NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID  
NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID  
NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID  
NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID  
NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID  
15 NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID  
NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID  
NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID  
NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID  
NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or the corresponding  
20 full-length amino acid sequence, or fragments thereof. A sequence that is substantially  
similar to a sequence selected from the group consisting of those set forth in SEQ ID  
NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID  
NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID  
NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID  
25 NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID  
NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID  
NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID  
NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID  
NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID  
30 NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID  
NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID  
NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID

NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242 will have at least 75% identity (preferably 90%, more preferably at least 95% and most preferably 99-100%) to a sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ

ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242 or portions of or the entire corresponding full-length amino acid sequences.

By "identity" is meant a property of sequences that measures their similarity or relationship. Identity is measured by dividing the number of identical residues between two sequences (either full-length or a defined domain) by the total number of residues in the known sequence, or the domain of the known sequence, and multiplying the product by 100. Thus, two copies of exactly the same sequence have 100% identity, but sequences that are less highly conserved, and have replacements and substitutions, have a lower degree of identity. "Gaps" are spaces in an alignment that can result from aligning a novel sequence with a known sequence when the novel sequence has additions or deletions of amino acids in comparison with the known sequence. These gaps do not factor into the assessment of % identity using the above calculation.

Those skilled in the art will recognize that several computer programs are also available for determining sequence identity using standard parameters, for example, Blast (Altschul, *et al.* (1997) *Nucleic Acids Res.* 25:3389-3402), Blast2 (Altschul, *et al.* (1990) *J. Mol. Biol.* 215:403-410), and Smith-Waterman (Smith, *et al.* (1981) *J. Mol. Biol.* 147:195-197).

In preferred embodiments, the invention features isolated, enriched, or purified nucleic acid molecules encoding a kinase polypeptide comprising a nucleotide sequence that: (a) encodes a polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ

ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or the corresponding full-length amino acid sequence, or fragments thereof. A sequence that is substantially similar to a sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID

NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242 will have at least 75% identity (preferably 90%, more preferably at least 95% and most preferably 99-100%) to the sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID

NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242; (b) is the complement of the nucleotide sequence of (a); (c) hybridizes under highly stringent conditions to the nucleotide molecule of (a) and encodes a naturally occurring kinase polypeptide; (d) encodes a kinase polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID

NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or the corresponding full-length amino acid sequence, or fragments thereof.

A sequence that is substantially similar to a sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242 will have at least 75% identity (preferably 90%, more preferably at least 95% and most preferably 99-100%) to the sequence of SEQ ID

NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID  
NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID  
NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID  
NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID  
5 NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID  
NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID  
NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID  
NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID  
NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID  
10 NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID  
NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID  
NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID  
NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID  
NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID  
15 NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID  
NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID  
NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID  
NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID  
NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID  
20 NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID  
NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID  
NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID  
NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID  
NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ  
25 ID NO:242, except that it lacks one or more, but not all, of a domain selected from the  
group consisting of an N-terminal domain, a catalytic domain, a C-terminal domain, a  
coiled-coil structure region, a proline-rich region, a spacer region, an insert, and a C-  
terminal tail; (e) is the complement of the nucleotide sequence of (d); (f) encodes a  
polypeptide having an amino acid sequence selected from the group consisting of those set  
30 forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID  
NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID  
NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID

NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID  
NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID  
NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID  
NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID  
5 NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID  
NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID  
NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID  
NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID  
NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID  
10 NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID  
NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID  
NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID  
NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID  
NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID  
15 NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID  
NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID  
NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID  
NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID  
NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID  
20 NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID  
NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID  
NO:241, and SEQ ID NO:242, or the corresponding full-length amino acid sequence, or  
fragments thereof. (The domain demarcations of the polypeptides of the invention are  
indicated in Table 2 by reference to the kinase domain.) A sequence that is substantially  
25 similar to a sequence selected from the group consisting of those set forth in SEQ ID  
NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID  
NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID  
NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID  
NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID  
30 NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID  
NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID  
NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID

NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242 will have at least 75% identity (preferably 90%, more preferably at least 95% and most preferably 99-100%) to the sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ

ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242; (b) is the complement of the nucleotide sequence of (a); (c) hybridizes under highly stringent conditions to the nucleotide molecule of (a) and encodes a naturally occurring kinase polypeptide; (d) encodes a kinase polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID

NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or the corresponding full-length amino acid sequence, or fragments thereof.

A sequence that is substantially similar to a sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235,

SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242 will have at least 75% identity (preferably 90%, more preferably at least 95% and most preferably 99-100%) to a domain of a polypeptide selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, 5 SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, 10 SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, 15 SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, 20 SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, 25 SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, where the domain is selected from the group consisting of an N-terminal domain, a catalytic domain, 30 a C-terminal domain, a coiled-coil structure region, a proline-rich region, a spacer region, an insert, and a C-terminal tail; (g) is the complement of the nucleotide sequence of (f); (h) encodes a polypeptide having an amino acid sequence selected from the group consisting

of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or the corresponding full-length amino acid sequence, or fragments thereof. A sequence that is substantially similar to a sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148,

SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153,  
SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158,  
SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163,  
SEQ ID NO:164, SEQ ID NO:165. SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168,  
5 SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173,  
SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178,  
SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183,  
SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188,  
SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193,  
10 SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198,  
SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203,  
SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208,  
SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213,  
SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218,  
15 SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223,  
SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228,  
SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233,  
SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238,  
SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242 will have at  
20 least 75% identity (preferably 90%, more preferably at least 95% and most preferably 99-  
100%) to the sequence selected from the group consisting of those set forth in SEQ ID  
NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID  
NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID  
NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID  
25 NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID  
NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID  
NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID  
NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID  
NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID  
30 NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165. SEQ ID NO:166, SEQ ID  
NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID  
NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID

NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID  
NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID  
NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID  
NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID  
5 NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID  
NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID  
NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID  
NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID  
NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID  
10 NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID  
NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID  
NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID  
NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ  
ID NO:242; (b) is the complement of the nucleotide sequence of (a); (c) hybridizes under  
15 highly stringent conditions to the nucleotide molecule of (a) and encodes a naturally  
occurring kinase polypeptide; (d) encodes a kinase polypeptide having an amino acid  
sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID  
NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID  
NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID  
20 NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID  
NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID  
NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID  
NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID  
NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID  
25 NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID  
NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID  
NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID  
NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID  
NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID  
30 NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID  
NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID  
NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID

NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or the corresponding full-length amino acid sequence, or fragments thereof. A sequence that is substantially similar to a sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226,

SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242 will have at least 75% identity (preferably 90%, more preferably at least 95% and most preferably 99-100%) to the sequence of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, except that it lacks one or more of the domains selected from the group consisting of a N-terminal domain, a catalytic domain, a C-terminal domain, a coiled-coil structure region, a proline-rich region, a spacer region, an insert, and a C-terminal tail; or (i) is the

complement of the nucleotide sequence of (h). The domain demarcations of the polypeptides of the invention are indicated in Table 2 by reference to the kinase domain.

The term "complement" refers to two nucleotides that can form multiple favorable interactions with one another. For example, adenine is complementary to thymine as they can form two hydrogen bonds. Similarly, guanine and cytosine are complementary since they can form three hydrogen bonds. A nucleotide sequence is the complement of another nucleotide sequence if all of the nucleotides of the first sequence are complementary to all of the nucleotides of the second sequence.

The term "domain" refers to a region of a polypeptide that contains a particular function. For instance, N-terminal or C-terminal domains of signal transduction proteins can serve functions including, but not limited to, binding molecules that localize the signal transduction molecule to different regions of the cell or binding other signaling molecules directly responsible for propagating a particular cellular signal. Some domains can be expressed separately from the rest of the protein and function by themselves, while others must remain part of the intact protein to retain function. The latter are termed functional regions of proteins and also relate to domains.

The term "N-terminal domain" refers to the extracatalytic region located between the initiator methionine and the catalytic domain of the protein kinase. The N-terminal domain can be identified following a Smith-Waterman alignment of the protein sequence against the non-redundant protein database to define the N-terminal boundary of the catalytic domain. Depending on its length, the N-terminal domain may or may not play a regulatory role in kinase function. An example of a protein kinase whose N-terminal domain has been shown to play a regulatory role is PAK65, which contains a CRIB motif used for Cdc42 and rac binding (Burbelo, P.D. *et al.* (1995) *J. Biol. Chem.* 270, 29071-29074). The N-terminal domain of a protein kinase of the invention is that portion of the protein kinase to the amino-terminal side of the kinase domain where the kinase domain is identified in Table 2, herein. Further, in some cases, portions of the N-terminal domains of the protein kinases of the invention have not been identified since the entire sequence is not available. However, with the methods described herein, the full-length sequences of the kinases of the invention can be determined and using the approaches described herein the N-terminal domain can be identified.

The term "catalytic domain" or "kinase domain" refers to a region of the protein kinase that is typically 25-300 amino acids long and is responsible for carrying out the phosphate transfer reaction from a high-energy phosphate donor molecule such as ATP or GTP to itself (autophosphorylation) or to other proteins (exogenous phosphorylation).

5 The catalytic domain of protein kinases is made up of 12 subdomains that contain highly conserved amino acid residues, and are responsible for proper polypeptide folding and for catalysis. The catalytic domain can be identified following a Smith-Waterman alignment of the protein sequence against the non-redundant protein database. The catalytic/kinase domains of the protein kinases of the invention are identified in Table 2, herein. Further,  
10 in some cases, the complete sequence of the catalytic/kinase domains of the protein kinases of the invention may not have been provided since the entire sequence is not available. However, with the methods described herein, the full-length sequences of the kinases of the invention can be determined, and using the approaches described herein, the catalytic/kinase domain can be identified.

15 The term "catalytic activity", as used herein, defines the rate at which a kinase catalytic domain phosphorylates a substrate. Catalytic activity can be measured, for example, by determining the amount of a substrate converted to a phosphorylated product as a function of time. Catalytic activity can be measured by methods of the invention by holding time constant and determining the concentration of a phosphorylated substrate  
20 after a fixed period of time. Phosphorylation of a substrate occurs at the active-site of a protein kinase. The active-site is normally a cavity in which the substrate binds to the protein kinase and is phosphorylated.

The term "substrate" as used herein refers to a molecule phosphorylated by a kinase of the invention. Kinases phosphorylate substrates on serine/threonine or tyrosine  
25 amino acids. The molecule may be another protein or a polypeptide.

The term "C-terminal domain" refers to the region located between the catalytic domain and the carboxy-terminal amino acid residue of the protein kinase. The C-terminal domain can be identified by using a Smith-Waterman alignment of the protein sequence against the non-redundant protein database to define the C-terminal boundary of  
30 the catalytic domain or of any functional C-terminal extracatalytic domain. Depending on its length and amino acid composition, the C-terminal domain may or may not play a regulatory role in kinase function. An example of a protein kinase whose C-terminal

domain may play a regulatory role is PAK3 which contains a heterotrimeric G<sub>b</sub> subunit-binding site near its C-terminus (Leeuw, T. *et al.* (1998) *Nature*, 391, 191-195). The C-terminal domain of a protein kinase of the invention is that portion of the protein kinase to the carboxy-terminal side of the kinase domain where the kinase domain is identified in Table 2, herein. In some cases, the C-terminal domains of the protein kinases of the invention have not been provided since the entire sequence is not available. However, with the methods described herein, the full-length sequences of the kinases of the invention can be determined, and using the approaches described herein, the C-terminal domain can be identified.

The term "signal transduction pathway" refers to the molecules that propagate an extracellular signal through the cell membrane to become an intracellular signal. This signal can then stimulate a cellular response. The polypeptide molecules involved in signal transduction processes are typically receptor and non-receptor protein tyrosine kinases, receptor and non-receptor protein phosphatases, SRC homology 2 and 3 domains, phosphotyrosine binding proteins (SRC homology 2 (SH2) and phosphotyrosine binding (PTB and PH) domain containing proteins), proline-rich binding proteins (SH3 domain containing proteins), nucleotide exchange factors, and transcription factors.

The term "coiled-coil structure region" as used herein, refers to a polypeptide sequence that has a high probability of adopting a coiled-coil structure as predicted by computer algorithms such as COILS (Lupas, A. (1996) *Meth. Enzymology* 266:513-525). Coiled-coils are formed by two or three amphipathic  $\alpha$ -helices in parallel. Coiled-coils can bind to coiled-coil domains of other polypeptides resulting in homo- or heterodimers (Lupas, A. (1991) *Science* 252:1162-1164). Coiled-coil-dependent oligomerization has been shown to be necessary for protein function including catalytic activity of serine/threonine kinases (Roe, J. *et al.* (1997) *J. Biol. Chem.* 272:5838-5845). Coiled-coil regions in the proteins of the invention can be identified using these methods. They may be present as sub-domains of the N-terminal, kinase, or C-terminal domains of the polypeptides of the invention.

The term "proline-rich region" as used herein, refers to a region of a protein kinase whose proline content over a given amino acid length is higher than the average content of this amino acid found in proteins (*i.e.*, >10%). Proline-rich regions are easily discernable by visual inspection of amino acid sequences and quantitated by standard computer

sequence analysis programs such as the DNASTar program EditSeq. Proline-rich regions have been demonstrated to participate in regulatory protein-protein interactions. Among these interactions, those that are most relevant to this invention involve the "PxxP" proline rich motif found in certain protein kinases (*i.e.*, human PAK1) and the SH3 domain of the adaptor molecule Nck (Galisteo, M.L. *et al.* (1996) J. Biol. Chem. 271:20997-21000).

Other regulatory interactions involving "PxxP" proline-rich motifs include the WW domain (Sudol, M. (1996) Prog. Biophys. Mol. Bio. 65:113-132). Proline rich regions in the proteins of the invention can be identified using these methods. They may be present as sub-domains of the N-terminal, kinase, or C-terminal domains of the polypeptides of the invention.

The term "spacer region" as used herein, refers to a region of the protein kinase located between predicted functional domains. The spacer region has no detectable homology to any amino acid sequence in the database, and can be identified by using a Smith-Waterman alignment of the protein sequence against the non-redundant protein database to define the C- and N-terminal boundaries of the flanking functional domains. Spacer regions may or may not play a fundamental role in protein kinase function. Precedence for the regulatory role of spacer regions in kinase function is provided by the role of the src kinase spacer in inter-domain interactions (Xu, W. *et al.* (1997) Nature 385:595-602). Spacer regions in the proteins of the invention can be identified using these methods. They may be present as sub-domains of the N-terminal, kinase, or C-terminal domains of the polypeptides of the invention.

The term "insert" as used herein refers to a portion of a protein kinase that is absent from a close homolog. Inserts may or may not be the product alternative splicing of exons. Inserts can be identified by using a Smith-Waterman sequence alignment of the protein sequence against the non-redundant protein database, or by means of a multiple sequence alignment of homologous sequences using the DNASTar program Megalign. Inserts may play a functional role by presenting a new interface for protein-protein interactions, or by interfering with such interactions. Insert regions in the proteins of the invention can be identified using these methods. They may be present as sub-domains of the N-terminal, kinase, or C-terminal domains of the polypeptides of the invention.

The term "C-terminal tail" as used herein, refers to a C-terminal domain of a protein kinase, that by homology extends or protrudes past the C-terminal amino acid of its closest homolog. C-terminal tails can be identified by using a Smith-Waterman sequence alignment of the protein sequence against the non-redundant protein database, or by means of a multiple sequence alignment of homologous sequences using the DNASTar program Megalign. Depending on its length, a C-terminal tail may or may not play a regulatory role in kinase function. C-terminal tail regions in the proteins of the invention can be identified using these methods. They may be present as sub-domains of the N-terminal, kinase, or C-terminal domains of the polypeptides of the invention.

Various low or high stringency hybridization conditions may be used depending upon the specificity and selectivity desired. These conditions are well-known to those skilled in the art. Under stringent hybridization conditions only highly complementary nucleic acid sequences hybridize. Preferably, such conditions prevent hybridization of nucleic acids having more than 1 or 2 mismatches out of 20 contiguous nucleotides, more preferably, such conditions prevent hybridization of nucleic acids having more than 1 or 2 mismatches out of 50 contiguous nucleotides, most preferably, such conditions prevent hybridization of nucleic acids having more than 1 or 2 mismatches out of 100 contiguous nucleotides. In some instances, the conditions may prevent hybridization of nucleic acids having more than 5 mismatches in the full-length sequence.

By stringent hybridization assay conditions is meant hybridization assay conditions at least as stringent as the following: hybridization in 50% formamide, 5X SSC, 50 mM  $\text{NaH}_2\text{PO}_4$ , pH 6.8, 0.5% SDS, 0.1 mg/mL sonicated salmon sperm DNA, and 5X Denhart solution at 42 °C overnight; washing with 2X SSC, 0.1% SDS at 45 °C; and washing with 0.2X SSC, 0.1% SDS at 45 °C. Under some of the most stringent hybridization assay conditions, the second wash can be done with 0.1X SSC at a temperature up to 70 °C (pg. 421, Berger *et al.* (1987) Guide to Molecular Cloning Techniques, Meth. Enzym. vol. 152, hereby incorporated by reference herein including any figures, tables, or drawings.). However, other applications may require the use of conditions falling between these sets of conditions. Methods of determining the conditions required to achieve desired hybridizations are well-known to those with ordinary skill in the art, and are based on several factors, including but not limited to, the sequences to be hybridized and the samples to be tested.

In other preferred embodiments, the invention features isolated, enriched, or purified nucleic acid molecules encoding kinase polypeptides, further comprising a vector or promoter effective to initiate transcription in a host cell. The invention also features recombinant nucleic acid, preferably in a cell or an organism. The recombinant nucleic acid may contain a sequence selected from the group consisting of those set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, and SEQ ID NO:121, or a functional derivative thereof and a vector or a promoter effective to initiate transcription in a host cell. The recombinant nucleic acid can alternatively contain a transcriptional initiation region functional in a cell, a sequence complementary to an RNA sequence encoding a kinase polypeptide and a transcriptional termination region functional in a cell. Specific

vectors and host cell combinations are discussed herein. The recombinant nucleic acid can also contain the full-length sequence encoding the protein kinase, or a domain, for example.

5 The term "vector" relates to a single or double-stranded circular nucleic acid molecule that can be transfected into cells and replicated within or independently of a cell genome. A circular double-stranded nucleic acid molecule can be cut and thereby linearized upon treatment with restriction enzymes. An assortment of nucleic acid vectors, restriction enzymes, and the knowledge of the nucleotide sequences cut by restriction enzymes are readily available to those skilled in the art. A nucleic acid molecule encoding  
10 a kinase can be inserted into a vector by cutting the vector with restriction enzymes and ligating the two pieces together.

The term "transfecting" defines a number of methods to insert a nucleic acid vector or other nucleic acid molecules into a cellular organism. These methods involve a variety of techniques, such as treating the cells with high concentrations of salt, an electric field, detergent, or DMSO to render the outer membrane or wall of the cells permeable to  
15 nucleic acid molecules of interest or use of various viral transduction strategies.

The term "promoter" as used herein, refers to nucleic acid sequence needed for gene sequence expression. Promoter regions vary from organism to organism, but are well known to persons skilled in the art for different organisms. For example, in prokaryotes,  
20 the promoter region contains both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal synthesis initiation. Such regions will normally include those 5'-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.

25 In preferred embodiments, the isolated nucleic acid comprises, consists essentially of, or consists of a nucleic acid sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,  
30 SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35,

SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, and SEQ ID NO:121, or the corresponding full-length sequence, encodes an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID

NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or the corresponding full-length amino acid sequence, a functional derivative thereof, or at least 10, 20, 40, 50, 75, 100, 200, 300 or 500 contiguous amino acids of a sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID

NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or the corresponding full-length sequences or derivatives thereof. The nucleic acid may be isolated from a natural source by cDNA cloning or by subtractive hybridization. The natural source may be mammalian, preferably human, blood, semen, or tissue, and the nucleic acid may be synthesized by the triester method or by using an automated DNA synthesizer.

The term "mammal" refers preferably to such organisms as mice, rats, rabbits, guinea pigs, sheep, and goats, more preferably to cats, dogs, monkeys, and apes, and most preferably to humans.

In yet other preferred embodiments, the nucleic acid is a conserved or unique region, for example those useful for: the design of hybridization probes to facilitate identification and cloning of additional polypeptides, the design of PCR probes to facilitate cloning of additional polypeptides, obtaining antibodies to polypeptide regions, and designing antisense oligonucleotides.

By "conserved nucleic acid regions", are meant regions present on two or more nucleic acids encoding a kinase polypeptide, to which a particular nucleic acid sequence can hybridize under lower stringency conditions. Examples of lower stringency conditions suitable for screening for nucleic acid encoding kinase polypeptides are provided in Berger *et al.* (1987) Guide to Molecular Cloning Techniques, Meth. Enzym. vol. 152, hereby incorporated by reference herein in its entirety, including any drawings, figures, or tables. Preferably, conserved regions differ by no more than 5 out of 20 nucleotides, even more preferably 2 out of 20 nucleotides or most preferably 1 out of 20 nucleotides.

By "unique nucleic acid region" is meant a sequence present in a nucleic acid coding for a kinase polypeptide that is not present in a sequence coding for any other naturally occurring polypeptide. Such regions preferably encode 10 (preferably 25, more preferably 50, most preferably 75) or more contiguous amino acids selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124,

SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129,  
SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134,  
SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139,  
SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144,  
5 SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149,  
SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154,  
SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159,  
SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164,  
SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169,  
10 SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174,  
SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179,  
SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184,  
SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189,  
SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194,  
15 SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199,  
SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204,  
SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209,  
SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214,  
SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219,  
20 SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224,  
SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229,  
SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234,  
SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239,  
SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or functional derivatives thereof.  
25 In particular, a unique nucleic acid region is preferably of mammalian origin and  
preferably human.

A second aspect of the invention features a nucleic acid probe for the detection of  
nucleic acid encoding a kinase polypeptide in a sample, wherein said polypeptide is  
selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124,  
30 SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129,  
SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134,  
SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139,

SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144,  
SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149,  
SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154,  
SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159,  
5 SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164,  
SEQ ID NO:165. SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169,  
SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174,  
SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179,  
SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184,  
10 SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189,  
SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194,  
SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199,  
SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204,  
SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209,  
15 SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214,  
SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219,  
SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224,  
SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229,  
SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234,  
20 SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239,  
SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242. Preferably, the nucleic acid  
probe encodes a kinase polypeptide that is a fragment of the protein encoded by an amino  
acid sequence selected from the group consisting of those set forth in SEQ ID NO:122,  
SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127,  
25 SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132,  
SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137,  
SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142,  
SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147,  
SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152,  
30 SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157,  
SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162,  
SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165. SEQ ID NO:166, SEQ ID NO:167,

SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172,  
SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177,  
SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182,  
SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187,  
5 SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199,  
SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197,  
SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202,  
SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207,  
SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212,  
10 SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217,  
SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222,  
SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227,  
SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232,  
SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237,  
15 SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID  
NO:242, or the corresponding full-length amino acid sequences. The nucleic acid probe  
contains a nucleotide base sequence that will hybridize to a sequence selected from the  
group consisting of those set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ  
ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9,  
20 SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ  
ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID  
NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25,  
SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ  
ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID  
25 NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41,  
SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ  
ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID  
NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57,  
SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ  
30 ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID  
NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73,  
SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ

5 ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID  
NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89,  
SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ  
ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID  
10 NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID  
NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID  
NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID  
NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID  
NO:120, and SEQ ID NO:121, or the corresponding full-length sequence, or a functional  
10 derivative thereof.

In preferred embodiments, the nucleic acid probe hybridizes to nucleic acid  
encoding at least 6, 12, 75, 90, 105, 120, 150, 200, 250, 300 or 350 contiguous amino  
acids of a sequence selected from the group consisting of those set forth in SEQ ID  
15 NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID  
NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID  
NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID  
NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID  
NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID  
20 NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID  
NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID  
NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID  
NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID  
NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID  
25 NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID  
NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID  
NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID  
NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID  
NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID  
30 NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID  
NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID  
NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID  
NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID

NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or the corresponding full-length amino acid sequence, or functional derivatives thereof.

Methods for using the probes include detecting the presence or amount of kinase RNA in a sample by contacting the sample with a nucleic acid probe under conditions such that hybridization occurs and detecting the presence or amount of the probe bound to kinase RNA. The nucleic acid duplex formed between the probe and a nucleic acid sequence coding for a kinase polypeptide may be used in the identification of the sequence of the nucleic acid detected (Nelson *et al.*, in *Nonisotopic DNA Probe Techniques*, Academic Press, San Diego, Kricka, ed., p. 275, 1992, hereby incorporated by reference herein in its entirety, including any drawings, figures, or tables). Kits for performing such methods may be constructed to include a container means having disposed therein a nucleic acid probe.

In a third aspect, the invention describes a recombinant cell or tissue comprising a nucleic acid molecule encoding a kinase polypeptide selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186,

SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191,  
SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196,  
SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201,  
SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206,  
5 SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211,  
SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216,  
SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221,  
SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226,  
SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231,  
10 SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236,  
SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241,  
and SEQ ID NO:242. In such cells, the nucleic acid may be under the control of the  
genomic regulatory elements, or may be under the control of exogenous regulatory  
elements including an exogenous promoter. By "exogenous" it is meant a promoter that is  
15 not normally coupled *in vivo* transcriptionally to the coding sequence for the kinase  
polypeptides.

The polypeptide is preferably a fragment of the protein encoded by an amino acid  
sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID  
NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID  
20 NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID  
NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID  
NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID  
NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID  
NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID  
25 NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID  
NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID  
NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID  
NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID  
NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID  
30 NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID  
NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID  
NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID

NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID  
NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID  
NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID  
NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID  
5 NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID  
NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID  
NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID  
NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID  
NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID  
10 NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or the  
corresponding full-length amino acid sequence. By "fragment," is meant an amino acid  
sequence present in a kinase polypeptide. Preferably, such a sequence comprises at least  
10, 20, 40, 50, 75, 100, 200, or 300 contiguous amino acids a sequence selected from the  
group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124,  
15 SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129,  
SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134,  
SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139,  
SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144,  
SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149,  
20 SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154,  
SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159,  
SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164,  
SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169,  
SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174,  
25 SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179,  
SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184,  
SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189,  
SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194,  
SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199,  
30 SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204,  
SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209,  
SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214,

SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219,  
SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224,  
SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229,  
SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234,  
5 SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239,  
SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or of the corresponding full-  
length amino acid sequence, or a functional derivative thereof.

In a fourth aspect, the invention features an isolated, enriched, or purified kinase  
polypeptide selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ  
10 ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ  
ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ  
ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ  
ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ  
ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ  
15 ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ  
ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ  
ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ  
ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ  
ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ  
20 ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ  
ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ  
ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ  
ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ  
ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ  
25 ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ  
ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ  
ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ  
ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ  
ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ  
30 ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ  
ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ

ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242.

By "isolated" in reference to a polypeptide is meant a polymer of amino acids (2 or more amino acids) conjugated to each other, including polypeptides that are isolated from a natural source or that are synthesized. The isolated polypeptides of the present invention are unique in the sense that they are not found in a pure or separated state in nature. Use of the term "isolated" indicates that a naturally occurring sequence has been removed from its normal cellular environment. Thus, the sequence may be in a cell-free solution or placed in a different cellular environment. The term does not imply that the sequence is the only amino acid chain present, but that it is essentially free (about 90 - 95% pure at least) of non-amino acid material naturally associated with it.

By the use of the term "enriched" in reference to a polypeptide is meant that the specific amino acid sequence constitutes a significantly higher fraction (2 - 5 fold) of the total amino acid sequences present in the cells or solution of interest than in normal or diseased cells or in the cells from which the sequence was taken. This could be caused by a person by preferential reduction in the amount of other amino acid sequences present, or by a preferential increase in the amount of the specific amino acid sequence of interest, or by a combination of the two. However, it should be noted that enriched does not imply that there are no other amino acid sequences present, just that the relative amount of the sequence of interest has been significantly increased. The term significant here is used to indicate that the level of increase is useful to the person making such an increase, and generally means an increase relative to other amino acid sequences of about at least 2-fold, more preferably at least 5- to 10-fold or even more. The term also does not imply that there is no amino acid sequence from other sources. The other source of amino acid sequences may, for example, comprise amino acid sequence encoded by a yeast or bacterial genome, or a cloning vector such as pUC19. The term is meant to cover only those situations in which man has intervened to increase the proportion of the desired amino acid sequence.

It is also advantageous for some purposes that an amino acid sequence be in purified form. The term "purified" in reference to a polypeptide does not require absolute purity (such as a homogeneous preparation); instead, it represents an indication that the sequence is relatively purer than in the natural environment. Compared to the natural level

this level should be at least 2-5 fold greater (*e.g.*, in terms of mg/mL). Purification of at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. The substance is preferably free of contamination at a functionally significant level, for example 90%, 95%, or 99% pure.

5           In preferred embodiments, the kinase polypeptide is a fragment of the protein encoded by an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, 10   SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, 15   SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, 20   SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, 25   SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, 30   SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or the corresponding full-length amino acid sequences. Preferably, the kinase polypeptide contains at least 10, 20, 40, 50, 75, 100, 200, or 300 contiguous

amino acids a sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or the corresponding full-length amino acid sequence, or a functional derivative thereof.

In preferred embodiments, the kinase polypeptide comprises an amino acid sequence having (a) an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ

5 ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ  
ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ  
ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ  
ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ  
ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ  
ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165. SEQ  
ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ  
ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ  
ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ  
10 ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ  
ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ  
ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ  
ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ  
ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ  
15 ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ  
ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ  
ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ  
ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ  
ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ  
20 ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ  
ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ  
ID NO:241, and SEQ ID NO:242; (b) an amino acid sequence selected from the group  
consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ  
ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ  
25 ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ  
ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ  
ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ  
ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ  
ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ  
30 ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ  
ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ  
ID NO:165. SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ

ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, except that it lacks one or more, but not all, of a domain selected from the group consisting of an N-terminal domain, a catalytic domain, a C-terminal domain, a coiled-coil structure region, a proline-rich region, a spacer region, an insert, and a C-terminal tail; (c) an amino acid sequence of a domain of a polypeptide selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187,

SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199,  
SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197,  
SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202,  
SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207,  
5 SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212,  
SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217,  
SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222,  
SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227,  
SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232,  
10 SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237,  
SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID  
NO:242 where the domain is selected from the group consisting of an N-terminal domain,  
a catalytic domain, a C-terminal domain, a coiled-coil structure region, a proline-rich  
region, a spacer region, an insert, and a C-terminal tail; or (d) an amino acid sequence  
15 selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123,  
SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128,  
SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133,  
SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138,  
SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143,  
20 SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148,  
SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153,  
SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158,  
SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163,  
SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168,  
25 SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173,  
SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178,  
SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183,  
SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188,  
SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193,  
30 SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198,  
SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203,  
SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208,

SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, 5 SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, except that it lacks one or more, but not all, of the domains selected from the group consisting of a C-terminal domain, a catalytic domain, an N-terminal domain, a spacer region, a proline-rich 10 region, a coiled-coil structure region, an insert, and a C-terminal tail. (The domain demarcations of the polypeptides of the invention are indicated in Table 2 by reference to the kinase domain.)

The polypeptide can be isolated from a natural source by methods well-known in the art. The natural source may be mammalian, preferably human, blood, semen, or tissue, 15 and the polypeptide may be synthesized using an automated polypeptide synthesizer. The isolated, enriched, or purified kinase polypeptide is preferably selected from the group consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ 20 ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ 25 ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ 30 ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ

ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242A.

In some embodiments the invention includes a recombinant kinase polypeptide selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229,

SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242. By "recombinant kinase polypeptide" is meant a polypeptide produced by recombinant DNA techniques such that it is distinct from a naturally occurring polypeptide either in its location (*e.g.*, present in a different cell or tissue than found in nature), purity or structure. Generally, such a recombinant polypeptide will be present in a cell in an amount different from that normally observed in nature.

In a fifth aspect, the invention features an antibody (*e.g.*, a monoclonal or polyclonal antibody) having specific binding affinity to a kinase polypeptide or a kinase polypeptide domain or fragment where the polypeptide is selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ

ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242. In preferred embodiments, the antibody binds  
5 specifically to domains of kinase polypeptides, that are defined *supra*.

By "specific binding affinity" is meant that the antibody binds to the target kinase polypeptide with greater affinity than it binds to other polypeptides under specified conditions. Antibodies or antibody fragments are polypeptides that contain regions that can bind other polypeptides. The term "specific binding affinity" describes an antibody  
10 that binds to a kinase polypeptide with greater affinity than it binds to other polypeptides under specified conditions.

The term "polyclonal" refers to antibodies that are heterogenous populations of antibody molecules derived from the sera of animals immunized with an antigen or an antigenic functional derivative thereof. For the production of polyclonal antibodies,  
15 various host animals may be immunized by injection with the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species.

"Monoclonal antibodies" are substantially homogenous populations of antibodies to a particular antigen. They may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. Monoclonal  
20 antibodies may be obtained by methods known to those skilled in the art (Kohler *et al.*, Nature 256:495-497, 1975, and U.S. Patent No. 4,376,110, both of which are hereby incorporated by reference herein in their entirety including any figures, tables, or drawings).

The term "antibody fragment" refers to a portion of an antibody, often the hyper variable region and portions of the surrounding heavy and light chains, that displays  
25 specific binding affinity for a particular molecule. A hyper variable region is a portion of an antibody that physically binds to the polypeptide target.

Antibodies or antibody fragments having specific binding affinity to a kinase polypeptide or domains of a kinase polypeptide of the invention may be used in methods  
30 for detecting the presence and/or amount of kinase polypeptide in a sample by probing the sample with the antibody under conditions suitable for kinase-antibody immunocomplex formation and detecting the presence and/or amount of the antibody conjugated to the

kinase polypeptide. Diagnostic kits for performing such methods may be constructed to include antibodies or antibody fragments specific for the kinase as well as a conjugate of a binding partner of the antibodies or the antibodies themselves.

5 An antibody or antibody fragment with specific binding affinity to a kinase polypeptide of the invention can be isolated, enriched, or purified from a prokaryotic or eukaryotic organism. Routine methods known to those skilled in the art enable production of antibodies or antibody fragments, in both prokaryotic and eukaryotic organisms. Purification, enrichment, and isolation of antibodies, which are polypeptide molecules, are described above.

10 Antibodies having specific binding affinity to a kinase polypeptide of the invention may be used in methods for detecting the presence and/or amount of kinase polypeptide in a sample by contacting the sample with the antibody under conditions such that an immunocomplex forms and detecting the presence and/or amount of the antibody conjugated to the kinase polypeptide. Diagnostic kits for performing such methods may  
15 be constructed to include a first container containing the antibody and a second container having a conjugate of a binding partner of the antibody and a label, such as, for example, a radioisotope. The diagnostic kit may also include notification of an FDA approved use and instructions therefor.

20 In a sixth aspect, the invention features a hybridoma which produces an antibody having specific binding affinity to a kinase polypeptide or a kinase polypeptide domain, where the polypeptide is selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID  
25 NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID  
30 NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID

NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID  
NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID  
NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID  
NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID  
5 NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID  
NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID  
NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID  
NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID  
NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID  
10 NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID  
NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID  
NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID  
NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242; and  
where the domains are defined as above. By "hybridoma" is meant an immortalized cell  
15 line that is capable of secreting an antibody, for example an antibody to a kinase of the  
invention. In preferred embodiments, the antibody to the kinase comprises a sequence of  
amino acids that is able to specifically bind a kinase polypeptide of the invention.

In a seventh aspect, the invention features a kinase polypeptide binding agent able  
to bind to a kinase polypeptide selected from the group consisting of SEQ ID NO:122,  
20 SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127,  
SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132,  
SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137,  
SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142,  
SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147,  
25 SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152,  
SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157,  
SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162,  
SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167,  
SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172,  
30 SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177,  
SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182,  
SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187,

SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199,  
SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197,  
SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202,  
SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207,  
5 SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212,  
SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217,  
SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222,  
SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227,  
SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232,  
10 SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237,  
SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID  
NO:242. The binding agent is preferably a purified antibody that recognizes an epitope  
present on a kinase polypeptide of the invention. Other binding agents include molecules  
that bind to kinase polypeptides and analogous molecules that bind to a kinase  
15 polypeptide. Such binding agents may be identified by using assays that measure kinase  
binding partner activity, such as those that measure PDGFR activity.

The invention also features a method for screening for human cells containing a  
kinase polypeptide of the invention or an equivalent sequence. The method involves  
identifying the novel polypeptide in human cells using techniques that are routine and  
20 standard in the art, such as those described herein for identifying the kinases of the  
invention (*e.g.*, cloning, Southern or Northern blot analysis, in situ hybridization, PCR  
amplification, etc.).

In an eighth aspect, the invention features methods for identifying a substance that  
modulates kinase activity comprising the steps of: (a) contacting a kinase polypeptide  
25 selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124,  
SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129,  
SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134,  
SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139,  
SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144,  
30 SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149,  
SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154,  
SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159,

SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164,  
SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169,  
SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174,  
SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179,  
5 SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184,  
SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189,  
SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194,  
SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199,  
SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204,  
10 SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209,  
SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214,  
SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219,  
SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224,  
SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229,  
15 SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234,  
SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239,  
SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242 with a test substance; (b)  
measuring the activity of said polypeptide; and (c) determining whether said substance  
modulates the activity of said polypeptide.

20 The term "modulates" refers to the ability of a compound to alter the function of a  
kinase of the invention. A modulator preferably activates or inhibits the activity of a  
kinase of the invention.

The term "activates" refers to increasing the cellular activity of the kinase. The  
term inhibit refers to decreasing the cellular activity of the kinase. Kinase activity is  
25 preferably the interaction with a natural binding partner.

The term "modulates" also refers to altering the function of kinases of the  
invention by increasing or decreasing the probability that a complex forms between the  
kinase and a natural binding partner. A modulator preferably increases the probability that  
such a complex forms between the kinase and the natural binding partner, more preferably  
30 increases or decreases the probability that a complex forms between the kinase and the  
natural binding partner depending on the concentration of the compound exposed to the

kinase, and most preferably decreases the probability that a complex forms between the kinase and the natural binding partner.

The term "complex" refers to an assembly of at least two molecules bound to one another. Signal transduction complexes often contain at least two protein molecules  
5 bound to one another. For instance, a protein tyrosine receptor protein kinase, GRB2, SOS, RAF, and RAS assemble to form a signal transduction complex in response to a mitogenic ligand.

The term "natural binding partner" refers to polypeptides, lipids, small molecules, or nucleic acids that bind to kinases in cells. A change in the interaction between a kinase  
10 and a natural binding partner can manifest itself as an increased or decreased probability that the interaction forms, or an increased or decreased concentration of kinase/natural binding partner complex.

The term "contacting" as used herein refers to mixing a solution comprising the test compound with a liquid medium bathing the cells of the methods. The solution  
15 comprising the compound may also comprise another component, such as dimethyl sulfoxide (DMSO), which facilitates the uptake of the test compound or compounds into the cells of the methods. The solution comprising the test compound may be added to the medium bathing the cells by utilizing a delivery apparatus, such as a pipet-based device or syringe-based device.

20 In a ninth aspect, the invention features methods for identifying a substance that modulates kinase activity in a cell comprising the steps of: (a) expressing a kinase polypeptide in a cell, wherein said polypeptide is selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131,  
25 SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156,  
30 SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171,

SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176,  
SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181,  
SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186,  
SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191,  
5 SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196,  
SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201,  
SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206,  
SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211,  
SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216,  
10 SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221,  
SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226,  
SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231,  
SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236,  
SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241,  
15 and SEQ ID NO:242; (b) adding a test substance to said cell; and (c) monitoring a change  
in cell phenotype or the interaction between said polypeptide and a natural binding  
partner.

The term "expressing" as used herein refers to the production of kinases of the  
invention from a nucleic acid vector containing kinase genes within a cell. The nucleic  
20 acid vector is transfected into cells using well known techniques in the art as described  
herein.

In a tenth aspect, the invention provides methods for treating a disease or abnormal  
condition by administering to a patient in need of such treatment a substance that  
modulates the activity of a polypeptide selected from the group consisting of SEQ ID  
25 NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID  
NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID  
NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID  
NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID  
NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID  
30 NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID  
NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID  
NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID

NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242. Preferably, the disease is selected from the group consisting of immune-related diseases and disorders, cardiovascular disease, neurodegenerative disorders, and cancer. Also included are metabolic disorders, such as diabetes mellitus, and reproductive disorders, such as infertility.

Preferably, the disease or disorder is selected from the group consisting of rheumatoid arthritis, atherosclerosis, autoimmune disorders, and organ transplantation. Preferably the disease or disorder is selected from the group consisting of immune-related diseases and disorders, myocardial infarction, cardiomyopathies, stroke, renal failure, and oxidative stress-related neurodegenerative disorders. Most preferably, the immune-related diseases and disorders are selected from the group consisting of rheumatoid arthritis, chronic inflammatory bowel disease, chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis, autoimmunity, and organ transplantation.

Substances useful for treatment of disorders or diseases preferably show positive results in one or more in vitro assays for an activity corresponding to treatment of the disease or disorder in question. Substances that modulate the activity of the polypeptides

preferably include, but are not limited to, antisense oligonucleotides and inhibitors of protein kinases.

The term "preventing" refers to decreasing the probability that an organism contracts or develops an abnormal condition.

5 The term "treating" refers to having a therapeutic effect and at least partially alleviating or abrogating an abnormal condition in the organism.

The term "therapeutic effect" refers to the inhibition or activation factors causing or contributing to the abnormal condition. A therapeutic effect relieves to some extent one or more of the symptoms of the abnormal condition. In reference to the treatment of  
10 abnormal conditions, a therapeutic effect can refer to one or more of the following: (a) an increase in the proliferation, growth, and/or differentiation of cells; (b) inhibition (*i.e.*, slowing or stopping) of cell death; (c) inhibition of degeneration; (d) relieving to some extent one or more of the symptoms associated with the abnormal condition; and (e) enhancing the function of the affected population of cells. Compounds demonstrating  
15 efficacy against abnormal conditions can be identified as described herein.

The term "abnormal condition" refers to a function in the cells or tissues of an organism that deviates from their normal functions in that organism. An abnormal condition can relate to cell proliferation, cell differentiation or cell survival. An abnormal condition may also include irregularities in cell cycle progression, *i.e.*, irregularities in  
20 normal cell cycle progression through mitosis and meiosis.

Abnormal cell proliferative conditions include cancers such as fibrotic and mesangial disorders, abnormal angiogenesis and vasculogenesis, wound healing, psoriasis, diabetes mellitus, and inflammation.

Abnormal differentiation conditions include, but are not limited to  
25 neurodegenerative disorders, slow wound healing rates, and slow tissue grafting healing rates.

Abnormal cell survival conditions relate to conditions in which programmed cell death (apoptosis) pathways are activated or abrogated. A number of protein kinases are associated with the apoptosis pathways. Aberrations in the function of any one of the  
30 protein kinases could lead to cell immortality or premature cell death.

The term "aberration", in conjunction with the function of a kinase in a signal transduction process, refers to a kinase that is over- or under-expressed in an organism, mutated such that its catalytic activity is lower or higher than wild-type protein kinase activity, mutated such that it can no longer interact with a natural binding partner, is no longer modified by another protein kinase or protein phosphatase, or no longer interacts with a natural binding partner.

The term "administering" relates to a method of incorporating a compound into cells or tissues of an organism. The abnormal condition can be prevented or treated when the cells or tissues of the organism exist within the organism or outside of the organism. Cells existing outside the organism can be maintained or grown in cell culture dishes. For cells harbored within the organism, many techniques exist in the art to administer compounds, including (but not limited to) oral, parenteral, dermal, injection, and aerosol applications. For cells outside of the organism, multiple techniques exist in the art to administer the compounds, including (but not limited to) cell microinjection techniques, transformation techniques, and carrier techniques.

The abnormal condition can also be prevented or treated by administering a compound to a group of cells having an aberration in a signal transduction pathway to an organism. The effect of administering a compound on organism function can then be monitored. The organism is preferably a mouse, rat, rabbit, guinea pig, or goat, more preferably a monkey or ape, and most preferably a human.

In an eleventh aspect, the invention features methods for detection the expression of a polypeptide in a sample as a diagnostic tool for diseases or disorders, wherein the method comprises the steps of: (a) contacting the sample with a nucleic acid probe which hybridizes under hybridization assay conditions to a nucleic acid target region of a kinase polypeptide selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ

5 ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ  
ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ  
ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ  
ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ  
10 ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ  
ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ  
ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ  
ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ  
ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ  
15 ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ  
ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ  
ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ  
ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ  
ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ  
20 ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ  
ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ  
ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, said probe  
comprising the nucleic acid sequence encoding the polypeptide, fragments thereof, and the  
complements of the sequences and fragments; and (b) detecting the presence or amount of  
the probe:target region hybrid as an indication of the disease.

25 In preferred embodiments of the invention, the disease or disorder is selected from  
the group consisting of rheumatoid arthritis, arteriosclerosis, autoimmune disorders, organ  
transplantation, myocardial infarction, cardiomyopathies, stroke, renal failure, oxidative  
stress-related neurodegenerative disorders, metabolic disorder including diabetes,  
reproductive disorders including infertility, and cancer.

30 The kinase "target region" is a nucleotide base sequence selected from the group  
consisting of those set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID  
NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ  
ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID  
NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20,  
SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ  
ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID

NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36,  
 SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ  
 ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID  
 NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52,  
 5 SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ  
 ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID  
 NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68,  
 SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ  
 ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID  
 10 NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84,  
 SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ  
 ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID  
 NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID  
 NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID  
 15 NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID  
 NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID  
 NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID  
 NO:120, and SEQ ID NO:121, or the corresponding full-length sequences, a functional  
 derivative thereof, or a fragment thereof to which the nucleic acid probe will specifically  
 20 hybridize. Specific hybridization indicates that in the presence of other nucleic acids the  
 probe only hybridizes detectably with the kinase of the invention's target region. Putative  
 target regions can be identified by methods well known in the art consisting of alignment  
 and comparison of the most closely related sequences in the database.

In preferred embodiments the nucleic acid probe hybridizes to a kinase target  
 25 region encoding at least 6, 12, 75, 90, 105, 120, 150, 200, 250, 300 or 350 contiguous  
 amino acids of the sequence set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID  
 NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID  
 NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID  
 NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID  
 30 NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID  
 NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID  
 NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID

NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or the corresponding full-length amino acid sequence, or a functional derivative thereof. Hybridization conditions should be such that hybridization occurs only with the kinase genes in the presence of other nucleic acid molecules. Under stringent hybridization conditions only highly complementary nucleic acid sequences hybridize. Preferably, such conditions prevent hybridization of nucleic acids having more than 1 or 2 mismatches out of 20 contiguous nucleotides. Such conditions are defined *supra*.

Hybridization conditions should be such that hybridization occurs only with the genes in the presence of other nucleic acid molecules. Under stringent hybridization conditions only highly complementary nucleic acid sequences hybridize. Preferably, such conditions prevent hybridization of nucleic acids having 1 or 2 mismatches out of 20 contiguous nucleotides. Such conditions are defined *supra*.

The diseases for which detection of kinase genes in a sample could be diagnostic include diseases in which kinase nucleic acid (DNA and/or RNA) is amplified in comparison to normal cells. By "amplification" is meant increased numbers of kinase

DNA or RNA in a cell compared with normal cells. In normal cells, kinases are typically found as single copy genes. In selected diseases, the chromosomal location of the kinase genes may be amplified, resulting in multiple copies of the gene, or amplification. Gene amplification can lead to amplification of kinase RNA, or kinase RNA can be amplified in the absence of kinase DNA amplification.

"Amplification" as it refers to RNA can be the detectable presence of kinase RNA in cells, since in some normal cells there is no basal expression of kinase RNA. In other normal cells, a basal level of expression of kinase exists, therefore in these cases amplification is the detection of at least 1-2-fold, and preferably more, kinase RNA, compared to the basal level.

The diseases that could be diagnosed by detection of kinase nucleic acid in a sample preferably include cancers. The test samples suitable for nucleic acid probing methods of the present invention include, for example, cells or nucleic acid extracts of cells, or biological fluids. The samples used in the above-described methods will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts to be assayed. Methods for preparing nucleic acid extracts of cells are well known in the art and can be readily adapted in order to obtain a sample that is compatible with the method utilized.

Another aspect of the invention involves a method of agonizing (stimulating) or antagonizing a target of the invention and a natural binding partner associated activity in a mammal comprising administering to said mammal an agonist or antagonist to one of the above disclosed polypeptides in an amount sufficient to effect said agonism or antagonism. A method of treating diseases in a mammal with an agonist or antagonist of the protein of the present invention activity comprising administering the agonist or antagonist to a mammal in an amount sufficient to agonize or antagonize associated functions is also encompassed in the present application.

In an effort to discover novel treatments for diseases, biomedical researchers and chemists have designed, synthesized, and tested molecules that inhibit the function of protein polypeptides. Some small organic molecules form a class of compounds that modulate the function of protein polypeptides. Examples of molecules that have been reported to inhibit the function of protein kinases include, but are not limited to, bis monocyclic, bicyclic or heterocyclic aryl compounds (PCT WO 92/20642, published

November 26, 1992 by Maguire *et al.*), vinylene-azaindole derivatives (PCT WO 94/14808, published July 7, 1994 by Ballinari *et al.*), 1-cyclopropyl-4-pyridyl-quinolones (U.S. Patent No. 5,330,992), styryl compounds (U.S. Patent No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Patent No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1), seleoindoles and selenides (PCT WO 94/03427, published February 17, 1994 by Denny *et al.*), tricyclic polyhydroxylic compounds (PCT WO 92/21660, published December 10, 1992 by Dow), and benzylphosphonic acid compounds (PCT WO 91/15495, published October 17, 1991 by Dow *et al.*), all of which are incorporated by reference herein, including any drawings.

Compounds that can traverse cell membranes and are resistant to acid hydrolysis are potentially advantageous as therapeutics as they can become highly bioavailable after being administered orally to patients. However, many of these protein inhibitors only weakly inhibit function. In addition, many inhibit a variety of protein kinases and will therefore cause multiple side-effects as therapeutics for diseases.

Some indolinone compounds, however, form classes of acid resistant and membrane permeable organic molecules. WO 96/22976 (published August 1, 1996 by Ballinari *et al.*) describes hydrosoluble indolinone compounds that harbor tetralin, naphthalene, quinoline, and indole substituents fused to the oxindole ring. These bicyclic substituents are in turn substituted with polar groups including hydroxylated alkyl, phosphate, and ether substituents. U.S. Patent Application Serial Nos. 08/702,232, filed August 23, 1996, entitled "Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease" by Tang *et al.* (Lyon & Lyon Docket No. 221/187) and 08/485,323, filed June 7, 1995, entitled "Benzylidene-Z-Indoline Compounds for the Treatment of Disease" by Tang *et al.* (Lyon & Lyon Docket No. 223/298) and International Patent Publication WO 96/22976, published August 1, 1996 by Ballinari *et al.*, all of which are incorporated herein by reference in their entirety, including any drawings, describe indolinone chemical libraries of indolinone compounds harboring other bicyclic moieties as well as monocyclic moieties fused to the oxindole ring. Applications 08/702,232, filed August 23, 1996, entitled "Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease" by Tang *et al.* (Lyon & Lyon Docket No. 221/187), 08/485,323, filed June 7, 1995, entitled "Benzylidene-Z-Indoline Compounds for the Treatment of Disease" by Tang *et al.* (Lyon

& Lyon Docket No. 223/298), and WO 96/22976, published August 1, 1996 by Ballinari *et al.* teach methods of indolinone synthesis, methods of testing the biological activity of indolinone compounds in cells, and inhibition patterns of indolinone derivatives, both of which are incorporated by reference herein, including any drawings.

5 Other examples of substances capable of modulating kinase activity include, but are not limited to, tyrphostins, quinazolines, quinoxolines, and quinolines. The quinazolines, tyrphostins, quinolines, and quinoxolines referred to above include well known compounds such as those described in the literature. For example, representative publications describing quinazolines include Barker *et al.*, EPO Publication No. 0 520 722  
10 A1; Jones *et al.*, U.S. Patent No. 4,447,608; Kabbe *et al.*, U.S. Patent No. 4,757,072; Kaul and Vougioukas, U.S. Patent No. 5,316,553; Kreighbaum and Comer, U.S. Patent No. 4,343,940; Pegg and Wardleworth, EPO Publication No. 0 562 734 A1; Barker *et al.*, Proc. of Am. Assoc. for Cancer Research 32:327 (1991); Bertino, J.R., Cancer Research 3:293-304 (1979); Bertino, J.R., Cancer Research 9(2 part 1):293-304 (1979); Curtin *et al.*, Br. J. Cancer 53:361-368 (1986); Fernandes *et al.*, Cancer Research 43:1117-1123 (1983); Ferris  
15 *et al.* J. Org. Chem. 44(2):173-178; Fry *et al.*, Science 265:1093-1095 (1994); Jackman *et al.*, Cancer Research 51:5579-5586 (1981); Jones *et al.* J. Med. Chem. 29(6):1114-1118; Lee and Skibo, Biochemistry 26(23):7355-7362 (1987); Lemus *et al.*, J. Org. Chem. 54:3511-3518 (1989); Ley and Seng, Synthesis 1975:415-522 (1975); Maxwell *et al.*,  
20 Magnetic Resonance in Medicine 17:189-196 (1991); Mini *et al.*, Cancer Research 45:325-330 (1985); Phillips and Castle, J. Heterocyclic Chem. 17(19):1489-1596 (1980); Reece *et al.*, Cancer Research 47(11):2996-2999 (1977); Sculier *et al.*, Cancer Immunol. and Immunother. 23:A65 (1986); Sikora *et al.*, Cancer Letters 23:289-295 (1984); and Sikora *et al.*, Analytical Biochem. 172:344-355 (1988), all of which are incorporated  
25 herein by reference in their entirety, including any drawings.

Quinoxaline is described in Kaul and Vougioukas, U.S. Patent No. 5,316,553, incorporated herein by reference in its entirety, including any drawings.

Quinolines are described in Dolle *et al.*, J. Med. Chem. 37:2627-2629 (1994); MaGuire, J. Med. Chem. 37:2129-2131 (1994); Burke *et al.*, J. Med. Chem. 36:425-432  
30 (1993); and Burke *et al.* BioOrganic Med. Chem. Letters 2:1771-1774 (1992), all of which are incorporated by reference in their entirety, including any drawings.

Tyrphostins are described in Allen et al., Clin. Exp. Immunol. 91:141-156 (1993); Anafi et al., Blood 82:12:3524-3529 (1993); Baker et al., J. Cell Sci. 102:543-555 (1992); Bilder et al., Amer. Physiol. Soc. pp. 6363-6143:C721-C730 (1991); Brunton et al., Proceedings of Amer. Assoc. Cancer Rsch. 33:558 (1992); Bryckaert et al., Experimental  
5 Cell Research 199:255-261 (1992); Dong et al., J. Leukocyte Biology 53:53-60 (1993); Dong et al., J. Immunol. 151(5):2717-2724 (1993); Gazit et al., J. Med. Chem. 32:2344-2352 (1989); Gazit et al., " J. Med. Chem. 36:3556-3564 (1993); Kaur et al., Anti-Cancer Drugs 5:213-222 (1994); Kaur et al., King et al., Biochem. J. 275:413-418 (1991); Kuo et al., Cancer Letters 74:197-202 (1993); Levitzki, A., The FASEB J. 6:3275-3282 (1992);  
10 Lyall et al., J. Biol. Chem. 264:14503-14509 (1989); Peterson et al., The Prostate 22:335-345 (1993); Pillemer et al., Int. J. Cancer 50:80-85 (1992); Posner et al., Molecular Pharmacology 45:673-683 (1993); Rendu et al., Biol. Pharmacology 44(5):881-888 (1992); Sauro and Thomas, Life Sciences 53:371-376 (1993); Sauro and Thomas, J. Pharm. and Experimental Therapeutics 267(3):119-1125 (1993); Wolbring et al., J. Biol. Chem. 269(36):22470-22472 (1994); and Yoneda et al., Cancer Research 51:4430-4435 (1991); all of which are incorporated herein by reference in their entirety, including any drawings.

Other compounds that could be used as modulators include oxindolinones such as those described in U.S. patent application Serial No. 08/702,232 filed August 23, 1996,  
20 incorporated herein by reference in its entirety, including any drawings.

Methods of Treating a Disease (Enablement - i.e., Dosing)

Methods of determining the dosages of compounds to be administered to a patient and modes of administering compounds to an organism are disclosed in U.S. Application Serial No. 08/702,282, filed August 23, 1996 and International patent publication number  
25 WO 96/22976, published August 1 1996, both of which are incorporated herein by reference in their entirety, including any drawings, figures or tables. Those skilled in the art will appreciate that such descriptions are applicable to the present invention and can be easily adapted to it.

The proper dosage depends on various factors such as the type of disease being  
30 treated, the particular composition being used and the size and physiological condition of the patient. Therapeutically effective doses for the compounds described herein can be estimated initially from cell culture and animal models. For example, a dose can be

formulated in animal models to achieve a circulating concentration range that initially takes into account the  $IC_{50}$  as determined in cell culture assays. The animal model data can be used to more accurately determine useful doses in humans.

5 Plasma half-life and biodistribution of the drug and metabolites in the plasma, tumors and major organs can also be determined to facilitate the selection of drugs most appropriate to inhibit a disorder. Such measurements can be carried out. For example, HPLC analysis can be performed on the plasma of animals treated with the drug and the location of radiolabeled compounds can be determined using detection methods such as X-ray, CAT scan and MRI. Compounds that show potent inhibitory activity in the  
10 screening assays, but have poor pharmacokinetic characteristics, can be optimized by altering the chemical structure and retesting. In this regard, compounds displaying good pharmacokinetic characteristics can be used as a model.

Toxicity studies can also be carried out by measuring the blood cell composition. For example, toxicity studies can be carried out in a suitable animal model as follows:  
15 1) the compound is administered to mice (an untreated control mouse should also be used); 2) blood samples are periodically obtained via the tail vein from one mouse in each treatment group; and 3) the samples are analyzed for red and white blood cell counts, blood cell composition and the percent of lymphocytes versus polymorphonuclear cells. A comparison of results for each dosing regime with the controls indicates if toxicity is  
20 present.

At the termination of each toxicity study, further studies can be carried out by sacrificing the animals (preferably, in accordance with the American Veterinary Medical Association guidelines Report of the American Veterinary Medical Assoc. Panel on Euthanasia, Journal of American Veterinary Medical Assoc., 202:229-249, 1993).  
25 Representative animals from each treatment group can then be examined by gross necropsy for immediate evidence of metastasis, unusual illness or toxicity. Gross abnormalities in tissue are noted and tissues are examined histologically. Compounds causing a reduction in body weight or blood components are less preferred, as are compounds having an adverse effect on major organs. In general, the greater the adverse  
30 effect the less preferred the compound.

For the treatment of cancers the expected daily dose of a hydrophobic pharmaceutical agent is between 1 to 500 mg/day, preferably 1 to 250 mg/day, and most preferably 1 to 50 mg/day. Drugs can be delivered less frequently provided plasma levels of the active moiety are sufficient to maintain therapeutic effectiveness.

5 Plasma levels should reflect the potency of the drug. Generally, the more potent the compound the lower the plasma levels necessary to achieve efficacy.

In a final aspect, the invention features a method for detection of a kinase polypeptide in a sample as a diagnostic tool for a disease or disorder, wherein the method comprises: (a) comparing a nucleic acid target region encoding the kinase polypeptide in  
10 a sample, where the kinase polypeptide is selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID  
15 NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID  
20 NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID  
25 NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID  
30 NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID

NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or one or more fragments thereof, with a control nucleic acid target region encoding the kinase polypeptide, or one or more fragments thereof; and (b) detecting  
5 differences in sequence or amount between the target region and the control target region, as an indication of the disease or disorder. Preferably, the disease or disorder is selected from the group consisting of immune-related diseases and disorders, organ transplantation, myocardial infarction, cardiovascular disease, stroke, renal failure, oxidative stress-related neurodegenerative disorders, and cancer. Immune-related diseases and disorders include,  
10 but are not limited to, those discussed previously.

The term "comparing" as used herein refers to identifying discrepancies between the nucleic acid target region isolated from a sample, and the control nucleic acid target region. The discrepancies can be in the nucleotide sequences, *e.g.* insertions, deletions, or point mutations, or in the amount of a given nucleotide sequence. Methods to determine  
15 these discrepancies in sequences are well-known to one of ordinary skill in the art. The "control" nucleic acid target region refers to the sequence or amount of the sequence found in normal cells, *e.g.* cells that are not diseased as discussed previously.

The term also includes anti-sense molecules drawn thereto.

The invention has been described broadly and generically herein. Each of the  
20 narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein. For example, in some instances the nucleotide sequence of particular kinase polypeptides may not be part of a preferred  
25 embodiment.

The summary of the invention described above is not limiting and other features and advantages of the invention will be apparent from the following detailed description of the invention, and from the claims.

### BRIEF DESCRIPTION OF THE FIGURES

Figures 1A to 1BB shows the amino acid sequences of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242.

Figures 2A to 2MMMM shows the nucleic acid sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID

NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34,  
SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ  
ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID  
NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50,  
5 SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ  
ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID  
NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66,  
SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ  
ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID  
10 NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82,  
SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ  
ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID  
NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98,  
SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103,  
15 SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108,  
SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113,  
SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118,  
SEQ ID NO:119, SEQ ID NO:120, and SEQ ID NO:121.

## 20 DETAILED DESCRIPTION OF THE INVENTION

The present invention relates in part to kinase polypeptides, nucleic acids encoding  
such polypeptides, cells containing such nucleic acids, antibodies to such polypeptides,  
assays utilizing such polypeptides, and methods relating to all of the foregoing. The  
present invention is based upon the isolation and characterization of new kinase  
25 polypeptides. The polypeptides and nucleic acids may be produced using well-known and  
standard synthesis techniques when given the sequences presented herein.

### I. The Nucleic Acids of the Invention

30 Included within the scope of this invention are the functional equivalents of the  
herein-described isolated nucleic acid molecules. The degeneracy of the genetic code  
permits substitution of certain codons by other codons that specify the same amino acid  
and hence would give rise to the same protein. The nucleic acid sequence can vary

substantially since, with the exception of methionine and tryptophan, the known amino acids can be coded for by more than one codon. Thus, portions or all of the kinase genes of the invention could be synthesized to give a nucleic acid sequence significantly different from one selected from the group consisting of those set forth in SEQ ID NO:1, 5  
SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, 10  
SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, 15  
SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, 20  
SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, and SEQ ID NO:121. The encoded amino acid sequence thereof would, however, be preserved.

In addition, the nucleic acid sequence may comprise a nucleotide sequence which 30  
results from the addition, deletion or substitution of at least one nucleotide to the 5'-end and/or the 3'-end of the nucleic acid sequence shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID

NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13,  
SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ  
ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID  
NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29,  
5 SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ  
ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID  
NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45,  
SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ  
ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID  
10 NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61,  
SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ  
ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID  
NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77,  
SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ  
15 ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID  
NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93,  
SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ  
ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID  
NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID  
20 NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID  
NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID  
NO:119, SEQ ID NO:120, and SEQ ID NO:121, or a derivative thereof. Any nucleotide  
or polynucleotide may be used in this regard, provided that its addition, deletion or  
substitution does not alter the amino acid sequence of SEQ ID NO:122, SEQ ID NO:123,  
25 SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128,  
SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133,  
SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138,  
SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143,  
SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148,  
30 SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153,  
SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158,  
SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163,

SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168,  
SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173,  
SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178,  
SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183,  
5 SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188,  
SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193,  
SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198,  
SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203,  
SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208,  
10 SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213,  
SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218,  
SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223,  
SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228,  
SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233,  
15 SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238,  
SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, that is encoded  
by the nucleotide sequence. For example, the present invention is intended to include any  
nucleic acid sequence resulting from the addition of ATG as an initiation codon at the 5'-  
end of the inventive nucleic acid sequence or its derivative, or from the addition of TTA,  
20 TAG or TGA as a termination codon at the 3'-end of the inventive nucleotide sequence or  
its derivative. Moreover, the nucleic acid molecule of the present invention may, as  
necessary, have restriction endonuclease recognition sites added to its 5'-end and/or 3'-  
end.

Such functional alterations of a given nucleic acid sequence afford an opportunity  
25 to promote secretion and/or processing of heterologous proteins encoded by foreign  
nucleic acid sequences fused thereto, for example. All variations of the nucleotide  
sequence of the kinase genes of the invention and fragments thereof permitted by the  
genetic code are, therefore, included in this invention.

Further, it is possible to delete codons or to substitute one or more codons with  
30 codons other than degenerate codons to produce a structurally modified polypeptide, but  
one which has substantially the same utility or activity as the polypeptide produced by the  
unmodified nucleic acid molecule. As recognized in the art, the two polypeptides are

functionally equivalent, as are the two nucleic acid molecules that give rise to their production, even though the differences between the nucleic acid molecules are not related to the degeneracy of the genetic code. This is discussed further in the "Functional Derivatives" section, herein.

5           Finally, many of the nucleic acid molecules of the invention are provided as a partial sequence only (Fig. 2A through 2QQ). However, it is standard for one of ordinary skill in the art to obtain a full-length sequence when provided with a partial sequence. Similarly, when provided with a partial or full-length sequence it is standard for one of ordinary skill in the art to obtain nucleic acid sequence coding for homologous proteins.  
10          Therefore, these nucleic acid molecules are also part of the invention.

          The characteristics of the protein kinase nucleic acid sequences of the invention are provided in Table 1. The protein kinases fall into 10 known groups: AGC, CAMK, CKI, CMGC, dsPK, EIFK, LIMK, MLK, STE and TK. In addition, there are a significant number of protein kinases that do not belong to any of the known groups, and therefore  
15          presumably define new protein kinase groups.

          Additional characteristics may be found, *inter alia*, in the tables, namely Table 1, Table 2, Table 3 and Table 4, shown below.

## 20          II.    Nucleic Acid Probes, Methods, and Kits for Detection of Protein Kinases.

          A nucleic acid probe of the present invention may be used to probe an appropriate chromosomal or cDNA library by usual hybridization methods to obtain other nucleic acid molecules of the present invention. A chromosomal DNA or cDNA library may be prepared from appropriate cells according to recognized methods in the art (cf. "Molecular Cloning: A Laboratory Manual", second edition, Cold Spring Harbor Laboratory,  
25          Sambrook, Fritsch, & Maniatis, eds., 1989).

          In the alternative, chemical synthesis can be carried out in order to obtain nucleic acid probes having nucleotide sequences that correspond to N-terminal, kinase or C-terminal portions, for example, of the amino acid sequence of the polypeptide of interest. The synthesized nucleic acid probes may be used as primers in a polymerase chain  
30          reaction (PCR) carried out in accordance with recognized PCR techniques, essentially according to PCR Protocols, "A Guide to Methods and Applications", Academic Press,

Michael, *et al.*, eds., 1990, utilizing the appropriate chromosomal or cDNA library to obtain the fragment of the present invention.

One skilled in the art can readily design such probes based on the sequence disclosed herein using methods of computer alignment and sequence analysis known in the art ("Molecular Cloning: A Laboratory Manual", 1989, *supra*). The hybridization probes of the present invention can be labeled by standard labeling techniques such as with a radiolabel, enzyme label, fluorescent label, biotin-avidin label, chemiluminescence, and the like. After hybridization, the probes may be visualized using known methods.

The nucleic acid probes of the present invention include RNA, as well as DNA probes, such probes being generated using techniques known in the art. The nucleic acid probe may be immobilized on a solid support. Examples of such solid supports include, but are not limited to, plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, and acrylic resins, such as polyacrylamide and latex beads. Techniques for coupling nucleic acid probes to such solid supports are well known in the art.

The test samples suitable for nucleic acid probing methods of the present invention include, for example, cells or nucleic acid extracts of cells, or biological fluids. The samples used in the above-described methods will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts to be assayed. Methods for preparing nucleic acid extracts of cells are well known in the art and can be readily adapted in order to obtain a sample that is compatible with the method utilized.

One method of detecting the presence of nucleic acids of the invention in a sample comprises (a) contacting said sample with the above-described nucleic acid probe under conditions such that hybridization occurs, and (b) detecting the presence of said probe bound to said nucleic acid molecule. One skilled in the art would select the nucleic acid probe according to techniques known in the art as described above. Samples to be tested include but should not be limited to RNA samples of human tissue.

A kit for detecting the presence of nucleic acids of the invention in a sample comprises at least one container means having disposed therein the above-described nucleic acid probe. The kit may further comprise other containers comprising one or more of the following: wash reagents and reagents capable of detecting the presence of bound nucleic acid probe. Examples of detection reagents include, but are not limited to

radiolabelled probes, enzymatic labeled probes (horseradish peroxidase, alkaline phosphatase), and affinity labeled probes (biotin, avidin, or streptavidin).

In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers or strips of plastic or paper. Such containers allow the efficient transfer of reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the probe or primers used in the assay, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, and the like), and containers which contain the reagents used to detect the hybridized probe, bound antibody, amplified product, or the like. One skilled in the art will readily recognize that the nucleic acid probes described in the present invention can readily be incorporated into one of the established kit formats that are well known in the art.

### III. DNA Constructs Comprising a Protein Kinase Nucleic Acid Molecule and Cells Containing These Constructs.

The present invention also relates to a recombinant DNA molecule comprising, 5' to 3', a promoter effective to initiate transcription in a host cell and the above-described nucleic acid molecules. In addition, the present invention relates to a recombinant DNA molecule comprising a vector and an above-described nucleic acid molecule. The present invention also relates to a nucleic acid molecule comprising a transcriptional region functional in a cell, a sequence complementary to an RNA sequence encoding an amino acid sequence corresponding to the above-described polypeptide, and a transcriptional termination region functional in said cell. The above-described molecules may be isolated and/or purified DNA molecules.

The present invention also relates to a cell or organism that contains an above-described nucleic acid molecule and thereby is capable of expressing a polypeptide. The polypeptide may be purified from cells that have been altered to express the polypeptide. A cell is said to be "altered to express a desired polypeptide" when the cell, through genetic manipulation, is made to produce a protein which it normally does not produce or

which the cell normally produces at lower levels. One skilled in the art can readily adapt procedures for introducing and expressing either genomic, cDNA, or synthetic sequences into either eukaryotic or prokaryotic cells.

5 A nucleic acid molecule, such as DNA, is said to be "capable of expressing" a polypeptide if it contains nucleotide sequences which contain transcriptional and translational regulatory information and such sequences are "operably linked" to nucleotide sequences which encode the polypeptide. An operable linkage is a linkage in which the regulatory DNA sequences and the DNA sequence sought to be expressed are connected in such a way as to permit gene sequence expression. The precise nature of the  
10 regulatory regions needed for gene sequence expression may vary from organism to organism, but shall in general include a promoter region which, in prokaryotes, contains both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal synthesis initiation. Such regions will normally include those 5'-non-coding sequences involved with initiation of  
15 transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.

If desired, the non-coding region 3' to the sequence encoding a kinase of the invention may be obtained by the above-described methods. This region may be retained for its transcriptional termination regulatory sequences, such as termination and  
20 polyadenylation. Thus, by retaining the 3'-region naturally contiguous to the DNA sequence encoding a kinase of the invention, the transcriptional termination signals may be provided. Where the transcriptional termination signals are not satisfactorily functional in the expression host cell, then a 3' region functional in the host cell may be substituted.

Two DNA sequences (such as a promoter region sequence and a sequence  
25 encoding a kinase of the invention) are said to be operably linked if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region sequence to direct the transcription of a gene sequence encoding a kinase of the invention, or (3) interfere with the ability of the gene sequence of a kinase of the invention to be transcribed by the  
30 promoter region sequence. Thus, a promoter region would be operably linked to a DNA sequence if the promoter were capable of effecting transcription of that DNA sequence.

Thus, to express a gene encoding a kinase of the invention, transcriptional and translational signals recognized by an appropriate host are necessary.

The present invention encompasses the expression of a gene encoding a kinase of the invention (or a functional derivative thereof) in either prokaryotic or eukaryotic cells. Prokaryotic hosts are, generally, very efficient and convenient for the production of recombinant proteins and are, therefore, one type of preferred expression system for kinases of the invention. Prokaryotes most frequently are represented by various strains of *E. coli*. However, other microbial strains may also be used, including other bacterial strains.

In prokaryotic systems, plasmid vectors that contain replication sites and control sequences derived from a species compatible with the host may be used. Examples of suitable plasmid vectors may include pBR322, pUC118, pUC119 and the like; suitable phage or bacteriophage vectors may include  $\gamma$ gt10,  $\gamma$ gt11 and the like; and suitable virus vectors may include pMAM-neo, pKRC and the like. Preferably, the selected vector of the present invention has the capacity to replicate in the selected host cell.

Recognized prokaryotic hosts include bacteria such as *E. coli*, *Bacillus*, *Streptomyces*, *Pseudomonas*, *Salmonella*, *Serratia*, and the like. However, under such conditions, the polypeptide will not be glycosylated. The prokaryotic host must be compatible with the replicon and control sequences in the expression plasmid.

To express a kinase of the invention (or a functional derivative thereof) in a prokaryotic cell, it is necessary to operably link the sequence encoding the kinase of the invention to a functional prokaryotic promoter. Such promoters may be either constitutive or, more preferably, regulatable (*i.e.*, inducible or derepressible). Examples of constitutive promoters include the *int* promoter of bacteriophage  $\lambda$ , the *bla* promoter of the  $\beta$ -lactamase gene sequence of pBR322, and the *cat* promoter of the chloramphenicol acetyl transferase gene sequence of pPR325, and the like. Examples of inducible prokaryotic promoters include the major right and left promoters of bacteriophage  $\lambda$  ( $P_L$  and  $P_R$ ), the *trp*, *recA*, *lacZ*, *lacI*, and *gal* promoters of *E. coli*, the  $\alpha$ -amylase (Ulmanen *et al.*, J. Bacteriol. 162:176-182, 1985) and the  $\zeta$ -28-specific promoters of *B. subtilis* (Gilman *et al.*, Gene Sequence 32:11-20, 1984), the promoters of the bacteriophages of *Bacillus* (Gryczan, In: The Molecular Biology of the Bacilli, Academic Press, Inc., NY, 1982), and *Streptomyces* promoters (Ward *et al.*, Mol. Gen. Genet. 203:468-478, 1986). Prokaryotic

promoters are reviewed by Glick (Ind. Microbiot. 1:277-282, 1987), Cenatiempo (Biochimie 68:505-516, 1986), and Gottesman (Ann. Rev. Genet. 18:415-442, 1984).

Proper expression in a prokaryotic cell also requires the presence of a ribosome-binding site upstream of the gene sequence-encoding sequence. Such ribosome-binding sites are disclosed, for example, by Gold *et al.* (Ann. Rev. Microbiol. 35:365-404, 1981). The selection of control sequences, expression vectors, transformation methods, and the like, are dependent on the type of host cell used to express the gene. As used herein, "cell", "cell line", and "cell culture" may be used interchangeably and all such designations include progeny. Thus, the words "transformants" or "transformed cells" include the primary subject cell and cultures derived therefrom, without regard to the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. However, as defined, mutant progeny have the same functionality as that of the originally transformed cell.

Host cells which may be used in the expression systems of the present invention are not strictly limited, provided that they are suitable for use in the expression of the kinase polypeptide of interest. Suitable hosts may often include eukaryotic cells. Preferred eukaryotic hosts include, for example, yeast, fungi, insect cells, mammalian cells either *in vivo*, or in tissue culture. Mammalian cells which may be useful as hosts include HeLa cells, cells of fibroblast origin such as VERO or CHO-K1, or cells of lymphoid origin and their derivatives. Preferred mammalian host cells include SP2/0 and J558L, as well as neuroblastoma cell lines such as IMR 332, which may provide better capacities for correct post-translational processing.

In addition, plant cells are also available as hosts, and control sequences compatible with plant cells are available, such as the cauliflower mosaic virus 35S and 19S, and nopaline synthase promoter and polyadenylation signal sequences. Another preferred host is an insect cell, for example the *Drosophila* larvae. Using insect cells as hosts, the *Drosophila* alcohol dehydrogenase promoter can be used (Rubin, Science 240:1453-1459, 1988). Alternatively, baculovirus vectors can be engineered to express large amounts of kinases of the invention in insect cells (Jasny, Science 238:1653, 1987; Miller *et al.*, In: Genetic Engineering, Vol. 8, Plenum, Setlow *et al.*, eds., pp. 277-297, 1986).

Any of a series of yeast expression systems can be utilized which incorporate promoter and termination elements from the actively expressed sequences coding for glycolytic enzymes that are produced in large quantities when yeast are grown in mediums rich in glucose. Known glycolytic gene sequences can also provide very efficient transcriptional control signals. Yeast provides substantial advantages in that it can also carry out post-translational modifications. A number of recombinant DNA strategies exist utilizing strong promoter sequences and high copy number plasmids which can be utilized for production of the desired proteins in yeast. Yeast recognizes leader sequences on cloned mammalian genes and secretes peptides bearing leader sequences (*i.e.*, pre-peptides). Several possible vector systems are available for the expression of kinases of the invention in a mammalian host.

A wide variety of transcriptional and translational regulatory sequences may be employed, depending upon the nature of the host. The transcriptional and translational regulatory signals may be derived from viral sources, such as adenovirus, bovine papilloma virus, cytomegalovirus, simian virus, or the like, where the regulatory signals are associated with a particular gene sequence which has a high level of expression. Alternatively, promoters from mammalian expression products, such as actin, collagen, myosin, and the like, may be employed. Transcriptional initiation regulatory signals may be selected which allow for repression or activation, so that expression of the gene sequences can be modulated. Of interest are regulatory signals which are temperature-sensitive so that by varying the temperature, expression can be repressed or initiated, or are subject to chemical (such as metabolite) regulation.

Expression of kinases of the invention in eukaryotic hosts requires the use of eukaryotic regulatory regions. Such regions will, in general, include a promoter region sufficient to direct the initiation of RNA synthesis. Preferred eukaryotic promoters include, for example, the promoter of the mouse metallothionein I gene sequence (Hamer *et al.*, J. Mol. Appl. Gen. 1:273-288, 1982); the TK promoter of Herpes virus (McKnight, Cell 31:355-365, 1982); the SV40 early promoter (Benoist *et al.*, Nature (London) 290:304-31, 1981); and the yeast gal4 gene sequence promoter (Johnston *et al.*, Proc. Natl. Acad. Sci. (USA) 79:6971-6975, 1982; Silver *et al.*, Proc. Natl. Acad. Sci. (USA) 81:5951-5955, 1984).

Translation of eukaryotic mRNA is initiated at the codon that encodes the first methionine. For this reason, it is preferable to ensure that the linkage between a eukaryotic promoter and a DNA sequence which encodes a kinase of the invention (or a functional derivative thereof) does not contain any intervening codons which are capable of encoding a methionine (*i.e.*, AUG). The presence of such codons results either in the formation of a fusion protein (if the AUG codon is in the same reading frame as the kinase of the invention coding sequence) or a frame-shift mutation (if the AUG codon is not in the same reading frame as the kinase of the invention coding sequence).

A nucleic acid molecule encoding a kinase of the invention and an operably linked promoter may be introduced into a recipient prokaryotic or eukaryotic cell either as a nonreplicating DNA or RNA molecule, which may either be a linear molecule or, more preferably, a closed covalent circular molecule. Since such molecules are incapable of autonomous replication, the expression of the gene may occur through the transient expression of the introduced sequence. Alternatively, permanent expression may occur through the integration of the introduced DNA sequence into the host chromosome.

A vector may be employed which is capable of integrating the desired gene sequences into the host cell chromosome. Cells which have stably integrated the introduced DNA into their chromosomes can be selected by also introducing one or more markers which allow for selection of host cells which contain the expression vector. The marker may provide for prototrophy to an auxotrophic host, biocide resistance, *e.g.*, antibiotics, or heavy metals, such as copper, or the like. The selectable marker gene sequence can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection. Additional elements may also be needed for optimal synthesis of mRNA. These elements may include splice signals, as well as transcription promoters, enhancers, and termination signals. cDNA expression vectors incorporating such elements include those described by Okayama (Mol. Cell. Biol. 3:280-, 1983).

The introduced nucleic acid molecule can be incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host. Any of a wide variety of vectors may be employed for this purpose. Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector may be recognized and selected from those recipient cells which do not contain the vector;

the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species.

Preferred prokaryotic vectors include plasmids such as those capable of replication in *E. coli* (such as, for example, pBR322, ColEI, pSC101, pACYC 184,  $\pi$ VX; "Molecular Cloning: A Laboratory Manual", 1989, *supra*). *Bacillus* plasmids include pC194, pC221, pT127, and the like (Gryczan, In: The Molecular Biology of the Bacilli, Academic Press, NY, pp. 307-329, 1982). Suitable *Streptomyces* plasmids include pIJ101 (Kendall *et al.*, J. Bacteriol. 169:4177-4183, 1987), and streptomyces bacteriophages such as  $\phi$ C31 (Chater *et al.*, In: Sixth International Symposium on Actinomycetales Biology, Akademiai Kiado, Budapest, Hungary, pp. 45-54, 1986). *Pseudomonas* plasmids are reviewed by John *et al.* (Rev. Infect. Dis. 8:693-704, 1986), and Izaki (Jpn. J. Bacteriol. 33:729-742, 1978).

Preferred eukaryotic plasmids include, for example, BPV, vaccinia, SV40, 2-micron circle, and the like, or their derivatives. Such plasmids are well known in the art (Botstein *et al.*, Miami Wntr. Symp. 19:265-274, 1982; Broach, In: "The Molecular Biology of the Yeast *Saccharomyces*: Life Cycle and Inheritance", Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p. 445-470, 1981; Broach, Cell 28:203-204, 1982; Bollon *et al.*, J. Clin. Hematol. Oncol. 10:39-48, 1980; Maniatis, In: Cell Biology: A Comprehensive Treatise, Vol. 3, Gene Sequence Expression, Academic Press, NY, pp. 563-608, 1980).

Once the vector or nucleic acid molecule containing the construct(s) has been prepared for expression, the DNA construct(s) may be introduced into an appropriate host cell by any of a variety of suitable means, *i.e.*, transformation, transfection, conjugation, protoplast fusion, electroporation, particle gun technology, calcium phosphate-precipitation, direct microinjection, and the like. After the introduction of the vector, recipient cells are grown in a selective medium, which selects for the growth of vector-containing cells. Expression of the cloned gene(s) results in the production of a kinase of the invention, or fragments thereof. This can take place in the transformed cells as such, or following the induction of these cells to differentiate (for example, by administration of bromodeoxyuracil to neuroblastoma cells or the like). A variety of incubation conditions can be used to form the peptide of the present invention. The most preferred conditions are those which mimic physiological conditions.

#### IV. The Proteins of the Invention

A variety of methodologies known in the art can be utilized to obtain the polypeptides of the present invention. The polypeptides may be purified from tissues or cells that naturally produce the polypeptides. Alternatively, the above-described isolated nucleic acid fragments could be used to express the kinases of the invention in any organism. The samples of the present invention include cells, protein extracts or membrane extracts of cells, or biological fluids. The samples will vary based on the assay format, the detection method, and the nature of the tissues, cells or extracts used as the sample.

Any eukaryotic organism can be used as a source for the polypeptides of the invention, as long as the source organism naturally contains such polypeptides. As used herein, "source organism" refers to the original organism from which the amino acid sequence of the subunit is derived, regardless of the organism the subunit is expressed in and ultimately isolated from.

One skilled in the art can readily follow known methods for isolating proteins in order to obtain the polypeptides free of natural contaminants. These include, but are not limited to: size-exclusion chromatography, HPLC, ion-exchange chromatography, and immuno-affinity chromatography.

Further, the polypeptides of the invention include the full-length polypeptides that can be identified from the full-length or partial sequences encoded by SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182,

SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187,  
 SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199,  
 SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197,  
 SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202,  
 5 SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207,  
 SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212,  
 SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217,  
 SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222,  
 SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227,  
 10 SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232,  
 SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237,  
 SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID  
 NO:242 (Figure 1). In addition, the polypeptides of the invention include the domains of  
 these polypeptides, including, but not limited to, the N-terminal, kinase/catalytic, and C-  
 15 terminal domains.

The characteristics of the protein kinase nucleic acid sequences of the invention are  
 provided in Table 1. The protein kinases fall into 10 known groups: AGC, CAMK, CKI,  
 CMGC, dsPK, EIFK, LIMK, MLK, STE and TK. In addition, there are a significant  
 number of protein kinases that do not belong to any of the known groups, and therefore  
 20 presumably define new protein kinase groups.

Additional characteristics are shown in, *inter alia*, the tables, namely Table 1,  
 Table 2, Table 3 and Table 4, provided below.

#### V. Antibodies, Hybridomas, Methods of Use and Kits for Detection of Protein 25 Kinases

The present invention relates to an antibody having binding affinity to a kinase of  
 the invention. The polypeptide may have an amino acid sequence selected from the group  
 consisting of those set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ  
 ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ  
 30 ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ  
 ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ  
 ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ

5 ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ  
ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ  
ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ  
ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ  
ID NO:165. SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ  
ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ  
ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ  
ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ  
ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ  
10 ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ  
ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ  
ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ  
ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ  
ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ  
15 ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ  
ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ  
ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ  
ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ  
ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ  
20 ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or a functional derivative thereof, or  
at least 9 contiguous amino acids thereof (preferably, at least 20, 30, 35, or 40 or more  
contiguous amino acids thereof). Alternatively, the antibody may bind to a part of the  
polypeptide not provided in the sequences above, but that is present in the full-length  
sequence of the polypeptide and that is easily obtained using methods standard in the art.  
25 Further, the antibody may bind specifically to particular domains of one or more of the  
kinases of the invention, including, but not limited to, the N-terminal, kinase/catalytic, or  
C-terminal domains.

The present invention also relates to an antibody having specific binding affinity to  
a kinase or kinase domain of the invention. Such an antibody may be isolated by  
30 comparing its binding affinity to a kinase of the invention with its binding affinity to other  
polypeptides. Those that bind selectively to a kinase of the invention would be chosen for  
use in methods requiring a distinction between a kinase of the invention and other

polypeptides. Such methods could include, but should not be limited to, the analysis of altered kinase expression in tissue containing other polypeptides.

The kinases of the present invention can be used in a variety of procedures and methods, such as for the generation of antibodies, for use in identifying pharmaceutical compositions, and for studying DNA/protein interaction.

The kinases of the present invention can be used to produce antibodies or hybridomas. One skilled in the art will recognize that if an antibody is desired, such a peptide could be generated as described herein and used as an immunogen. The antibodies of the present invention include monoclonal and polyclonal antibodies, as well fragments of these antibodies, and humanized forms. Humanized forms of the antibodies of the present invention may be generated using one of the procedures known in the art such as chimerization or CDR grafting.

The present invention also relates to a hybridoma that produces the above-described monoclonal antibody, or binding fragment thereof. A hybridoma is an immortalized cell line that is capable of secreting a specific monoclonal antibody.

In general, techniques for preparing monoclonal antibodies and hybridomas are well known in the art (Campbell, "Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology," Elsevier Science Publishers, Amsterdam, The Netherlands, 1984; St. Groth *et al.*, J. Immunol. Methods 35:1-21, 1980).

Any animal (mouse, rabbit, and the like) which is known to produce antibodies can be immunized with the selected polypeptide. Methods for immunization are well known in the art. Such methods include subcutaneous or intraperitoneal injection of the polypeptide. One skilled in the art will recognize that the amount of polypeptide used for immunization will vary based on the animal that is immunized, the antigenicity of the polypeptide and the site of injection.

The polypeptide may be modified or administered in an adjuvant in order to increase the peptide antigenicity. Methods of increasing the antigenicity of a polypeptide are well known in the art. Such procedures include coupling the antigen with a heterologous protein (such as globulin or  $\beta$ -galactosidase) or through the inclusion of an adjuvant during immunization.

For monoclonal antibodies, spleen cells from the immunized animals are removed, fused with myeloma cells, such as SP2/0-Ag14 myeloma cells, and allowed to become monoclonal antibody producing hybridoma cells. Any one of a number of methods well known in the art can be used to identify the hybridoma cell that produces an antibody with the desired characteristics. These include screening the hybridomas with an ELISA assay, western blot analysis, or radioimmunoassay (Lutz *et al.*, Exp. Cell Res. 175:109-124, 1988). Hybridomas secreting the desired antibodies are cloned and the class and subclass are determined using procedures known in the art (Campbell, "Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology", *supra*, 1984).

For polyclonal antibodies, antibody-containing antisera is isolated from the immunized animal and is screened for the presence of antibodies with the desired specificity using one of the above-described procedures. The above-described antibodies may be detectably labeled. Antibodies can be detectably labeled through the use of radioisotopes, affinity labels (such as biotin, avidin, and the like), enzymatic labels (such as horse radish peroxidase, alkaline phosphatase, and the like) fluorescent labels (such as FITC or rhodamine, and the like), paramagnetic atoms, and the like. Procedures for accomplishing such labeling are well-known in the art, for example, *see* Stemberger *et al.*, J. Histochem. Cytochem. 18:315, 1970; Bayer *et al.*, Meth. Enzym. 62:308-, 1979; Engval *et al.*, Immunol. 109:129-, 1972; Goding, J. Immunol. Meth. 13:215-, 1976. The labeled antibodies of the present invention can be used for *in vitro*, *in vivo*, and *in situ* assays to identify cells or tissues that express a specific peptide.

The above-described antibodies may also be immobilized on a solid support. Examples of such solid supports include plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, acrylic resins and such as polyacrylamide and latex beads. Techniques for coupling antibodies to such solid supports are well known in the art (Weir *et al.*, "Handbook of Experimental Immunology" 4th Ed., Blackwell Scientific Publications, Oxford, England, Chapter 10, 1986; Jacoby *et al.*, Meth. Enzym. 34, Academic Press, N.Y., 1974). The immobilized antibodies of the present invention can be used for *in vitro*, *in vivo*, and *in situ* assays as well as in immunochromatography.

Furthermore, one skilled in the art can readily adapt currently available procedures, as well as the techniques, methods and kits disclosed herein with regard to antibodies, to generate peptides capable of binding to a specific peptide sequence in order to generate rationally designed antipeptide peptides (Hurby *et al.*, "Application of Synthetic Peptides: Antisense Peptides", In Synthetic Peptides, A User's Guide, W.H. Freeman, NY, pp. 289-307, 1992; Kaspczak *et al.*, Biochemistry 28:9230-9238, 1989).

Anti-peptide peptides can be generated by replacing the basic amino acid residues found in the peptide sequences of the kinases of the invention with acidic residues, while maintaining hydrophobic and uncharged polar groups. For example, lysine, arginine, and/or histidine residues are replaced with aspartic acid or glutamic acid and glutamic acid residues are replaced by lysine, arginine or histidine.

The present invention also encompasses a method of detecting a kinase polypeptide in a sample, comprising: (a) contacting the sample with an above-described antibody, under conditions such that immunocomplexes form, and (b) detecting the presence of said antibody bound to the polypeptide. In detail, the methods comprise incubating a test sample with one or more of the antibodies of the present invention and assaying whether the antibody binds to the test sample. Altered levels of a kinase of the invention in a sample as compared to normal levels may indicate disease.

Conditions for incubating an antibody with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the antibody used in the assay. One skilled in the art will recognize that any one of the commonly available immunological assay formats (such as radioimmunoassays, enzyme-linked immunosorbent assays, diffusion based Ouchterlony, or rocket immunofluorescent assays) can readily be adapted to employ the antibodies of the present invention. Examples of such assays can be found in Chard ("An Introduction to Radioimmunoassay and Related Techniques" Elsevier Science Publishers, Amsterdam, The Netherlands, 1986), Bullock *et al.* ("Techniques in Immunocytochemistry," Academic Press, Orlando, FL Vol. 1, 1982; Vol. 2, 1983; Vol. 3, 1985), Tijssen ("Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology," Elsevier Science Publishers, Amsterdam, The Netherlands, 1985).

The immunological assay test samples of the present invention include cells, protein or membrane extracts of cells, or biological fluids such as blood, serum, plasma, or urine. The test samples used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing protein extracts or membrane extracts of cells are well known in the art and can be readily be adapted in order to obtain a sample which is testable with the system utilized.

A kit contains all the necessary reagents to carry out the previously described methods of detection. The kit may comprise: (i) a first container means containing an above-described antibody, and (ii) second container means containing a conjugate comprising a binding partner of the antibody and a label. In another preferred embodiment, the kit further comprises one or more other containers comprising one or more of the following: wash reagents and reagents capable of detecting the presence of bound antibodies.

Examples of detection reagents include, but are not limited to, labeled secondary antibodies, or in the alternative, if the primary antibody is labeled, the chromophoric, enzymatic, or antibody binding reagents that are capable of reacting with the labeled antibody. The compartmentalized kit may be as described above for nucleic acid probe kits. One skilled in the art will readily recognize that the antibodies described in the present invention can readily be incorporated into one of the established kit formats that are well known in the art.

#### VI. Isolation of Compounds That Interact With Protein Kinases

The present invention also relates to a method of detecting a compound capable of binding to a protein kinase of the invention, comprising incubating the compound with a kinase of the invention and detecting the presence of the compound bound to the kinase. The compound may be present within a complex mixture, for example, serum, body fluid, or cell extracts.

The present invention also relates to a method of detecting an agonist or antagonist of kinase activity or kinase binding partner activity comprising incubating cells that produce a kinase of the invention in the presence of a compound and detecting changes in the level of kinase activity or kinase binding partner activity. The compounds thus identified would produce a change in activity indicative of the presence of the compound.

The compound may be present within a complex mixture, for example, serum, body fluid, or cell extracts. Once the compound is identified it can be isolated using techniques well known in the art.

5 The present invention also encompasses a method of agonizing (stimulating) or antagonizing kinase associated activity in a mammal comprising administering to said mammal an agonist or antagonist to a kinase of the invention in an amount sufficient to effect said agonism or antagonism. A method of treating diseases in a mammal with an agonist or antagonist of kinase activity comprising administering the agonist or antagonist to a mammal in an amount sufficient to agonize or antagonize kinase associated functions  
10 is also encompassed in the present application.

In an effort to discover novel treatments for diseases, biomedical researchers and chemists have designed, synthesized, and tested molecules that inhibit the function of protein kinases. Some small organic molecules form a class of compounds that modulate the function of protein kinases. Examples of molecules that have been reported to inhibit  
15 the function of protein kinases include, but are not limited to, bis monocyclic, bicyclic or heterocyclic aryl compounds (PCT WO 92/20642, published November 26, 1992 by Maguire *et al.*), vinylene-azaindole derivatives (PCT WO 94/14808, published July 7, 1994 by Ballinari *et al.*), 1-cyclopropyl-4-pyridyl-quinolones (U.S. Patent No. 5,330,992), styryl compounds (U.S. Patent No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Patent No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1),  
20 seleoindoles and selenides (PCT WO 94/03427, published February 17, 1994 by Denny *et al.*), tricyclic polyhydroxylic compounds (PCT WO 92/21660, published December 10, 1992 by Dow), and benzylphosphonic acid compounds (PCT WO 91/15495, published October 17, 1991 by Dow *et al.*).

25 Compounds that can traverse cell membranes and are resistant to acid hydrolysis are potentially advantageous as therapeutics as they can become highly bioavailable after being administered orally to patients. However, many of these protein kinase inhibitors only weakly inhibit the function of protein kinases. In addition, many inhibit a variety of protein kinases and will cause multiple side-effects as therapeutics for diseases.

30 Some indolinone compounds, however, form classes of acid resistant and membrane permeable organic molecules. WO 96/22976 (published August 1, 1996 by Ballinari *et al.*) describes hydrosoluble indolinone compounds that harbor tetralin,

naphthalene, quinoline, and indole substituents fused to the oxindole ring. These bicyclic substituents are in turn substituted with polar moieties including hydroxylated alkyl, phosphate, and ether moieties. U.S. Patent Application Serial Nos. 08/702,232, filed August 23, 1996, entitled "Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease" by Tang *et al.* (Lyon & Lyon Docket No. 221/187) and 08/485,323, filed June 7, 1995, entitled "Benzylidene-Z-Indoline Compounds for the Treatment of Disease" by Tang *et al.* (Lyon & Lyon Docket No. 223/298) and International Patent Publication WO 96/22976, published August 1, 1996 by Ballinari *et al.*, all of which are incorporated herein by reference in their entirety, including any drawings, describe indolinone chemical libraries of indolinone compounds harboring other bicyclic moieties as well as monocyclic moieties fused to the oxindole ring. Applications 08/702,232, filed August 23, 1996, entitled "Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease" by Tang *et al.* (Lyon & Lyon Docket No. 221/187), 08/485,323, filed June 7, 1995, entitled "Benzylidene-Z-Indoline Compounds for the Treatment of Disease" by Tang *et al.* (Lyon & Lyon Docket No. 223/298), and WO 96/22976, published August 1, 1996 by Ballinari *et al.* teach methods of indolinone synthesis, methods of testing the biological activity of indolinone compounds in cells, and inhibition patterns of indolinone derivatives.

Other examples of substances capable of modulating kinase activity include, but are not limited to, tyrphostins, quinazolines, quinoxolines, and quinolines. The quinazolines, tyrphostins, quinolines, and quinoxolines referred to above include well known compounds such as those described in the literature. For example, representative publications describing quinazolines include Barker *et al.*, EPO Publication No. 0 520 722 A1; Jones *et al.*, U.S. Patent No. 4,447,608; Kabbe *et al.*, U.S. Patent No. 4,757,072; Kaul and Vougioukas, U.S. Patent No. 5, 316,553; Kreighbaum and Comer, U.S. Patent No. 4,343,940; Pegg and Wardleworth, EPO Publication No. 0 562 734 A1; Barker *et al.*, Proc. of Am. Assoc. for Cancer Research 32:327 (1991); Bertino, J.R., Cancer Research 3:293-304 (1979); Bertino, J.R., Cancer Research 9(2 part 1):293-304 (1979); Curtin *et al.*, Br. J. Cancer 53:361-368 (1986); Fernandes *et al.*, Cancer Research 43:1117-1123 (1983); Ferris *et al.*, J. Org. Chem. 44(2):173-178; Fry *et al.*, Science 265:1093-1095 (1994); Jackman *et al.*, Cancer Research 51:5579-5586 (1981); Jones *et al.*, J. Med. Chem. 29(6):1114-1118; Lee and Skibo, Biochemistry 26(23):7355-7362 (1987); Lemus *et al.*, J.

Org. Chem. 54:3511-3518 (1989); Ley and Seng, Synthesis 1975:415-522 (1975); Maxwell *et al.*, Magnetic Resonance in Medicine 17:189-196 (1991); Mini *et al.*, Cancer Research 45:325-330 (1985); Phillips and Castle, J. Heterocyclic Chem. 17(19):1489-1596 (1980); Reece *et al.*, Cancer Research 47(11):2996-2999 (1977); Sculier *et al.*, Cancer Immunol. and Immunother. 23:A65 (1986); Sikora *et al.*, Cancer Letters 23:289-295 (1984); Sikora *et al.*, Analytical Biochem. 172:344-355 (1988); all of which are incorporated herein by reference in their entirety, including any drawings.

Quinoxaline is described in Kaul and Vougioukas, U.S. Patent No. 5,316,553, incorporated herein by reference in its entirety, including any drawings.

Quinolines are described in Dolle *et al.*, J. Med. Chem. 37:2627-2629 (1994); MaGuire, J. Med. Chem. 37:2129-2131 (1994); Burke *et al.*, J. Med. Chem. 36:425-432 (1993); and Burke *et al.*, BioOrganic Med. Chem. Letters 2:1771-1774 (1992), all of which are incorporated by reference in their entirety, including any drawings.

Tyrphostins are described in Allen *et al.*, Clin. Exp. Immunol. 91:141-156 (1993); Anafi *et al.*, Blood 82:12:3524-3529 (1993); Baker *et al.*, J. Cell Sci. 102:543-555 (1992); Bilder *et al.*, Amer. Physiol. Soc. pp. 6363-6143:C721-C730 (1991); Brunton *et al.*, Proceedings of Amer. Assoc. Cancer Rsch. 33:558 (1992); Bryckaert *et al.*, Experimental Cell Research 199:255-261 (1992); Dong *et al.*, J. Leukocyte Biology 53:53-60 (1993); Dong *et al.*, J. Immunol. 151(5):2717-2724 (1993); Gazit *et al.*, J. Med. Chem. 32:2344-2352 (1989); Gazit *et al.*, " J. Med. Chem. 36:3556-3564 (1993); Kaur *et al.*, Anti-Cancer Drugs 5:213-222 (1994); Kaur *et al.*, King *et al.*, Biochem. J. 275:413-418 (1991); Kuo *et al.*, Cancer Letters 74:197-202 (1993); Levitzki, A., The FASEB J. 6:3275-3282 (1992); Lyall *et al.*, J. Biol. Chem. 264:14503-14509 (1989); Peterson *et al.*, The Prostate 22:335-345 (1993); Pillemer *et al.*, Int. J. Cancer 50:80-85 (1992); Posner *et al.*, Molecular Pharmacology 45:673-683 (1993); Rendu *et al.*, Biol. Pharmacology 44(5):881-888 (1992); Sauro and Thomas, Life Sciences 53:371-376 (1993); Sauro and Thomas, J. Pharm. and Experimental Therapeutics 267(3):119-1125 (1993); Wolbring *et al.*, J. Biol. Chem. 269(36):22470-22472 (1994); and Yoneda *et al.*, Cancer Research 51:4430-4435 (1991); all of which are incorporated herein by reference in their entirety, including any drawings.

Other compounds that could be used as modulators include oxindolinones such as those described in U.S. patent application Serial No. 08/702,232 filed August 23, 1996, incorporated herein by reference in its entirety, including any drawings.

VII. Biological Significance, Applications and Clinical Relevance of Novel Protein Kinases

For each protein kinase in this application, we provide a classification of the protein class and family to which it belongs, a summary of non-catalytic protein motifs, a profile of its expression in several hundred tissue and cell sources, and a chromosomal location. This information can be used to suggest potential function, regulation or therapeutic utility for each of the proteins.

The kinase classification and protein domains often reflect pathways, cellular roles, or mechanisms of up- or down-stream regulation. Also disease-relevant genes often occur in families of related genes. For example if one member of a kinase family functions as an oncogene, a tumor suppressor, or has been found to be disrupted in an immune, neurologic, cardiovascular, or metabolic disorder, frequently other family members may play a related role.

The expression analysis organizes kinases into groups that are transcriptionally upregulated in tumors and those that are more restricted to specific tumor types such as melanoma or prostate. This analysis also identifies genes that are regulated in a cell cycle dependent manner, and are therefore likely to be involved in maintaining cell cycle checkpoints, entry, progression, or exit from mitosis, oversee DNA repair, or are involved in cell proliferation and genome stability. Expression data also can identify genes expressed in endothelial sources or other tissues that suggest a role in angiogenesis, thereby implicating them as targets for control of diseases that have an angiogenic component, such as cancer, endometriosis, retinopathy and macular degeneration, and various ischemic or vascular pathologies. A proteins' role in cell survival can also be suggested based on restricted expression in cells subjected to external stress such as oxidative damage, hypoxia, drugs such as cisplatin, or irradiation. Metastases-associated genes can be implicated when expression is restricted to invading regions of a tumor, or is only seen in local or distant metastases compared to the primary tumor, or when a gene is upregulated during cell culture models of invasion, migration, or motility.

Chromosomal location can identify candidate targets for a tumor amplicon or a tumor-suppressor locus. Summaries of prevelant tumor amplicons are available in the literature, and can identify tumor types to experimentally be confirmed to contain amplified copies of a kinase gene which localizes to an adjacent region.

5       Based on these criteria several kinases immediately stand out as being of potential therapeutic relevance. The protein kinases can be divided into the following disease-relevant categories (nucleotide Seq ID #s in parentheses):

10       Tumor associated: Mok (SEQ ID NO:NO:57), EPK2, AA316804 (SEQ ID NO:11), AA435956 (SEQ ID NO:NO:48), AA278842 (SEQ ID NO:88), AA599286 (SEQ ID NO:89), AA826850 (SEQ ID NO:3), HRI (SEQ ID NO:73), MLK4 AA232253 (SEQ ID NO:82), AA883975 SGK 235 (SEQ ID NO:95), AA311714 (SEQ ID NO:101), MPSK1 (SEQ ID NO:110), R19609 (Seq ID111), AA383293 (SEQ ID NO:26).

      Prostate-specific: AA234451 (SEQ ID NO:47), TSK4 (SEQ ID NO:93), RIP4 (SEQ ID NO:84), KIAA0965 (SEQ ID NO:8).

15       Oncogenic or proliferation associated: KIAA0781 (SEQ ID NO:38), AA789239 (SEQ ID NO:52), CCRK (SEQ ID NO:54), CLK4 (SEQ ID NO:55), H85389 (SEQ ID NO:97).

      Neuronal restricted: CAMKKB (SEQ ID NO:66)

20       Hematopoietic expressed: PTK9L (SEQ ID NO:22), DRAK2 (SEQ ID NO:29), AI025291 (SEQ ID NO:94)

      Angiogenic or endothelial expressed: DRAK1 (SEQ ID NO:31), MAK-V (SEQ ID NO:40), TRAD (SEQ ID NO:44), MOK (SEQ ID NO:57), AA08847 (SEQ ID NO:78), HGP\_66444466 (SEQ ID NO:79), RSK4 (SEQ ID NO:16).

25       Cell cycle regulated: AA454060 (SEQ ID NO:45), KIAA0999 (Mitotic – SEQ ID NO:32), AA579641 (Mitotic – SEQ ID NO:60), AA305176 (Mitotic – SEQ ID NO:6), AA018361 (S1 phase – SEQ ID NO:100).

#### VIII. Transgenic Animals.

30       A variety of methods are available for the production of transgenic animals associated with this invention. DNA can be injected into the pronucleus of a fertilized egg before fusion of the male and female pronuclei, or injected into the nucleus of an embryonic cell (e.g., the nucleus of a two-cell embryo) following the initiation of cell division (Brinster *et al.*, Proc. Nat. Acad. Sci. USA 82: 4438-4442, 1985). Embryos can

be infected with viruses, especially retroviruses, modified to carry inorganic-ion receptor nucleotide sequences of the invention.

5 Pluripotent stem cells derived from the inner cell mass of the embryo and stabilized in culture can be manipulated in culture to incorporate nucleotide sequences of the invention. A transgenic animal can be produced from such cells through implantation into a blastocyst that is implanted into a foster mother and allowed to come to term. Animals suitable for transgenic experiments can be obtained from standard commercial sources such as Charles River (Wilmington, MA), Taconic (Germantown, NY), Harlan Sprague Dawley (Indianapolis, IN), etc.

10 The procedures for manipulation of the rodent embryo and for microinjection of DNA into the pronucleus of the zygote are well known to those of ordinary skill in the art (Hogan *et al.*, *supra*). Microinjection procedures for fish, amphibian eggs and birds are detailed in Houdebine and Chourrout (Experientia 47: 897-905, 1991). Other procedures for introduction of DNA into tissues of animals are described in U.S. Patent No.,  
15 4,945,050 (Sanford *et al.*, July 30, 1990).

By way of example only, to prepare a transgenic mouse, female mice are induced to superovulate. Females are placed with males, and the mated females are sacrificed by CO<sub>2</sub> asphyxiation or cervical dislocation and embryos are recovered from excised oviducts. Surrounding cumulus cells are removed. Pronuclear embryos are then washed  
20 and stored until the time of injection. Randomly cycling adult female mice are paired with vasectomized males. Recipient females are mated at the same time as donor females. Embryos then are transferred surgically. The procedure for generating transgenic rats is similar to that of mice (Hammer *et al.*, Cell 63:1099-1112, 1990).

25 Methods for the culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods such as electroporation, calcium phosphate/DNA precipitation and direct injection also are well known to those of ordinary skill in the art (Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, E.J. Robertson, ed., IRL Press, 1987).

30 In cases involving random gene integration, a clone containing the sequence(s) of the invention is co-transfected with a gene encoding resistance. Alternatively, the gene encoding neomycin resistance is physically linked to the sequence(s) of the invention.

Transfection and isolation of desired clones are carried out by any one of several methods well known to those of ordinary skill in the art (E.J. Robertson, *supra*).

DNA molecules introduced into ES cells can also be integrated into the chromosome through the process of homologous recombination (Capecchi, Science 244: 1288-1292, 1989). Methods for positive selection of the recombination event (*i.e.*, neo resistance) and dual positive-negative selection (*i.e.*, neo resistance and gancyclovir resistance) and the subsequent identification of the desired clones by PCR have been described by Capecchi, *supra* and Joyner *et al.* (Nature 338: 153-156, 1989), the teachings of which are incorporated herein in their entirety including any drawings. The final phase of the procedure is to inject targeted ES cells into blastocysts and to transfer the blastocysts into pseudopregnant females. The resulting chimeric animals are bred and the offspring are analyzed by Southern blotting to identify individuals that carry the transgene. Procedures for the production of non-rodent mammals and other animals have been discussed by others (Houdebine and Chourrout, *supra*; Pursel *et al.*, Science 244:1281-1288, 1989; and Simms *et al.*, Bio/Technology 6:179-183, 1988).

Thus, the invention provides transgenic, nonhuman mammals containing a transgene encoding a kinase of the invention or a gene effecting the expression of the kinase. Such transgenic nonhuman mammals are particularly useful as an *in vivo* test system for studying the effects of introduction of a kinase, or regulating the expression of a kinase (*i.e.*, through the introduction of additional genes, antisense nucleic acids, or ribozymes).

A "transgenic animal" is an animal having cells that contain DNA which has been artificially inserted into a cell, which DNA becomes part of the genome of the animal which develops from that cell. Preferred transgenic animals are primates, mice, rats, cows, pigs, horses, goats, sheep, dogs and cats. The transgenic DNA may encode human STE20-related kinases. Native expression in an animal may be reduced by providing an amount of anti-sense RNA or DNA effective to reduce expression of the receptor.

#### IX. Gene Therapy

Protein kinases of the invention, or their genetic sequences will also be useful in gene therapy (reviewed in Miller, Nature 357:455-460, 1992). Miller states that advances have resulted in practical approaches to human gene therapy that have demonstrated

positive initial results. The basic science of gene therapy is described in Mulligan (Science 260:926-931, 1993).

5 In one preferred embodiment, an expression vector containing protein kinase coding sequence is inserted into cells, the cells are grown *in vitro*, and then are infused in large numbers into patients. In another preferred embodiment, a DNA segment containing a promoter of choice (for example a strong promoter) is transferred into cells containing an endogenous gene encoding kinases of the invention in such a manner that the promoter segment enhances expression of the endogenous kinase gene (for example, the promoter segment is transferred to the cell such that it becomes directly linked to the endogenous kinase gene).

10 The gene therapy may involve the use of an adenovirus containing kinase cDNA targeted to a tumor, systemic kinase increase by implantation of engineered cells, injection with kinase-encoding virus, or injection of naked kinase DNA into appropriate tissues.

15 Target cell populations may be modified by introducing altered forms of one or more components of the protein complexes in order to modulate the activity of such complexes. For example, by reducing or inhibiting a complex component activity within target cells, an abnormal signal transduction event(s) leading to a condition may be decreased, inhibited, or reversed. Deletion or missense mutants of a component, that retain the ability to interact with other components of the protein complexes but cannot function in signal transduction may be used to inhibit an abnormal, deleterious signal transduction event.

20 Expression vectors derived from viruses such as retroviruses, vaccinia virus, adenovirus, adeno-associated virus, herpes viruses, several RNA viruses, or bovine papilloma virus, may be used for delivery of nucleotide sequences (*e.g.*, cDNA) encoding recombinant kinase of the invention protein into the targeted cell population (*e.g.*, tumor cells). Methods which are well known to those skilled in the art can be used to construct recombinant viral vectors containing coding sequences (Maniatis *et al.*, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y., 1989; Ausubel *et al.*, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, N.Y., 1989). Alternatively, recombinant nucleic acid molecules encoding protein sequences can be used as naked DNA or in a reconstituted system *e.g.*, liposomes or other lipid systems for delivery to target cells (*e.g.*, Felgner *et al.*, Nature 337:387-8,

1989). Several other methods for the direct transfer of plasmid DNA into cells exist for use in human gene therapy and involve targeting the DNA to receptors on cells by complexing the plasmid DNA to proteins (Miller, *supra*).

5 In its simplest form, gene transfer can be performed by simply injecting minute amounts of DNA into the nucleus of a cell, through a process of microinjection (Capecchi, Cell 22:479-88, 1980). Once recombinant genes are introduced into a cell, they can be recognized by the cell's normal mechanisms for transcription and translation, and a gene product will be expressed. Other methods have also been attempted for introducing DNA into larger numbers of cells. These methods include: transfection, wherein DNA is  
10 precipitated with  $\text{CaPO}_4$  and taken into cells by pinocytosis (Chen *et al.*, Mol. Cell Biol. 7:2745-52, 1987); electroporation, wherein cells are exposed to large voltage pulses to introduce holes into the membrane (Chu *et al.*, Nucleic Acids Res. 15:1311-26, 1987); lipofection/liposome fusion, wherein DNA is packaged into lipophilic vesicles which fuse with a target cell (Felgner *et al.*, Proc. Natl. Acad. Sci. USA. 84:7413-7417, 1987); and  
15 particle bombardment using DNA bound to small projectiles (Yang *et al.*, Proc. Natl. Acad. Sci. 87:9568-9572, 1990). Another method for introducing DNA into cells is to couple the DNA to chemically modified proteins.

It has also been shown that adenovirus proteins are capable of destabilizing endosomes and enhancing the uptake of DNA into cells. The admixture of adenovirus to  
20 solutions containing DNA complexes, or the binding of DNA to polylysine covalently attached to adenovirus using protein crosslinking agents substantially improves the uptake and expression of the recombinant gene (Curiel *et al.*, Am. J. Respir. Cell. Mol. Biol., 6:247-52, 1992).

As used herein "gene transfer" means the process of introducing a foreign nucleic acid molecule into a cell. Gene transfer is commonly performed to enable the expression  
25 of a particular product encoded by the gene. The product may include a protein, polypeptide, anti-sense DNA or RNA, or enzymatically active RNA. Gene transfer can be performed in cultured cells or by direct administration into animals. Generally gene transfer involves the process of nucleic acid contact with a target cell by non-specific or  
30 receptor mediated interactions, uptake of nucleic acid into the cell through the membrane or by endocytosis, and release of nucleic acid into the cytoplasm from the plasma membrane or endosome. Expression may require, in addition, movement of the nucleic

acid into the nucleus of the cell and binding to appropriate nuclear factors for transcription.

As used herein "gene therapy" is a form of gene transfer and is included within the definition of gene transfer as used herein and specifically refers to gene transfer to express  
5 a therapeutic product from a cell *in vivo* or *in vitro*. Gene transfer can be performed *ex vivo* on cells which are then transplanted into a patient, or can be performed by direct administration of the nucleic acid or nucleic acid-protein complex into the patient.

In another preferred embodiment, a vector having nucleic acid sequences encoding a protein kinase polypeptide of the invention is provided in which the nucleic acid  
10 sequence is expressed only in specific tissue. Methods of achieving tissue-specific gene expression are set forth in International Publication No. WO 93/09236, filed November 3, 1992 and published May 13, 1993.

In all of the preceding vectors set forth above, a further aspect of the invention is that the nucleic acid sequence contained in the vector may include additions, deletions or  
15 modifications to some or all of the sequence of the nucleic acid, as defined above.

In another preferred embodiment, a method of gene replacement is set forth. "Gene replacement" as used herein means supplying a nucleic acid sequence which is capable of being expressed *in vivo* in an animal and thereby providing or augmenting the function of an endogenous gene that is missing or defective in the animal.

20 X. Administration of Substances

Methods of determining the dosages of compounds to be administered to a patient and modes of administering compounds to an organism are disclosed in U.S. Application Serial No. 08/702,282, filed August 23, 1996 and International patent publication number WO 96/22976, published August 1 1996, both of which are incorporated herein by  
25 reference in their entirety, including any drawings, figures, or tables. Those skilled in the art will appreciate that such descriptions are applicable to the present invention and can be easily adapted to it.

The proper dosage depends on various factors such as the type of disease being treated, the particular composition being used, and the size and physiological condition of  
30 the patient. Therapeutically effective doses for the compounds described herein can be estimated initially from cell culture and animal models. For example, a dose can be formulated in animal models to achieve a circulating concentration range that initially

takes into account the  $IC_{50}$  as determined in cell culture assays. The animal model data can be used to more accurately determine useful doses in humans.

5 Plasma half-life and biodistribution of the drug and metabolites in the plasma, tumors, and major organs can be also be determined to facilitate the selection of drugs most appropriate to inhibit a disorder. Such measurements can be carried out. For example, HPLC analysis can be performed on the plasma of animals treated with the drug and the location of radiolabeled compounds can be determined using detection methods such as X-ray, CAT scan, and MRI. Compounds that show potent inhibitory activity in the screening assays, but have poor pharmacokinetic characteristics, can be optimized by  
10 altering the chemical structure and retesting. In this regard, compounds displaying good pharmacokinetic characteristics can be used as a model.

Toxicity studies can also be carried out by measuring the blood cell composition. For example, toxicity studies can be carried out in a suitable animal model as follows: 1) the compound is administered to mice (an untreated control mouse should also be used);  
15 2) blood samples are periodically obtained via the tail vein from one mouse in each treatment group; and 3) the samples are analyzed for red and white blood cell counts, blood cell composition, and the percent of lymphocytes versus polymorphonuclear cells. A comparison of results for each dosing regime with the controls indicates if toxicity is present.

20 At the termination of each toxicity study, further studies can be carried out by sacrificing the animals (preferably, in accordance with the American Veterinary Medical Association guidelines Report of the American Veterinary Medical Assoc. Panel on Euthanasia, *Journal of American Veterinary Medical Assoc.*, 202:229-249, 1993). Representative animals from each treatment group can then be examined by gross  
25 necropsy for immediate evidence of metastasis, unusual illness, or toxicity. Gross abnormalities in tissue are noted, and tissues are examined histologically. Compounds causing a reduction in body weight or blood components are less preferred, as are compounds having an adverse effect on major organs. In general, the greater the adverse effect the less preferred the compound.

For the treatment of cancers the expected daily dose of a hydrophobic pharmaceutical agent is between 1 to 500 mg/day, preferably 1 to 250 mg/day, and most preferably 1 to 50 mg/day. Drugs can be delivered less frequently provided plasma levels of the active moiety are sufficient to maintain therapeutic effectiveness.

5 Plasma levels should reflect the potency of the drug. Generally, the more potent the compound the lower the plasma levels necessary to achieve efficacy.

### EXAMPLES

10 The examples below are not limiting and are merely representative of various aspects and features of the present invention. The examples below demonstrate the isolation and characterization of the protein kinases of the invention.

15 EXAMPLE 1: Isolation of cDNA clones Encoding Novel Mammalian Protein Kinases  
Materials and Methods Identification from cDNA databases and isolation of clones  
encoding novel protein kinases

Novel kinases were identified from the public EST databases using a Hidden Markov model, abbreviated HMM (Krogh, A., Brown, M., Mian, I. S., Sjolander, K., and Haussler, D. 1994. Hidden Markov models in computational biology: Applications to protein modeling. *J. Mol. Biol.*, 235:1501-1531). The model was built with 70 mammalian and yeast kinase catalytic domain sequences. These sequences were chosen from a comprehensive collection of kinases such that no two sequences had more than 50% sequence identity. ESTs were translated in six open reading frames and were searched against the model. ESTs that had a score of at least 10 against the HMM were then masked for repetitive sequences and vectors and were clustered using MSA. The resulting contigs were searched against known kinases to identify EST clones that encode novel kinases.

Approximately 40% of the ESTs encoding potentially novel kinases did not correspond to the correct EST upon sequence analysis. Most of these discrepancies were resolved by ordering additional clones, however, 14 remained unavailable. These 14 ESTs were amplified from a variety of single-stranded cDNA sources with primers derived from the corresponding EST entry as shown on Table 5. The PCR product was subcloned into a bluescript vector, digested to confirm the presence of a correct size insert and sequenced. Full sequencing of EST and PCR was carried out using a cycle sequencing Big-dye kit

with AmpliTaq DNA Polymerase, FS (ABI, Foster City, CA). Sequencing reaction products were run on an ABI Prism 377 DNA Sequencer.

Table 5: Primers used to clone PCR products corresponding to novel kinases

	ID#	ID#	Parent	5' primer	3' primer
sp	na	aa	Sequence	Sequence*	Sequence*
H	33	153	2R22-5-11	GAGATCGRNTTYAARGA RTTYGA	TGTCACNCCNAGNSWCCAN AYRTT
M	81	200	5R57_10_2_ m TESK2_m	GCTGCTGGACAGTGACT TGTATTT	GAAAGCAAAGCCTTCACAC CTT
H	67	187	5R69_17_2_h	CTCTCACCTCAGGAACT GG	GCTTGCGGATCTTCTCA
H	46	166	SGK309_h	GACATCCTGCCGCGCAA CTACG	CGGCCCTGGAGCTGCATCA CTA
M	67	228	5R72_16_2_h	TGCGCGACACCATTGAC CAG	CTCAGGGCTTACATACAGA G
H	45	165	5R72_8_2_h	AAAGGAGAACTACATTT TGAAAAT	CTTCATCATCTCTAATACAT TGGTTGG
H	41	161	Z36720	CAAATTAAGATCATTGA CTTTGGG	GGAAACAAAGTCCTTGCC TC
H	115	234	AL031652 - Pak6	GTGGACATCTGGTCCCT CG	GTAGGTCCTTCACTCTTGG AG

- degenerate oligonucleotide residue designation:

5 N= A,C,G or T

R= A or G

Y= C or T

S = C or G

W= A or T

10

#### Full-length sequence extension of protein kinases using cDNA and genomic databases

Extension of partial cDNA sequences to encompass the full-length open-reading frame was carried out by iterative blastn searching of the cDNA databases listed in Table 6. All blastn searches were conducted using a blosum62 matrix, a penalty for a nucleotide mismatch of -3 and reward for a nucleotide match of 1. The gapped blast algorithm is described in: (Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and

15

PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402).

Table 6. Databases used for cDNA-based sequence extensions

Database	Database Date
LifeGold templates	Feb 2000
LifeGold compseqs	Feb 2000
LifeGold compseqs	Mar 2000
LifeGold compseqs	Apr 2000
LifeGold fl	Feb 2000
LifeGold flft	Apr 2000
NCBI human Ests	May 2000
NCBI murine Ests	May 2000
NCBI nonredundant	May 2000

5

Extension of partial cDNA sequences to encompass the full-length open-reading frame was also carried out by iterative searches of genomic databases. Three methods were used. The first method made use of the Smith-Waterman algorithm to carry out protein-protein searches of the closest homologue or orthologue to the partial kinase. The target databases consisted of Genescan and open-reading frame (ORF) predictions of all human genomic sequence derived from the human genome project (HGP) as well as from Celera. The complete set of genomic databases searched is shown in Table 7 below. Genomic sequences encoding potential extensions were further assessed by blastp analysis against the NCBI nonredundant to confirm the novelty of the hit. The extending genomic sequences were incorporated into the cDNA sequence after removal of potential introns using the Seqman program from DNASTar. The default parameters used for Smith-Waterman searches were as shown next. Matrix: blosum 62; gap-opening penalty: 12; gap extension penalty: 2. Genescan predictions were made using the Genescan program as detailed in (Chris Burge and Sam Karlin "Prediction of Complete Gene Structures in Human Genomic DNA", JMB (1997) 268(1):78-94). ORF predictions from genomic DNA were made using a standard 6-frame translation.

10

15

20

The second method for genomic sequence-based extensions made use of tBlastn searches of the homologue or orthologue to the partial kinase against the cDNA databases listed in Table 7. The recognition of significant hits in these databases made possible to identify bridging partial cDNA clones. The iterative application of the two methods made possible the assemblage of the virtual full-length sequence for a large number of the kinases presented in this application. All tblastn searches were conducted using a blosum62 matrix, a penalty for a nucleotide mismatch of -3 and reward for a nucleotide match of 1.

The last method for defining cDNA extensions from genomic sequence used iterative searches of genomic databases through the Genescan program to predict exon splicing and the Genewise program (<http://www.sanger.ac.uk/Software/Wise2/>) to predict potential ORFs based on homology to the closest orthologue/homologue.

Table 7. Databases used for genomic-based sequence extensions

Database	Number of entries	Database Date
Celera v. 1-5	5,306,158	Jan 19/00
Celera v. 6-10	4,209,980	Mar 24/00
Celera v. 11-14	7,222,425	Apr 24/00
Celera v. 15	243,044	May 14/00
HGP all Genescan	25,885	Apr 04/00
HGP; Phase 0	4,944	May 04/00
HGP; Phase 1	28,478	May 05/00
HGP; Phase 2	1,508	May 04/00
HGP; Phase 3	9,971	May 05/00

#### Virtual Extensions

Human AA826850 (SEQ ID NO: 3, SEQ ID NO:124)

Blastn analysis of the partial AA826850 sequence revealed an extension to encompass the complete ORF in the Incyte EST 238299.1. A frame-shift correction at position 595 of this EST (marked by X in NA sequence) generated an uninterrupted ORF.

Human AA960957 (SEQ ID NO: 4, SEQ ID NO:125)

Since the initial filing of this application, the partial AA960957 sequence appeared in the public database as the full-length gene for a protein kinase encoded by a gene that maps adjacent to the *evc* (AJ250839) (ellis-van creveld syndrome and weyers acrodermal dysostosis) gene from 4p16.1.

5 Human 5R79-46-1\_h (SEQ ID NO: 5, SEQ ID NO:126)

Blastn analysis of the partial 5R79-46-1 sequence revealed an extension to encompass the complete ORF in the Incyte EST 463894.6. Since the initial filing of this application, the full-length virtual 5R79-46-1 appeared in the public database as the full-length gene for the TANK-binding kinase (TBK1) (Pomerantz, J.L. and Baltimore, D.  
10 (1999) EMBO J. 18 (23), 6694-6704). TBK1 participates in NF- $\kappa$ B activation through the formation of a signaling complex with TRAF2 and TANK.

Human AA305176 (SEQ ID NO: 6, SEQ ID NO:127)

Blastn analysis of the partial AA305176 sequence revealed an extension to encompass the complete ORF in the Incyte EST 220937.1.

15 Human AA256100 (SEQ ID NO: 8, SEQ ID NO:129)

Blastn analysis of the partial AA256100 sequence revealed an extension to encompass the complete ORF through the assembly of three partial clones: Incyte EST 480815.6, KIAA0965 (BAA76809) and AA256100.

Human AA210825 (SEQ ID NO: 9, SEQ ID NO: 130)

20 Blastn analysis of the partial AA210825 sequence revealed an extension to encompass the nearly complete ORF through the assembly of three partial clones: Incyte EST 014721.7, and the NCBI EST's AW01158 and AA210825. An insertion of two "N's" at positions 1915 and 1916 generated an uninterrupted ORF. Blastx analysis indicated the possibility of a start Met in the range of 400-450 nucleotides (i.e. compared to the closest  
25 homolog, human PKCmu (CAA53384.1). However, no Met was found in this region; rather ORF ends in an in-frame stop preceeded by the sequence "RGLLAPGDPPCPPNPAPATPPSSRLPTLFSNFCDS". It is possible that part of the sequence covered by nucleotide positions 1-400 derived from AW01158 comes from an intron, explaining the absence of a start Met.

30 Human AA127299 (SEQ ID NO:10, SEQ ID NO:131)

No entries in the database extended this sequence. The 1684 bp insert of this EST contains a 1369 bp intron at the 3' end. Blastx and SW analysis of the 315 bp coding

region revealed homology to the extracatalytic C2 domain of PKC. This EST, may or may not encode a kinase.

Human AA316804 (SEQ ID NO:11, SEQ ID NO:132)

5 Since the initial filing of this application, the partial AA316804 sequence appeared in the public database as the full-length gene for the PKC family protein kinase EPK2 or PKC $\eta$  (AB015982).

Human H19102 (SEQ ID NO:14, SEQ ID NO:135)

10 Genewise and Genescan analyses of the partial H19102 sequence revealed an extension from the HGP phase 3 contig 3810672 to encompass the complete catalytic domain of this EST. Blastn analysis against the non-redundant database revealed that this gene is found in the cosmid AC005726 from chromosome 17. H19102 may encode a dual catalytic kinase given the homology to S6 kinase. Analysis of genomic sequence upstream of the 5' end of H19102 revealed a non-kinase gene oriented in the same polarity as H19102 suggestive of the start Met for H19102 being close to the 5' end of the H19102  
15 sequence. From this analysis it is deduced that the second catalytic domain of H19102, if present, is most likely located within the 47334-185,215 bp region of the genomic sequence of AC005726.

Human AA476563 (SEQ ID NO:15, SEQ ID NO:136)

20 Since the initial filing of this application, the partial AA476563 sequence appeared in the public database as the full-length gene for the protein kinase RPS6KC1 (NM\_012424) (Zhang, H. et al Genomics (1999) 61, 314-318), which is an S6 kinase mapping to 12q12-q13.1.

Human AA626690 (SEQ ID NO:16, SEQ ID NO:137)

25 Since the initial filing of this application, the partial AA626690 sequence appeared in the public database as the full-length gene for the protein kinase RPS6KA6 (AF184965) (Yntema, H.G et al (1999) Genomics 62, 332-343), an S6 kinase commonly deleted in patients with complex X-linked (Xq21.1 ) mental retardation.

Human AI215680 (SEQ ID NO: 17, SEQ ID NO:138)

30 Since the initial filing of this application, the partial AI215680 sequence appeared in the public database as the full-length gene encoding a hypothetical protein (AAD30182) from the locus AC006530.4 from chromosome 14.

Human AA887783 (SEQ ID NO:21, SEQ ID NO:142)

Blastn analysis of the partial AA887783 sequence revealed an extension to encompass the nearly complete ORF through the assembly of three partial clones: Incyte 415390R6 and the NCBI EST's AA887783 and N94726. Since the initial filing of this application, the nearly full-length virtual AA887783 sequence appeared in the public database as the full-length gene encoding SGK3 (AF169035), a serum- and glucocorticoid-induced protein kinase (Kobayashi, T. et al (1999) Biochemical J. 344, 189-197.

Human R47805 (SEQ ID NO:22, SEQ ID NO:143)

A cDNA clone encoding the full-length ORF of R47805 was isolated using R47805 as a screening probe. A full-length form for R47805 has also appeared in the public database as

PTK9L (NM\_007284), an A6-related protein kinase.

Human H60215 (SEQ ID NO:23, SEQ ID NO:144)

Blastn analysis of the partial H60215 sequence revealed an extension to encompass the complete ORF in the public EST AI275726. This was confirmed through the full insert sequencing of this EST (2,310 bp) which corresponds to the sequence under SEQ ID NO:144.

A different stop codon was predicted for AI275726 compared to H60215 due to a single nucleotide insertion at position 1586 in AI275726. Evidence for the extra nucleotide comes from EST AI191922.

SGK324\_h orthologue of W30246\_m (SEQ ID NO:24, SEQ ID NO:145)

Blastn, blastx and Smith-Waterman analyses of genomic databases revealed an extension to encompass the complete ORF corresponding to the human orthologue of murine W30246. Exons predicted from the following sequences were used for contig construction: Celera 17000189645083, 17000057549105 and 11000501939981; Incyte142404.1, HGP\_7249119, Incyte 7196489H1, Celera 11000501939981, 17000028165594; Incyte 7249119\_3, Celera 17000035772368, 11000502081575 and 17000140274329. The latter Celera sequence provides the N-terminus.

Human AA383293 (SEQ ID NO:26, SEQ ID NO:147)

Blastn, blastx and Smith-Waterman analyses of genomic databases revealed an extension to encompass the complete ORF corresponding for AA383293. Exons predicted from the following sequences were used for contig construction: (numbers in parenthesis

refer to the aa sequence of the closest homolog (RU2S, NP\_057440) used for the Smith-Waterman query): N-term from Incyte 6010175\_2 (14-97), Incyte 6981981 (134-184) 7596749 (186-232) Celera 17000020789545 (243-301) CAB75619.1 (310-341)--(56-145 DCX homology) 6010175\_2, Celera 17000030058129 (241-262 DCX homology).

5 Human AA021445 (SEQ ID NO:32, SEQ ID NO:152)

Blastn analysis revealed an extension to encompass the nearly complete ORF corresponding for AA021445. Contig reconstruction was as follows: nucleotides 1-802 from KIAA0999 (AB023216); nucleotides 803-4321 from full-insert sequence of AA021445. A pairwise alignment between the AA021445 and KIAA0999 revealed three  
10 inserts in the extracatalytic C-terminus of 48, 48 and 161 aminoacids. In addition, both AA021445 and KIAA0999 have 15 copies of a CAG repeat. Trinucleotide repeats are often found in genes that linked to neurodegenerative diseases.

Human 2R22-55-1 (SEQ ID NO:33, SEQ ID NO:153)

Blastn analysis revealed an extension in the Incyte EST clone 321074.1 to  
15 encompass the complete ORF corresponding to 2R22-55-1.

Human orthologue of AA544838\_m (SEQ ID NO:36, SEQ ID NO:156)

tBlastn analysis identified the partial human KIAA0135 (U79240) clone as the human orthologue of murine AA544838. Blastn revealed an extension KIAA0135\_h (U79240) to encompass the complete ORF. The full ORF was reconstructed from  
20 Incyte406786.5, KFZp430051 and KIAA0135 (U79240).

Human orthologue of AI785735\_m (SEQ ID NO:38, SEQ ID NO:158)

tBlastn analysis identified the partial human KIAA0781 (AB018324) clone as the human orthologue of murine AI785735. Blastn revealed an extension KIAA0135\_h (U79240) to encompass the complete ORF. The full ORF was reconstructed from Incyte  
25 986123.37 KIAA0781 (AB018324).

Human AA207220 (SEQ ID NO: 39, SEQ ID NO:159)

Blastn analysis revealed an extension to encompass the nearly complete ORF corresponding for AA021445. The full ORF was reconstructed from Incyte 402740.1 and AA207220. Frame corrections: deletion of 441 and 595 over Inc402740.1 seq based on  
30 blastx to keep frame open; two n insertions 940, 941 over AA207220 to keep frame open.

Human AA426580 (SEQ ID NO:40, SEQ ID NO:160)

Since the initial filing of this application, the partial AA426580 sequence appeared in the public database as the full-length gene encoding MAK-V (AJ271722) from chromosome 21q22.1.

Human 5R79-54-1 (SEQ ID NO: 41, SEQ ID NO:161)

5 Genewise and Genescan analyses of the partial 5R79-54-1 sequence revealed an extension from genomic sequence to encode the full ORF for 5R79-54-1.

Human orthologue of AA542015\_m (SEQ ID NO: 42, SEQ ID NO:162)

tBlastn analysis identified KIAA1297 (AB037718). Blastn extended the KIAA1297 sequence to provide the C-terminus through the Incyte 224074.1 EST. The  
10 partial ORF consists of a dual catalytic domain flanked by 6 Ig domains and 2 fibronectin repeats. Based on homology to the bt drosophila protein (AAF59316.1), the human form of AA542015 is expected to be missing 16 Ig domains.

Human R19772 (SEQ ID NO:44, SEQ ID NO:164)

The full-length ORF for R19772 was isolated by screening a cDNA library using a  
15 probe derived from R19772. Since the initial filing of this application, the R19772 sequence appeared in the public database as the full-length gene encoding Trio (Duet) (AB011422). CDNA library screening revealed multiple isoforms for this gene which are summarized in the Table below.

20 Table 8. Isoforms for R19772

Kestrl Name	Kestrl AA Acc #	Isoform type	Source	Description*
Trad (Duet)	R19772	B	Skeletal muscle	Deletion of K at 124
				Deletion of Q at 616
				Substitution of E for G at 762
		C	Skeletal muscle	Deletion of K at 124
				Deletion of Q at 616
				Substitution of E for G at 762

				Deletion of 32 aa (160-191)
		D	Lung tumor	Deletion of Q at 616
				Deletion of 32 aa (160-191)
		E	Lung tumor	Deletion of Q at 616
				Deletion of 32 aa (160-191)

\* reference amino acid position are with respect to sequence of Trad (AB011422)

Human AA435956 (SEQ ID NO:48, SEQ ID NO:168)

5        Blastn analysis revealed an extension to encompass the nearly complete catalytic region of AA435956. 5' end sequence extension was provided by genomic locus AC007242.3\_h (range 44880-43801). Based on blastx analysis, the extended sequence encodes is full-length at the C-terminus.

Human AA397553 (SEQ ID NO: 51, SEQ ID NO:171)

10        Since the initial filing of this application, the partial AA397553 sequence appeared in the public database as the full-length gene encoding CRK7 (AF227198), a novel CDC2-related protein kinase that colocalizes with interchromatin granule clusters.

Human AA789239 (SEQ ID NO: 52, SEQ ID NO:172)

15        Since the initial filing of this application, the partial AA789239 sequence appeared in the public database as the full-length gene encoding NKIAMRE (AF130372), a novel kinase deleted in human leukemia.

Human AA631990 (SEQ ID NO:55, SEQ ID NO:175)

20        Blastn analysis revealed an extension to encompass the full-length ORF for AA631990. The full ORF was reconstructed from 253847.5 and AA631990 and AA207220. Frame corrections: delete 1 C at 1380, delete 2N's at 2033/2034.

Human AA557536 (SEQ ID NO:56, SEQ ID NO:176)

25        Blastn analysis revealed an extension to encompass full-length ORF for AA557536. The full ORF was reconstructed from AA557536, celera 11000504061899 and the Incyte 097089.1 EST. An 85bp intron was removed from AA557536.

Human N34132 (SEQ ID NO: 63, SEQ ID NO:183)

Full sequencing of EST N34132 (1.3 kb) confirmed that this cDNA encodes a novel NEK-subfamily kinase. Blast analysis against the EST database showed that four

EST sequences (AA283140, AA283140, AA282911 and N53011) extended the sequence of N34132 at the 3' end to form a 2.31 kb contig. Blast analysis of the new contig against the nonredundant public database showed that the N34132 extended contig overlapped (100% identity) over 228 bp at its 3' end with human KIAA0344 (AB002342), a 5,787 bp cDNA encoding a 1246 aa polypeptide. The 5' 790 bp of the KIAA0344 cDNA (encoding the 58 N-terminal protein sequence) were found to be divergent with respect to the extended 2.32 kb N34132 contig. Evidence that the extended N34132 contig (2.31kb) and KIAA0344 (AB002342) belong to the same gene is the following. First, blast analysis of the nucleotide sequences for N34132 and KIAA0344 against the NR database confirmed that these cDNA's are transcribed from the same genomic locus defined by two overlapping BACs (AC004765 and AC004803) from chromosome 12p13.3. Second, full sequence determination of a PCR fragment amplified from single-stranded cDNA confirmed the junction between the extended N34132 contig and KIAA0344\_h (AB002342). The 462 PCR product was amplified with primers CTCCTCAACAGACAGTGCAG (5' primer) and GACATTCTACTACTCGGTCTC (3' primer) designed from the N34132 extended contig and KIAA0344 sequences, respectively. The region of N34132 containing the start Met was isolated by PCR from a testis cDNA library (Clontech).

Human 5R69-17-2 (SEQ ID NO:67, SEQ ID NO:187)

The full-length ORF for 5R69-17-2 was isolated by screening a cDNA library using a probe derived from 5R69-17-2.

Human H85811 (SEQ ID NO:68, SEQ ID NO:188)

Tblastn, Smith-Waterman and blastn analyses using cDNA databases revealed an extension to encompass full-length ORF for H85811. The full ORF was reconstructed from Incyte ESTs 202971.8, 034583.3 and 034583.1 and public ESTs H85811 and AI570599.

Human R43524 (SEQ ID NO:73, SEQ ID NO:192)

Blastn analysis revealed an extension to encompass the complete catalytic region and the C-terminus of R43524. Since the initial filing of this application, the partial R43524 sequence appeared in the public database as the full-length gene encoding the heme-regulated initiation factor 2-alpha kinase (HRI) (AF181071).

Human AA088547 (SEQ ID NO:78, SEQ ID NO:197)

Genewise and Genescan analyses of genomic databases revealed an extension to encompass the complete ORF for AA088547.

Human orthologue of AA139478\_m (SEQ ID NO:80, SEQ ID NO:199)

5 Tblastn identified the Incyte 211475.1 as the potential full-length human orthologue of murine AA139478

Human AA232253 (SEQ ID NO:82, SEQ ID NO:201)

The full-length ORF for AA232253 was isolated by screening a cDNA library using a probe derived from AA232253. Since the initial filing of this application, the AA232253 sequence appeared in the public database as the full-length gene encoding SLK (AB011422). SLK is a stress-regulated mixed lineage kinase-like protein that activation of Rac and induction of apoptosis. cDNA library screening revealed multiple isoforms for this gene which are summarized in the Table below.

Table 9. Isoforms for AA232253

15

Kestrl Name	Kestrl AA Acc #	Isoform type	Description*
MLK4	AA232253	MLK4	Substitution of C for W at 346
		MLK4B	Different Cterm (332-800); seq in MLK4B is as shown in *

\* C-terminus specific to MLK4B

LPLAARMSEESYFESKTEESNSAEMSCQITATSN GEGHGMNPSLQAMMLMGFGDI  
FSMNKAGAVMHSGMQINMQAKQNSS

20 KTTSKRRGKKVNMALGFSDFDLSEGDDDDDDDGEEEDNDMDNSE

Human H97685 (SEQ ID NO:84, SEQ ID NO:203)

Blastn analysis revealed an extension to encompass the full-length ORF for H97685. The full ORF was reconstructed from Incyte 474824.1 and the public ESTs H97685 and M62021.

25

Human AI052250 (SEQ ID NO:87, SEQ ID NO:206)

Blastn analysis revealed an extension to encompass the full-length ORF for AI052250. The full ORF was reconstructed from Incyte 396868.1, the public partial cDNA FLJ10074 (minus intron) and the public ESTs and the public ESTs AI052250 and H97685, AI499220 and M62021.

5 Human AA278842 (SEQ ID NO:88, SEQ ID NO:206)

A nearly full-length cDNA (FL4F12) for AA278842 was isolated by screening a cDNA library using a probe derived from AA278842. A full-length virtual ORF was generated using FL4F12 and AA278842.

Human AA599286 (SEQ ID NO:89, SEQ ID NO:208)

10 Since the initial filing of this application, the partial AA599286 sequence appeared in the public database as a full-length ORF (AK000342).

Human AA425725 (SEQ ID NO:90, SEQ ID NO:209)

Since the initial filing of this application, the partial AA425725 sequence appeared in the public database as MSSK1, a serine kinase gene located from human chromosome Xq28.

15 Human SGK022 orthologue of AA060026\_m (SEQ ID NO:91, SEQ ID NO:210)

Tblastn, Smith-Waterman and blastn analyses of cDNA and genomic databases revealed a potential human orthologue for murine AA060026. The full-length ORF for SGK022 was reconstructed from genomic locus AC022307.

20 Human AA399669 (SEQ ID NO:93, SEQ ID NO:212)

Blastn analysis revealed an extension to encompass the full-length ORF for AA399669. The full ORF was reconstructed as follows: sequence 1-1007 from AL136295.2; sequence 1008-2319 from AA399669 and Incyte 428177.1.

Human AA883975 (SEQ ID NO:95, SEQ ID NO:214)

25 Genescan and Genewise analyses of the genomic databases revealed an extension for AA883975 to encompass the full-length ORF

Human AA905446 (SEQ ID NO:96, SEQ ID NO:215)

30 Tblastn, Smith-Waterman and blastn analyses of cDNA and genomic databases revealed an extension for AA905446 to encompass the full-length ORF. For the Smith-Waterman analysis murine STK22 (NP\_033462) was used as the closest orthologue. Contig formation: range 162133-163687 from HGP\_h 6921333\_9; removed intron (146-893) predicted from blastx analysis.

Human H29974 (SEQ ID NO: 97 SEQ ID NO:216)

Blastn analysis revealed an extension to encompass a complete catalytic ORF for AA399669. The nearly full-length ORF was reconstructed using Incyte 213829.1 and H29974.

5 Human AA215311 (SEQ ID NO:99, SEQ ID NO:218)

Blastn analysis revealed an extension to encompass the full-length ORF for AA21531. The full ORF was reconstructed from Incyte 067584.1, 022456.1, AA215311 and the reverse complement of CPG\_043208.

Human AA018361 (SEQ ID NO:100, SEQ ID NO:219)

10 The full-length ORF for AA018361 was isolated by screening a cDNA library using a probe derived from AA018361. This yielded clone Sug4-30. Clone Sug4-30, like multiple, independent cDNA clones contained a 181bp intron. The existence of intron-less RNA's was confirmed by a PCR reaction that generated a product that upon sequence analysis skipped the intron region. The full-length virtual ORF for AA018361 was  
15 generated through a contig between AL117482 (seq 1-367) and the sequence for clone Sug4-30.

Human orthologue of AA396601\_m (SEQ ID NO:106, SEQ ID NO:225)

tBlastn and Smith-Waterman analyses of genomic sequence revealed an extension to encompass the full catalytic region for the human orthologue of AA396601. The ORF  
20 was reconstructed from Incyte 018653.9 (7261449H1, 6891740J1) and genomic sequence CPG\_040010.

Human orthologue of AA671275\_m (SEQ ID NO:108, SEQ ID NO:227)

Since the initial filing of this application, a potential human orthologue for murine AA671275 appeared in the public database as the full-length ORF for vaccinia related  
25 kinase 3 (BAA90769).

Human H05721 (SEQ ID NO:111, SEQ ID NO:230)

Genescan and Genewise analyses of genomic sequence revealed an extension to encompass the full-length ORF for H05721.

Human AI086865 (SEQ ID NO:112, SEQ ID NO:231)

30 Genescan and Genewise analyses of genomic sequence revealed an extension to encompass the full-length ORF for AI086865. The full-length ORF was reconstructed from Celera 17000102901516, Incyte 243269.1 and public AL1377531.

Human AA836348 (SEQ ID NO:113, SEQ ID NO:232)

Genescan and Genewise analyses of genomic sequence revealed an extension to encompass the full-length ORF for AA836348.

Human R86668 (SEQ ID NO:14, SEQ ID NO:233)

5 The full-length ORF for R86668 was isolated by screening a cDNA library using a probe derived from R86668. Since the initial filing of this application, the R8668 sequence appeared in the public database as the full-length gene mitogen-activated protein kinase kinase kinase 6 (MAP3K6) (NM\_00467).

Human 2R41-9-4 (SEQ ID NO: 16, SEQ ID NO:235)

10 The full-length virtual ORF for 2R41-9-4 was generated using genomic sequence to provide the Nterminus for the partial ORF predicted from clone 2R41-9-4

Table 10. Sequences deleted from the provisional patent due to duplication with other genes in the patent

Prov. SEQ ID NO: (na)	Prov. SEQ ID NO: (aa)
160	196
213	214
215	216
122	126
119	123
148	184
4	20
7	23
205	206
14	30
15	31
35	56
42	63
51	72
44	65
77	91

78	92
79	93
80	94
157	193

### Results

Table 1 documents the results from the analysis of the nucleic acid sequence data. From left to right the data presented is as follows. "Gene name" refers to the EST or PCR fragment that defined the novel kinase. "Species" refers to the organism the sequence was derived from. "ID#" refers to the nucleic acid and amino acid sequence ID number designation from this patent. "Kinase family" and "Kinase group" refers to the protein kinase classification defined by sequence homology and based on previously established phylogenetic analysis [Hardie, G. and Hanks S. The Protein Kinase Book, Academic Press (1995) and Hunter T. and Plowman, G. Trends in Biochemical Sciences (1977) 22:18-22 and Plowman G.D. *et al.* (1999) Proc. Natl. Acad. Sci. 96:13603-13610]. "ORF Start", "ORF End", "ORF Length" refer to the open reading frame range and length as calculated by standard nucleic acid translation programs such as MapDraw (DNASStar). "DNA Repeats" refers to regions of low complexity sequence or repetitive elements such as Alu, LINE, SINE, and LTR sequences. The chromosomal location (CHR localization) for 37 of the 110 novel protein kinases is shown on Table 1 (NA, not available). The methods for determining chromosomal position are outlined below, in Example 2.

Table 2 documents the results from the analysis of the amino acid sequence data. From left to right the data presented is as follows. "Gene name" refers to the EST or PCR fragment that defined the novel kinase. "Species" refers to the organism the sequence was derived from. "ID#" refers to the nucleic acid and amino acid sequence ID number designation from this patent. "Kinase family" and "Kinase group" refers to the protein kinase classification defined by sequence homology and based on previously established phylogenetic analysis [Hardie, G. and Hanks S. The Protein Kinase Book, Academic Press (1995) and Hunter T. and Plowman, G. Trends in Biochemical Sciences (1977) 22:18-22 and Plowman G.D. *et al.* (1999) Proc. Natl. Acad. Sci. 96:13603-13610]. "nraa Score", "ID match aa", "Identity", "Similar", "nraa Match Acc#", "Description" refer to the data obtained using a Smith-Waterman search of the amino acid sequence against the non-

redundant protein database (Matrix: Pam100; gap open/extension penalties 14/1). "Kinase Domain Start", "Kinase Domain End", "Profile Start" and "Profile End" refer to data obtained using a Hidden-Markov Model to define catalytic range boundaries. The profile has a length of 261 amino acids, corresponding to the complete protein kinase catalytic domain. Proteins in which the profile recognizes a full length catalytic domain have a "Profile Start" of 1 and a "Profile End" of 261. The boundaries of the catalytic domain within the overall protein are noted in the "Kinase Domain Start" and "Kinase Domain End" columns.

10 The following abbreviations were used for kinases:

ASK	Apoptosis signal-regulating kinase
CaMK	Ca <sup>2+</sup> /calmodulin-dependent protein kinase
CCRK	Cell cycle-related kinase
CDK	Cyclin-dependent kinase
CK	Casein kinase
DAPK	Death-associated protein kinase
DM	myotonic dystrophy kinase
Dyrk	dual-specificity-tyrosine phosphorylating-regulated kinase
GAK	Cyclin G-associated kinase
GRK	G-protein coupled receptor
GuC	Guanylate cyclase
HIPK	Homeodomain-interacting protein
IRAK	Interleukin-1 receptor-associated kin
MAPK	Mitogen activated protein kinase
MAST	Micotubule-associated STK
MLCK	Myosin-light chain kinase
MLK	Mixed lineage kinase
NIMA	NimA-related protein kinase
PKA	cAMP-dependent protein kinase
RSK	Ribosomal protein S6 kinase
RTK	Receptor tyrosine kinase

SGK	Serum and glucocorticoid-regulated kinase
STK	serine threonine kinase
ULK	UNC-51-like kinase

The following abbreviations were used for species

H	Human
M	Murine
R	Rat
FV	Fowlpox virus
MT	<i>M. thermoautotrophicum</i>
CE	<i>Caenorhabditis elegans</i>
DM	<i>Drosophila melanogaster</i>
OS	<i>Oryza sativa</i>
SP	<i>Schizosaccharomyces pombe</i>
TP	<i>Tetrahymena pyriformis</i>
PI	<i>Petunia inflata</i>
NC	<i>Neurospora crassa</i>
MSV	<i>Medicago sativa</i>
MSV	Moloney murine sarcoma virus
SA	<i>Squalus acanthias</i>
CS	<i>Cucumis sativus</i>
GM	<i>Glycine max</i>
LL	<i>Lilium longiflorum</i>
TV	<i>Trichomonas vaginalis</i>
MP	<i>Mycoplasma pneumoniae</i>
DD	<i>Dictyostelium discoideum</i>
SC	<i>Saccharomyces cerevisiae</i>
MT	<i>Methanobacterium thermoautotrophicum</i>

### Domain and Motif Identification

A Hidden Markov model (HMM) (Krogh, A., Brown, M., Mian, I. S., Sjolander, K., and Haussler, D. (1994). Hidden Markov models in computational biology: Applications to protein modeling. J. Mol. Biol., 235:1501-1531) was used to identify, both catalytic and extracatalytic domains. Table 4 shows extra-catalytic domains that were identified using the HMM program. Other domains such as coiled-coil and pest motifs were identified as described next.

Potential coiled-coil domains were identified using the COILS program ([www.ch.embnet.org/software/COILS\\_form.html](http://www.ch.embnet.org/software/COILS_form.html)). The matrix used was MTIDK with windows of 14, 21, 28 amino acids. Only regions scoring 0.5 or higher were considered to have potential coiled-coil domain region.

Protein sequences containing potential pest motifs were identified using the program PESTfind ([www.at.embnet.org/embnet/tools/bio/PESTfind/](http://www.at.embnet.org/embnet/tools/bio/PESTfind/)). PEST regions in proteins are by definition sequences that tend to be rich in proline, glutamic or aspartic acid, arginine and histidine; they have been associated with increased protein turnover rates (Rogers S. *et al.* (1986) Science 234, 364-368. The algorithm defines PEST sequences as hydrophilic stretches of amino acids greater than or equal to 12 residues in length. Such regions contain at least one P, one E or D and one S or T. They are flanked by lysine (K), arginine (R) or histidine (H) residues, but positively charged residues are disallowed within the PEST sequence. PESTfind produces a score ranging from about -50 to +50. By definition, a score above zero denotes a possible PEST region; a value greater than +5 defines a high probability that there is a PEST domain.

### **Identification of potential coiled-coil domains and PEST domains in N34132**

Potential coiled-coil domains were identified in N34132 (SEQ ID NO:183) using the COILS program. Only regions scoring 0.5 or higher were considered to have potential coiled-coil domain region. The amino acid positions within N34231 scoring for potential coil-coil regions are shown below.

Table 11 coiled-coil domains predicted for N34132

Coiled-coil Region	Amino acid range	Length (aa)
1	124-147	24
2	437-451	15
3	495-526	32
4	1,723-1,749	27

5 Potential PEST domains were identified in N34132 using PESTfind, a value greater than +5 defines a high probability that there is a PEST domain. The amino acid positions within N34132 scoring for potential PEST regions are shown below.

Table 12 Potential PEST domains identified in N34132

PEST Region	Score	Amino acid range	Amino Acid Length
1	+ 4.91	54-95	42
2	+11.4	537-570	34
3	+31.08	1293-1304	12
4	+10.15	1543-1565	23
5	+ 6.17	1698-1732	35

10 **EXAMPLE 2. Chromosomal Localization of Novel Mammalian Protein Kinases**  
**Materials and Methods**

Several sources were used to find information about the chromosomal localization of each of the genes described in this patent. First, the accession number for the nucleic acid sequence was used to query the Unigene database. The site containing the Unigene search engine is: <http://www.ncbi.nlm.nih.gov/UniGene/Hs.Home.html>. Information on map position within the Unigene database is imported from several sources, including the Online Mendelian Inheritance in Man (OMIM, <http://www.ncbi.nlm.nih.gov/Omim/searchomim.html>), The Genome Database (<http://gdb.infobiogen.fr/gdb/simpleSearch.html>), and the Whitehead Institute human physical map ([http://carbon.wi.mit.edu:8000/cgi-bin/contig/sts\\_info?database=release](http://carbon.wi.mit.edu:8000/cgi-bin/contig/sts_info?database=release)). For example, searching Unigene with W56561, an EST for a MAK-like kinase, the

following information is retrieved: Chr.14, D14S65-qTEL. The location of this gene on an "ideogram" of the cytogenetic map of chromosome 14 is also provided, showing that W56561 maps to the bottom of chromosome 14, between 14q31 and 14qTel. If Unigene has not mapped the EST, then the nucleic acid for the gene of interest is used as a query  
5 against databases, such as dbsts and htgs (described at [http://www.ncbi.nlm.nih.gov/BLAST/blast\\_databases.html](http://www.ncbi.nlm.nih.gov/BLAST/blast_databases.html)) containing sequences that have been mapped already. The nucleic acid sequence is searched using BLAST-2 at NCBI (<http://www.ncbi.nlm.nih.gov/cgi-bin/BLAST/nph-newblast>) and is used to query either dbsts or htgs. In addition to the Whitehead and GDB sites mentioned above,  
10 Stanford University maintains a useful site for chromosomal mapping from STS data (<http://www-shgc.stanford.edu/RH/rhserverformnew.html>). Matches in htgs are often resolved immediately because the genomic region hit is annotated in the htgs entry. If an exact match match is found (defined roughly as 99% identity over a region of about 100 base pairs or longer, excluding any repetitive sequence), then the mapped position of the  
15 entry in the database is assigned to the original kinase query. Once a cytogenetic region has been identified by one of these approaches, disease association is established by searching OMIM (see above for URL) with the cytogenetic location. OMIM maintains a searchable catalog of cytogenetic map locations organized by disease. A thorough search of available literature for the cytogenetic region is also made using Medline  
20 (<http://www.ncbi.nlm.nih.gov/PubMed/medline.html>). References for association of the mapped sites with chromosomal abnormalities found in human cancer can be found in: Knuutila, *et al.*, Am J Pathol, 1998, 152:1107-1123.

### Results

25 The chromosomal location for 37 of the 110 novel protein kinases is shown on Table 1. Three of the novel protein kinases were mapped to regions associated with cancer amplicons, as shown on this table. The regions were also cross-checked with the Mendelian Inheritance in Man database, which tracks genetic information for many human diseases, including cancer. References for association of the mapped sites with  
30 chromosomal abnormalities found in human cancer can be found in: Knuutila, *et al.*, Am J Pathol, 1998, 152:1107-1123. Association of these mapped regions with other diseases is

documented in the Online Mendelian Inheritance in Man (OMIM)  
(<http://www.ncbi.nlm.nih.gov/htbin-post/Omim>).

### EXAMPLE 3: Generation of Specific Immunoreagents

5

#### Materials and Methods

Peptide sequences to extra-catalytic regions of novel kinases are chosen which are not homologous to other known kinases based on a Smith Waterman homology search against the non-redundant protein database and predicted to be antigenic based on the DNASTar Protean program. These peptides are conjugated to KLH using Glutaraldehyde.

10

Rabbits are immunized with the KLH-peptide conjugates by four injections three weeks apart. The rabbits are bled ten and fourteen days following the third injection and bled out ten days after the fourth. The serum is checked against the peptide by ELISA.

Table 13. Peptides to be used as immunogens for raising antibodies

Clone Name	SEQ ID NO (aa)	Peptide Sequence	Amino Location
AA8256850	124	KSRDNSRDSSQSEND	339-353
		TEKLKRSQDLPRELP	372-386
		RGWRPYDIHS	223-232
5R79-46-1	126	FEGPRRNKEVMYK	224-236
		KDDYNETVHKKTE	451-463
		GTHPKDRNVEKLQ	541-553
		EVSKYQEYTNELQET	643-657
AA256100	129	IDDTSNFDDFPESDI	405-419
		TEPDYKSKDWVFL	427-439
		EEKKLRRSQHARKET	61-75
AA210825	130	SNKDTLRKRHYWRLD	507-521
		RHTTRKSSTTLRE	488-500
		FQNNTNRYYYKEIPL	528-542
		GKHRKTGRDVAVK	668-680
		FPTKQESQLRNE	687-698

AA316804	132	ESHVHQEPSKRIPS	239-252
		HTKRKSSTMVKEGW	409-422
		PSDLDVERDEEAVK	375-388
		SPGQGKDHKDLSTSI	543-557
R47805	143	EPVGRWDQDYDRAVL	44-58
		KPKGPGGKRGHKRLI	325-339
		PTDVAQLPSRVPRDA	219-233
AA234451	167	DPFDWEKTGNDGSLT	293-307
		HPRPQEKDVWEE	374-385
		RENTDEVFPDEQLSD	340-354
		RSEITQPDRDIPLVR	427-441
AA460132	180	LKSYSTSSKKARPVL	222-236
		KKLDEVRLRGRKRS	237-251
		ETEKTAQGLSNLAKT	131-145
N34132	183	SGRRRRPTKSKGSKS	1848-1862
		PGTAPSKPPLTKAPV	1474-1488
		VDSDTQPKAPGIDD	1365-1378
		AHSLDKTSHSSTTGL	1253-1267
5R69-17-2	187	GTTREKTDRVKST	178-190
		HSEAPELHGKIRSSN	138-152
		DETVTPPQFSIV	87-98
		QYDVKSEIYS	204-213
AA278842	206	TVDPEKSVRDQAFKA	515-529
		DSSTADRWDDEDWGS	637-651
		SVSEDPTQLEEVEKD	539-553
AA836348	232	NAPTKRPRSSTVTEA	323-337
		LDSEEDYYTPQKVDV	514-528
		GDKASYRQPKHVEKL	409-423

EXAMPLE 4. Expression analysis of Novel Mammalian Protein KinasesGENE EXPRESSION ANALYSIS

## Tissue Arrays

5 "cDNA libraries" derived from a variety of sources were immobilized onto nylon membranes and probed with <sup>32</sup>P-labeled cDNA fragments derived from the gene(s) of interest.

Total RNA or mRNA was used as template in a reverse transcription reaction to generate single-stranded cDNAs (ss cDNA) that were tagged with specific sequences at each end. An oligo dT primer containing a specific sequence (CDS:  
10 AAGCAGTGGTAACAACGCAGAGTACT30VN (V=A,G,C N=A,G,C,T)) anneals at the polyA track at the 3' end of the mRNA and the reverse transcriptase (MMLV RnaseH-) transcribes the antisense strand until it reaches the end of the RNA strand when it adds additional C residues. If a primer (SMII:  
AAGCAGTGGTAACAACGCAGAGTACGCGGG or ML2G:  
15 AAGTGGCAACAGAGATAACGCGTACGCGGG) ending with 3 Gs is added, it anneals to the added Cs and the MMLV recognizes the rest of the primer sequence as template and continues transcription. As a result, the synthesized cDNAs contain specific sequence tags at both the 5' and the 3' end. When the 5' and the 3' ends are tagged with the same sequence (CDS and SMII) it is referred to as "symmetric." When the 5' end is tagged  
20 with a different sequence than the 3' end (CDS and ML2G) is referred to as "asymmetric" A double-stranded "cDNA library" is then generated by PCR amplification using the 3'PCR and ML2 primers (3' PCR: AAGCAGTGGTAACAACGCAGAGT and ML2: AAGTGGCAACAGAGATAACGCGT) that anneal to the added sequence tags.

The amplified "cDNA libraries" were manually arrayed onto nylon membranes  
25 with a 384 pin replicator. The DNA was denatured by alkali treatment, neutralized and cross-linked by UV light. The arrays were pre-hybridized with Express Hyb (Clontech) and hybridized with <sup>32</sup>P labeled probes generated by random hexamer priming of cDNA fragments corresponding to the genes of interest. After washing, the blots were exposed to phosphorimaging cassettes and the intensity of the signal was quantified. The amount of  
30 the DNA on the arrays was also quantified by treating non-denatured or denatured arrays with Syber Green I or Syber Green II respectively (1:100,000 in 50mM Tris, pH8.0) for 2 minutes. After washing with 50mM Tris, pH8.0, the fluorescent emission was detected

with a phosphorimager (Molecular Dynamics) and quantified. The amount of the arrayed DNA was used to normalize the hybridization signal and the corrected values are tabulated in Table 3.

## 5     Results

The results of the microarray expression analysis of the protein kinases presented in this application is shown in Table 3. Data presentation from left to right is as follows: "Tissue": tissue type of the cDNA; "Tumor sym", indicates that the tissue is derived from a tumor, "sym" refers to the fact that the 5' and 3' primers used to make the sample are the same; "Normal Sym", indicates normal tissue was used to make the sample, with symmetric primers as described above; "Tumor 1o", indicates that primary tumor tissue was used to make the cDNA; "Tumor cells", indicates that these cDNA samples were made from cultured tumor cells; "Normal", indicates that these samples are derived from normal tissue or cell lines; "Endos", indicates that these samples are derived from endothelium-related tissue sources; "p53" refers to the status, mutant or wild-type, of the p53 gene in the source samples. Normalized expression values are presented for each gene referred to by its SEQ ID# on the subsequent columns. Genes represented in expression Table 3 are: SEQ ID NO:3 (AA826850), SEQ ID NO:5 (TBK1), SEQ ID NO:6 (AA305176), SEQ ID NO:8 (AA256100), SEQ ID NO:9 (CAB43292), SEQ ID NO:11 (EPK2), SEQ ID NO:12 (PKNbeta), SEQ ID NO:14 (H19102), SEQ ID NO:16 (RSK4), SEQ ID NO:17 (AAD30182), SEQ ID NO:20 (SGK2), SEQ ID NO:22 (PTK9L), SEQ ID NO:26 (AA383293), SEQ ID NO:29 (DRAK2), SEQ ID NO:31 (DRAK1), SEQ ID NO:032 (AA015726), SEQ ID NO:40 (MAK-V), SEQ ID NO:044 (TRAD), SEQ ID NO:044 (TRAD), SEQ ID NO:45 (AA454060), SEQ ID NO:47 (AA234451), SEQ ID NO:48 (AA436054), SEQ ID NO:49 (AA626859), SEQ ID NO:51 (KIAA0904), SEQ ID NO:52 (AA789239), SEQ ID NO:54 (CCRK), SEQ ID NO:55 (CLK4), SEQ ID NO:56 (AA557536), SEQ ID NO:57 (W56561), SEQ ID NO:60 (AA579641), SEQ ID NO:63 (NEK7), SEQ ID NO:66 (CAMKKB), SEQ ID NO:68 (HIPK2), SEQ ID NO:72 (R19609), SEQ ID NO:73 (HRI), SEQ ID NO:78 (AA088547), SEQ ID NO:79 (AA449542), SEQ ID NO:082a (MLK4), SEQ ID NO:82 (MLK4b), SEQ ID NO:84 (RIP4), SEQ ID NO:88 (AA278842), SEQ ID NO:89 (AA195964), SEQ ID NO:90 (MSSK1), SEQ ID NO:93 (TSK4), SEQ ID NO:94 (AI025291), SEQ ID NO:95

(AA948538), SEQ ID NO:96 (AA905446), SEQ ID NO:97 (H85389), SEQ ID NO:100 (AA018361), SEQ ID NO:101 (AA311714), SEQ ID NO:110 (AA452647), SEQ ID NO:111 (AA310219), SEQ ID NO:112 (AI086865), SEQ ID NO:114 (MEKK6), and SEQ ID NO:116 (SuRTK106).

5

EXAMPLE 5. Kinase assays for Erk, JNK1 and p38 MAP kinases

293T cells were transiently transfected with HA- p38 or co-transfected with Flag-tagged wt MLK4A, kinase-dead MLK4A, wild-type MLK4B or kinase-dead MLK4B using Lipofectamine 2000 (Lifetech). Cells were lysed 36 hr post-transfection. Cell lysates normalized to contain equivalent amounts of HA-p38 were immunoprecipitated with anti-HA antibody (Mab HA-11, Babco). Immunoprecipitates were split in two portions, one portion was Western-blotted with anti- HA antibody and the other with a phospho-specific p38 antibody (Promega) to detect activated levels of p38. Activation of Erk1 and Jnk1 was measured similarly. (This example applies to AA232253 (SEQ ID NO:82, SEQ ID NO:201).)

15

Results:

In transient assays wild-type MLK4A and MLK4B (but not kinase-inactive MLK4A(K45M) or MLK4B(K45M)) activate Erk, JNK1 and p38 MAP kinases.

20 EXAMPLE 6. RAC1 guanine-exchange factor assay

293T cells were transiently transfected with HA-Rac1 or co-transfected with Flag-tagged Duet C, Duet E, Dbl and HA-Tiam-1. Cells were lysed 36 hour post-transfection. Cell lysates normalized to contain equivalent amounts of Rac1 were affinity precipitated with immobilized GST-PBD (p21-binding domain of Pak3). Bound proteins were Western blotted and probed with anti-HA antibody to detect levels of activated Rac1. ((This example applies to R199772 (Trad/Duet)(SEQ ID NO:44, SEQ ID NO:164).)

25

Results:

Duet C and Duet E both act as guanine nucleotide exchange factors on Rac1.

### CONCLUSION

One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The molecular complexes and the methods, procedures, treatments, molecules, specific compounds described herein are presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention are defined by the scope of the claims.

It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains.

The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of" and "consisting of" may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed.

In particular, although some formulations described herein have been identified by the excipients added to the formulations, the invention is meant to also cover the final formulation formed by the combination of these excipients. Specifically, the invention includes formulations in which one to all of the added excipients undergo a reaction during formulation and are no longer present in the final formulation, or are present in modified forms.

In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush

group. For example, if X is described as selected from the group consisting of bromine, chlorine, and iodine, claims for X being bromine and claims for X being bromine and chlorine are fully described.

Other embodiments are within the following claims.

What is claimed is:

CLAIMS

1. An isolated, enriched, or purified nucleic acid molecule encoding a kinase polypeptide selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ  
5 ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ  
ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ  
ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ  
ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ  
ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ  
10 ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ  
ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ  
ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ  
ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ  
ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ  
15 ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ  
ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ  
ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ  
ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ  
ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ  
20 ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ  
ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ  
ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ  
ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ  
ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ  
25 ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ  
ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ  
ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ  
ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242.

2. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises a nucleotide sequence that:

- (a) encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242;
- (b) is the complement of the nucleotide sequence of (a);
- (c) hybridizes under highly stringent conditions to the nucleotide molecule of (a) and encodes a naturally occurring kinase polypeptide;

- (d) encodes a kinase polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, except that it lacks one or more, but not all, of a domain selected from the group consisting of an N-terminal domain, a catalytic domain, a C-terminal domain, a coiled-coil structure region, a proline-rich region, a spacer region, an insert, and a C-terminal tail;
- (e) is the complement of the nucleotide sequence of (d);

- (f) encodes a domain of an amino acid sequence selected from the group set forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, wherein said domain is selected from the group consisting of an N-terminal domain, a catalytic domain, a C-terminal domain, a coiled-coil structure region, a proline-rich region, a spacer region, an insert, and a C-terminal tail;
- (g) is the complement of the nucleotide sequence of (f);
- (h) encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID

NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID  
 NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID  
 NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID  
 NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID  
 5 NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID  
 NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID  
 NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID  
 NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID  
 NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID  
 10 NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID  
 NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID  
 NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID  
 NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID  
 NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID  
 15 NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID  
 NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID  
 NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID  
 NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID  
 NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID  
 20 NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID  
 NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID  
 NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID  
 NO:240, SEQ ID NO:241, and SEQ ID NO:242, except that it lacks one or more, but not  
 all, of the domains selected from the group consisting of an N-terminal domain, a catalytic  
 25 domain, a C-terminal domain, a spacer region, a proline-rich region, a coiled-coil structure  
 region, and a C-terminal tail; or

(i) is the complement of the nucleotide sequence of (h).

3. The nucleic acid molecule of claim 1, further comprising a vector or promoter effective to initiate transcription in a host cell.

4. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is isolated, enriched, or purified from a mammal.

5. The nucleic acid molecule of claim 4, wherein said mammal is a human.

6. A nucleic acid probe for the detection of nucleic acid encoding a kinase polypeptide in a sample, wherein said polypeptide is selected from the group consisting of

5 SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146,

10 SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242.

15

20

25

30

7. The probe of claim 6, wherein said polypeptide is a fragment of the protein encoded by an amino acid sequence selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242.

8. A recombinant cell comprising a nucleic acid molecule encoding a kinase polypeptide selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242.

9. The cell of claim 8, wherein said polypeptide is a fragment of a protein encoded by an amino acid sequence selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242.

10. An isolated, enriched, or purified kinase polypeptide selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242.

11. The polypeptide of claim 10, wherein said polypeptide is a fragment of the protein encoded by an amino acid sequence selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242.

12. The polypeptide of claim 10, wherein said polypeptide comprises:

(a) an amino acid sequence selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ

5 ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ  
ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ  
ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ  
ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ  
10 ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ  
ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ  
ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ  
ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ  
ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ  
15 ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ  
ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ  
ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ  
ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ  
ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ  
20 ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ  
ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ  
ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ  
ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ  
ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ  
ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ  
ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and  
SEQ ID NO:242;

(b) an amino acid sequence selected from the group consisting of SEQ  
ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ  
25 ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ  
ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ  
ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ  
ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ  
ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ  
30 ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ  
ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ  
ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ

5 ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ  
ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ  
ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ  
ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ  
10 ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ  
ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ  
ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ  
ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ  
ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ  
15 ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ  
ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ  
ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ  
ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ  
ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ  
20 ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and  
SEQ ID NO:242, except that it lacks one or more, but not all of the domains selected from  
the group consisting of an N-terminal domain, a catalytic domain, a C-terminal domain, a  
spacer region, a proline-rich region, a coiled-coil structure region, and a C-terminal tail  
(c) a domain of an amino acid sequence selected from the group set  
25 forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID  
NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID  
NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID  
NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID  
NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID  
30 NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID  
NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID  
NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID  
NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165. SEQ ID  
NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID  
NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID  
NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID  
NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID

NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242 wherein said domain is selected from the group consisting of a C-terminal domain, a catalytic domain, an N-terminal domain, a spacer region, a proline-rich region, a coiled-coil structure region, and a C-terminal tail.

13. The kinase polypeptide of claim 10, wherein said polypeptide is isolated, purified, or enriched from a mammal.

14. The kinase polypeptide of claim 13, wherein said mammal is a human.

15. The kinase polypeptide of claim 10, wherein said polypeptide is a AA144574, AA116841, AA256100, AA305176, AA210825, AA316804, AA980090, N42050, AA476563, AA626690, AA960957, H19102, AA045601, AA107515, AA109508 or AA887783 polypeptide.

16. The kinase polypeptide of claim 10, wherein said polypeptide is a H60215, AA197883, AA297313, W30246, AA172300, AA383293, AA542015, H01248, N23936, W44160, 2R22-5-11, 5R72-18-1, AA021445, AA207220, AA426580, AA544838, W90839, 5R79-54-1, AA839940, R19772 or 5R72-8-2 polypeptide.

17. The kinase polypeptide of claim 10, wherein said polypeptide is a AA234451 polypeptide.

18. The kinase polypeptide of claim 10, wherein said polypeptide is a 5R65-16-1, AA061797, AA065538, AA124976, AA397553, AA435956, AA575635, AA626859, AA789239, AI086865, H17727, H29974, AA557536 or N28606 polypeptide.

19. The kinase polypeptide of claim 10, wherein said polypeptide is a AA631990 or W08549 polypeptide.

20. The kinase polypeptide of claim 10, wherein said polypeptide is a 5R72-16-2, R19927 or R43524 polypeptide.

21. The kinase polypeptide of claim 10, wherein said polypeptide is a 5R57-10-2 polypeptide.

5 22. The kinase polypeptide of claim 10, wherein said polypeptide is a AA232253 polypeptide.

23. The kinase polypeptide of claim 10, wherein said polypeptide is a AA430250, AA836348, R86668 or N34132 polypeptide.

10 24. The kinase polypeptide of claim 10, wherein said polypeptide is a AA098024 or SuRTK106 polypeptide.

25. The kinase polypeptide of claim 10, wherein said polypeptide is a R47805, AA099102, AA589241, H85811, AA013524, AA452647, AA840598, AA088547, AA139478, AA826850, R87679, W65887, H97685, W20810, AA599286, AA425725, AA103218, AA711829, AA060026, AA399669, AA758539, AA883975, AA948538, 15 AA018361, AA215311, AA311714, AA498104, 5R69-17-2, 5R69-23-3, 5R69-26-2, AA118352, AA396601, AA671275, AA278842, AA460132 or H05721 polypeptide.

26. An antibody or antibody fragment having specific binding affinity to a kinase polypeptide selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242.

27. The antibody or antibody fragment of claim 26, wherein said polypeptide comprises:

(a) an amino acid sequence selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ

5 ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ  
ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ  
ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ  
ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ  
10 ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ  
ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165. SEQ ID NO:166, SEQ  
ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ  
ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ  
ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ  
15 ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ  
ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ  
ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ  
ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ  
ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ  
20 ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ  
ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ  
ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ  
ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ  
ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ  
ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ  
ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and  
SEQ ID NO:242;

(b) an amino acid sequence selected from the group consisting of SEQ  
ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ  
25 ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ  
ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ  
ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ  
ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ  
ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ  
30 ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ  
ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ  
ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165. SEQ ID NO:166, SEQ

5 ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ  
ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ  
ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ  
ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ  
ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ  
ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ  
ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ  
ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ  
ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ  
10 ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ  
ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ  
ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ  
ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ  
ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ  
15 ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and  
SEQ ID NO:242, except that it lacks one or more, but not all, of the domains selected from  
the group consisting of a C-terminal domain, a catalytic domain, an N-terminal domain, a  
spacer region, a proline-rich region, a coiled-coil structure region, and a C-terminal tail.

(c) a domain of an amino acid sequence selected from the group set  
20 forth in SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID  
NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID  
NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID  
NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID  
NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID  
25 NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID  
NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID  
NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID  
NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID  
NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID  
30 NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID  
NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID  
NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID

NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID  
NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID  
NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID  
NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID  
5 NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID  
NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID  
NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID  
NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID  
NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID  
10 NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID  
NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID  
NO:241, and SEQ ID NO:242 wherein said domain is selected from the group consisting  
of a C-terminal domain, a catalytic domain, an N-terminal domain, a spacer region, a  
proline-rich region, a coiled-coil structure region, and a C-terminal tail.

28. A hybridoma which produces an antibody having specific binding affinity to a kinase polypeptide selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242.

29. A method for identifying a substance that modulates kinase activity comprising:

(a) contacting a kinase polypeptide selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136,

SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141,  
 SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146,  
 SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151,  
 SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156,  
 5 SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161,  
 SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166,  
 SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171,  
 SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176,  
 SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181,  
 10 SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186,  
 SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191,  
 SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196,  
 SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201,  
 SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206,  
 15 SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211,  
 SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216,  
 SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221,  
 SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226,  
 SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231,  
 20 SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236,  
 SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241,  
 and SEQ ID NO:242 with a test substance;

- (b) measuring the activity of said polypeptide; and
  - (c) determining whether said substance modulates the activity of said
- 25 polypeptide.

30. A method for identifying a substance that modulates kinase activity in a cell comprising:

- (a) expressing a kinase polypeptide in a cell, wherein said polypeptide is selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID
- 30

NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID  
NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID  
NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID  
NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID  
5 NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID  
NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID  
NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID  
NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID  
NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID  
10 NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID  
NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID  
NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID  
NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID  
NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID  
15 NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID  
NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID  
NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID  
NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID  
NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID  
20 NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID  
NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242;

- (b) adding a test substance to said cell; and
- (c) monitoring a change in cell phenotype or the interaction between  
said polypeptide and a natural binding partner.

31. A method for treating a disease or disorder by administering to a patient in need of such treatment a substance that modulates the activity of a kinase selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242.

32. The method of claim 31, wherein said disease or disorder is selected from the group consisting of immune-related diseases and disorders, cardiovascular disease, neurodegenerative disorders, and cancer.

33. The method of claim 31, wherein said substance modulates kinase activity *in vitro*.

34. The method of claim 33, wherein said substance is a kinase inhibitor.

35. A method for detection of a kinase polypeptide in a sample as a diagnostic tool for a disease or disorder, wherein said method comprises:

- (a) contacting said sample with a nucleic acid probe which hybridizes
- 5 under hybridization assay conditions to a nucleic acid target region of a kinase polypeptide selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139,
- 10 SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164,
- 15 SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189,
- 20 SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214,
- 25 SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239,
- 30 SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, said probe comprising the nucleic acid sequence encoding said polypeptide, fragments thereof, or the complements of said sequences and fragments; and

(b) detecting the presence or amount of the probe:target region hybrid as an indication of said disease.

36. The method of claim 35, wherein said disease or disorder is selected from the group consisting of immune-related diseases and disorders, cardiovascular disease, neurodegenerative disorders, and cancer.

37. A method for detection of a kinase polypeptide in a sample as a diagnostic tool for a disease or disorder, wherein said method comprises:

(a) comparing a nucleic acid target region encoding said kinase polypeptide in a sample, wherein said kinase polypeptide is selected from the group consisting of SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:199, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ

ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, and SEQ ID NO:242, or one or more fragments thereof, with a control nucleic acid target region encoding said kinase polypeptide, or one or more fragments thereof; and

- 5 (b) detecting differences in sequence or amount between said target region and said control target region, as an indication of said disease or disorder.

38. The method of claim 37, wherein said disease or disorder is selected from the group consisting of immune-related diseases and disorders, cardiovascular disease, neurodegenerative disorders, and cancer.

Table 1

[illegible]

Table 1 (cont'd)

Table 2

Patent	Seq	Patent	Family	Group	nrna	Length	ID	%	%	Similar	Match	ACC#	Description	Kinase Domain(s)	Kinase Domain(s)	Profile start	Profile end
SP 122	122	AGC	GRK	GRK	2.7e-314	888	887	100	100	100	100	CAB55657.1	BAR2 [Homo sapiens]	161	453	1	281
M 2	123	AGC	GRK	GRK	1.30E-180	378	371	98	98	98	98	NP 037029.1	Adrenoreceptor kinase, beta 2 (G-protein-linked receptor k)	3	143	121	261
H 3	124	AGC	GRK	GRK	5.80E-108	419	262	71	86	86	86	CAB76471.1	Serine/threonine protein kinase [Homo sapiens]	26	286	1	281
H 4	125	AGC	GRK	GRK	1.40E-137	414	262	100	100	100	100	CAB76471.1	Serine/threonine protein kinase [Homo sapiens]	23	283	1	281
H 5	126	AGC	GRK	GRK	0	729	729	100	100	100	100	NP 037388.1	TANK-binding kinase 1 [Homo sapiens]	9	304	1	261
H 6	127	AGC	NDR	NDR	1.20E-09	329	73	48	68	68	68	BAAT76817.1	KIAA0973 protein [Homo sapiens]	35	310	1	261
M 7	128	AGC	NDR	NDR	1.30E-19	88	42	49	71	71	71	AAF55594.1	GGT719 gene product [Drosophila melanogaster]	24	44	242	281
H 8	129	AGC	NDR	NDR	6.10E-181	484	483	100	100	100	100	BAAT76808.1	KIAA0965 protein [Homo sapiens]	80	383	1	261
H 9	130	AGC	PKC	PKC	8.80E-160	678	615	67	80	80	80	NP 002733.1	Protein kinase C, nu [Homo sapiens]	651	907	1	281
H 10	131	AGC	PKC	PKC	1.10E-10	105	42	42	57	57	57	P05127	Protein kinase C, nu [Homo sapiens]	19	24	256	261
H 11	132	AGC	PKC	PKC	0	890	890	100	100	100	100	NP 005804.1	Protein kinase C, nu [Homo sapiens]	578	832	1	261
H 12	133	AGC	PKC	PKC	9.4e-319	889	889	100	100	100	100	NP 037487.1	PKNbeta [Homo sapiens]	559	818	1	261
M 13	134	AGC	PKC	PKC	1.20E-108	205	204	100	100	100	100	JG7083	Protein kinase N beta [Homo sapiens]	1	134	126	261
H 14	135	AGC	PKC	PKC	3.80E-12	384	94	36	55	55	55	AA02495.1	Ribosomal protein S8 kinase 3 [Homo sapiens]	81	333	1	261
H 15	136	AGC	PKC	PKC	2.90E-257	489	489	100	100	100	100	NP 036558.1	Ribosomal protein S8 kinase, 52KD, polypeptide 1 [Homo sapiens]	225	459	1	261
H 16	137	AGC	PKC	PKC	7.00E-178	745	745	100	100	100	100	NP 055311.1	Ribosomal protein S8 kinase, 90KD, polypeptide 2 [Homo sapiens]	73 & 428	330 & 883	1	261
H 17	138	AGC	PKC	PKC	9.80E-222	549	549	100	100	100	100	AA030182.1	Unknown [Homo sapiens]	153	539	1	261
H 18	139	AGC	PKC	PKC	9.20E-103	431	430	100	100	100	100	AD04109.1	SGK [Homo sapiens]	98	355	1	261
M 19	140	AGC	PKC	PKC	2.90E-157	430	426	98	99	99	99	NP 035491.1	Serum/glucocorticoid regulated kinase [Mus musculus]	88	354	1	261
M 20	141	AGC	PKC	PKC	2.00E-76	244	244	100	100	100	100	AAF12757.2	Protein kinase [Homo sapiens]	1	189	24	261
H 21	142	AGC	PKC	PKC	4.10E-211	448	375	88	88	88	88	AAF27051.1	SGK-like protein SGK [Homo sapiens]	162	389	1	261
H 22	143	AGC	PKC	PKC	5.80E-216	348	349	100	100	100	100	NP 009215.1	Protein tyrosine kinase 6-like (AS-related protein) [Homo sapiens]	10	17	253	261
H 23	144	AGC	PKC	PKC	1.40E-19	440	38	61	61	61	61	CA04119.1	Phosphoprotein [Homo sapiens]	40	333	1	261
M 24	145	CAMK	CAMK	CAMK	1.50E-165	699	466	65	77	77	77	O15075	DCAMK1 [DOUBLECORTIN-LIKE AND CAM KINASE-LIKE 1]	388	625	1	261
M 25	146	CAMK	CAMK	CAMK	1.80E-62	267	199	67	83	83	83	AAF28675.1	CPG16 [Mus musculus]	59	297	1	261
H 26	147	CAMK	CAMK	CAMK	2.80E-48	708	181	44	60	60	60	O15075	DCAMK1 [DOUBLECORTIN-LIKE AND CAM KINASE-LIKE 1]	415	673	1	261
M 28	148	CAMK	CAMK	CAMK	2.80E-31	806	147	55	73	73	73	AAF28675.1	CPG16 [Mus musculus]	514	771	1	261
H 29	149	CAMK	CAMK	CAMK	3.10E-121	372	372	100	100	100	100	NP 004217.1	Death-associated protein kinase-related 2	33	293	1	261
M 30	150	CAMK	CAMK	CAMK	7.90E-93	372	340	91	95	95	95	NP 004217.1	Death-associated protein kinase-related 2	32	283	1	261
H 31	151	CAMK	CAMK	CAMK	1.20E-113	414	414	100	100	100	100	NP 004761.1	Death-associated protein kinase-related 1	61	321	1	261
H 32	152	CAMK	CAMK	CAMK	5.90E-185	1311	1053	80	80	80	80	BAAT76843.1	KIAA0998 protein [Homo sapiens]	8	258	1	261
H 33	153	CAMK	CAMK	CAMK	1.20E-48	436	153	51	70	70	70	T22427	Hypothetical protein F49C5.4 - [Caenorhabditis elegans]	74	325	1	261
H 34	154	CAMK	CAMK	CAMK	1.40E-32	436	122	46	65	65	65	AAG15093.1	Cdc25C associated protein kinase C-TAK1 [Homo sapiens]	56	307	1	261
M 35	155	CAMK	CAMK	CAMK	1.30E-184	729	728	100	100	100	100	AAC15083.1	Cdc25C associated protein kinase C-TAK1 [Homo sapiens]	58	340	1	261
M 36	156	CAMK	CAMK	CAMK	3.50E-126	462	462	100	100	100	100	R31237	partial CDS [Homo sapiens]	999	1258	1	261
M 37	157	CAMK	CAMK	CAMK	0	1330	1235	100	100	100	100	BAAT76843.1	KIAA0135 gene is related to p1m-1 oncogene, [Homo sapiens]	1	158	23	261
M 38	158	CAMK	CAMK	CAMK	5.10E-59	230	183	79	85	85	85	BAAT76843.1	KIAA0135 gene is related to p1m-1 oncogene, [Homo sapiens]	20	271	1	261
H 39	159	CAMK	CAMK	CAMK	3.00E-111	928	638	100	100	100	100	BAAT76843.1	KIAA0135 gene is related to p1m-1 oncogene, [Homo sapiens]	53	304	1	261
H 40	160	CAMK	CAMK	CAMK	7.30E-80	628	397	57	69	69	69	BAAT76843.1	KIAA0135 gene is related to p1m-1 oncogene, [Homo sapiens]	61	321	1	261
H 41	161	CAMK	CAMK	CAMK	1.40E-244	714	714	100	100	100	100	NP 055401.1	Homomally upregulated neu tumor-associated kinase [Homo sapiens]	81	320	1	261
H 42	162	CAMK	CAMK	CAMK	8.20E-76	874	211	63	80	80	80	AAAT3168.1	Skeletal muscle myosin light chain kinase [Gallus gallus]	570	825	1	261
M 43	163	CAMK	CAMK	CAMK	0	2288	2227	100	100	100	100	BAAT76843.1	KIAA1297 protein [Homo sapiens]	620 & 1086	873 & 1356	1	261
M 44	164	CAMK	CAMK	CAMK	7.80E-37	127	67	99	99	99	99	BAAT76843.1	KIAA1297 protein [Homo sapiens]	3	78	186	261
H 45	165	CAMK	CAMK	CAMK	5.00E-20	514	114	41	63	63	63	NP 008895.1	STK with Dbl- and pleckstrin homology domains [Homo sapiens]	995	1239	1	261
H 46	166	CAMK	CAMK	CAMK	3.30E-68	508	181	53	65	65	65	P25323	MLCK [Drosophila melanogaster]	116	381	1	261
H 47	167	CAMK	CAMK	CAMK	8.60E-98	478	188	57	68	68	68	AAF59340.1	CG11533 gene product [Drosophila melanogaster]	34	313	1	261
H 48	168	CAMK	CAMK	CAMK	9.60E-39	266	138	62	78	78	78	NP 036527.1	PFTAIR protein kinase 1 [Homo sapiens]	21	471	1	261
H 49	169	CAMK	CAMK	CAMK	7.10E-48	247	146	59	75	75	75	NP 004187.1	Cyclin-dependent kinase-like 1 (CDC2-related kinase) [Homo sapiens]	1	181	23	261

## FIGURE 1F

MLVEEMETATELFLVMELVKGGDLFDAITSSTKYTERDGSAMVYNLANALRYLHGLSIVH  
RDIKPENLLVCEYPDGTSLKLGDFGLATVVEGPLYTVCGTPTYVAPXIIAETGYGLKVD  
IWAAGVITYILLCGFPFRSENNLQEDLFDQILAGKLEFPAPYWDNITDSAKELISQMLQ  
VNVEARCTAGQILSHPWVSDDASQENMQAEVTGKLGKQHFNNALPKQNSTTTGVSIVMVS  
GRRQVWPDCGAGLEVFEGLSRELPSHGSWCLP

SEQ ID NO: 146\_W30246\_M SGK324\_M

TKSSSSSPTSPGSFRGLKISAQGRSSSNVNGGPELDRCLSPGVNGNRCSESFPLLEKYR  
IGKVIDGDNFAVVKECDRYTGKEFALKIIDKAKCCGKEHLIENEVSILRRVKHPNII ML  
VEEMETATDLFLVMELVKGGDLFDAITSSTKYTERDGSAMVYNLANALRYLHLSIVHRD  
IKPENLLVCEYPDGTSLKLGDFGLATVVEGPLYTVCGTPTYVAPEIIAETGYGLKVDVW  
AAGVITYILLCGFPFRSENNLQEDLFDQILAGKLEFPAPYWDNITDPCVCFRKCL

SEQ ID NO: 147\_AA383293\_H

PAAKRVVYRNGDPFFPGSQLVVTQRRFPTMEAFLEVTSAVQAPLAVRALYTPCHGHPV  
TNLADLKNRGQYVAAGFERFHKLPYQAFCLSVFRNGDLVSPFSLKLSQAASQDWETVL  
KLLTEKVKLQSGAVRLCTLEGLPLSAGKELVTGHYYVAVGEDEFKDLPPALSTRGLLAA  
GNEAHLRSGVGTVAGSPKPLGRKAKKETCLIVTLTLKYQQSETSRDGQSFPSPGVIGVYGA  
PHRRKETAGALEVADDEDQTTEEPLDQRAAQIVEQVTCLODFGDDDFIACGPEKFRYA  
QDDFVLDHSRRRLREHQAGFEKLRRTRGEEKEAEKEKKPCMSGGRMTLRDDQPAKLEK  
EPKTRPEENKPERPSGRKPRPMGIIAANVEKHYETGRVIGDGNFAVVKECRHRETRQAYA  
MKIIDKSRLKGKEDMVDSEILIIQSLSHPNIVKLHEVYETDMEIYLILEYVQGGDLFDAI  
IESVKFPEPDAAIMIMDLCKALVHMHDKSI VHRDLKPENLLVQRNEDKSTTLKLADFGLA  
KHVVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPFRSPXXGDQDE  
LFNIIQLGHFEFLPPYWDNISDAKDLSRLLVVDPPKKRYTAHQVLQHPWIETAGKTNTV  
KRQKQVSPSSDGHFRSQHKRVVEQVS

SEQ ID NO: 148\_AA197883\_M

MPTAPVLRPPPPATPAPPAPSRPAPPPIPGHRGPCDHSLKCLSSKISERKLPGPWLPAGR  
GPLEKPVLGPRGAVMPLFSPQSSLSHVSRAEHSPLKPRVTVVKLGQPLRKATLLLNRRS  
VOTFEQLLSDI SEALGFPRWKNDVRKLF TLKGREVKSVSDFFREGDAFIAMGKEPLTLK  
SIQLAMEELYPKNRALALAPHSRVSPRLRSRLPSKLLKGSHRCGEAGSYSAEMESKAVS  
RHQOKTSTVLAPEDKARAQKWVRGKQSESEPGGPPSPGAATQEETHASGEKHLGVEIEKTS  
GEIVRCEKCKRERELQLGLQREPCPLGTSELDLGRAQKRDSEKLVRTKSCRRPSKAKFTD  
GEEGWKGDSHRGSPRDPPQEMRRPNSNSDKKEIRGSESQDSYPQAPKAQKDFVEGPPAV  
EEGPIDMRREDRHTCRSKHAAWLREQQAEPPQLPRTRGEEKQAEHEKKPGGLGERRAPE  
KESKRKLEEKRPERPSGRKPRPKGII SADVEKHYDIGGVIGDGNFATVKECRHRETRQAY  
AMKMIDKSQKKGKEDIVDSEILIIQSLSHPNIVKLHEVYETEAEIYLIMEYVQGGDLFDA  
IVENVKFPEPEAAVMITDLCKAFVHMHDKNI VHRDVKPENLLVQRNEDKSI TLKLADFG  
LAKYVVRPIFTVCGTPTYVAPEILSEKGYGLEVDMWAAGVILYILLCGFPFRSPERDQDE  
LFNIIQVQGFELSPYWDNISDAKDLSRLLVVDPPKKRYTAEQVLQHPWIEMVGHNTG  
NSQKEESPNSLGHFQSQHKKVAEQMP

SEQ ID NO: 149\_DRAK2\_H

MSRRRFDRCRSISGLLTTPQIPIKMFNNFYILTSKELGRGKFAVVVRQCISKSTGQEYA  
AKFLKKRRRGQDCRAEILHEIAVLELAKSCPRVINLHEVYENTSEIILILEYAAGGEIFS  
LCLPELAEMVSENDVIRLIKQILEGVYYLHQNINIVHLDLKPQNILLSSIYPLGDIKIVDF  
GMSRKIGHACELREIMGTPEYLAPEILNYDPITTATDMWNIGIIAYMLLTHTSPFVGEDN  
QETYLNISQVNVYDSEETFSSVSQLATDFIQSLLVKNPEKRPTAEICLSHSLWQQWDFEN

## FIGURE 2R

GTGAGTGGAAAGGCGGCAGGTCTGGCCTGACTGCGGAGCCGGCCTTGAAGTTTTTGAATTA  
GGTAGCCGGGAGCTGCCCTCACATGGAAAGTTGGTGCCTTCCGTAGTCCTATTTTCATATGA  
AGATTGGCTTGGCATGTGGAGGGCACTCATTGGGCAACTCCCAGGCTTTGGGCACTGTGT  
GGAGGGGCTTGTGTAGGGACCAGCAGGCCTGGTGTGAGGGGTCCAGGCGTCAAGGAGCTC  
CTGGCTGGGCCCTCTGGGCAGCTGCTTCCACTCTTGTCTCTGCCTTCTCATCTAGAGAGA  
CTCCCAAGCCCTGGAGGGGTGTGTTGTGTTAGGAATTAACCTCCCTGCCTACCCCAAGGCC  
TCAGAAATAGATTATTAGAGATGTGAATTATTCTTTGAGACTTGGGATAAGAAACAGCCA  
AAGCTAAACATATTTTCAGTTTTTAAAAAATCAGTGTTTTTATAAAACACAGTTTGGGGCTTT  
TAAAGGTACATAATCAAGGAAAAAATATATATTCTTTTTCAGGGTTGGTAACATTTTA  
TGAGATGTCAGTGACAACGATGGCCTTATTTTTTTTTCAGCCTTTTCTTCTTCCAAAAATGTT  
TCTTAAGGCAACTCTCCTAAATACATAAAACACAACAAATTAATAAGTGAAGTGACATGAG  
AGTAAATGAATCAAAAGGAAAAAACATTGAACCAGAGGTGAGGGCAGCACACCCCGCAGCA  
GCTGTCCAGGCCTGAGCCAATGCAACCCTGGGCGGGAAGGCCAGCTCACCGTGAGCAGGT  
AGAAGCCAGCCAGCCACCCAGGCAGGGACCTTGGTTCTCCCCACACACTCCCAGGAGCAG  
GGAACAGGGGTGGAGTGGCCTTTCCAGAGCTGGAGTTGGCTGCAGCAGCTTTTGAATCA  
GACCTGCCAAGGTGATGGGCGTCTGAGTTTTCACATCTGGGCCCCCGTGACCCCACTGAG  
TCCTGACAGCTAAGGATGGGCCACCTCCACAGCTCCGTCACTCGTACTTGGGACAGGCCT  
CTCATCCTCTGGGAAGGTCTCCTTGTCTTCTTACCCAACTAGAAGGGAACAGTGGCATA  
TTCTCATGGTACATGGTTGTCTGAAAGCCTTACCTAGGAAGACGCAGGGTCTAGATAGAA  
GCTATAAGGAAGCCACACACATAACCCACATCCCCACACCCCCAACATCCCCCACACTCC  
CCACACCCCCCACACCCCCACATCCCCACCATAATTACCCCCACCTCCAAATATCTCAT

SEQ ID NO: 25\_W30246\_M SGK324\_M

ACCAAGTCCTCCAGCTCCTCTCCAACCAGCCCGGGAAGTTTCAGAGGATTGAAGATTTCT  
GCTCAGGGCAGATCTTCTTCCAACGTAAACGGTGGGCCTGAACTTGACCGTTGCCTGAGC  
CCTGAAGGTGTGAATGGAAACCGGTGCTCCGAGTCGTTCCCCCTTCTGGAGAAATACAGA  
ATAGGGAAGGTGATCGGGGACGGCAACTTCGCGGTAGTTAAGGAGTGCCTGGACAGGTAC  
ACTGGAAAAGAGTTTGCATTAAAGATTATAGACAAAGCCAAATGCTGTGGAAAGGAGCAT  
CTGATTGAGAACGAAGTGTCAATCCTGCGCCGAGTGAAGCACCCCAACATCATCATGTTG  
GTTGAAGAGATGGAAACAGCAACTGACCTCTTTCTAGTGATGGAAGTGGTCAAAGGTGGA  
GATCTCTTTGATGCGATTACCTCTTCAACCAAGTACACTGAGAGAGATGGAAAGCGCCATG  
GTGTACAACCTAGCCAATGCCCTCCGGTACCTGCACAGCCTCAGCATCGTCCACAGGGAC  
ATCAAGCCTGAGAATCTGCTGGTGTGCGAATACCCAGATGGAACCAAGTCTTTGAAGCTG  
GGAGACTTTGGGCTGGCGACGGTGGTTGAAGGCCCGTTGTACACGGTCTGTGGCACGCCA  
ACTTATGTGGCACCAGAGATCATAGCTGAAACAGGTTATGGCCTGAAGGTGGATGTTTGG  
GCAGCTGGTGTGATTACATACATACTTCTCTGTGGATTCCCACCATTCCGGAGTGAGAAC  
AATCTCCAGGAAGATCTCTTTGACCAGATCTTGGCTGGAAAGCTGGAATTCCCAGCCCCC  
TACTGGGACAACATTACAGACTCTCCTTGTGTGTGTTTTAGGAAATGCTTATGAAGCTGG  
CCCGTGGGCTTCCCAGTGGGACGTGCAGCAGTTCTTGGCAGAGCAGGGCCAGCTCTGCTG  
TGTCATCTCCAGGGTCTCCCATCACCTCTGCTCTTTGCCATGGCAGGTCTGCTGAGACCC  
CGCGGGGACGGGGGCATGGTGTCTCCCTGATTGGCCTGTGACCAACCTTCTGGAAGGCTGC  
TGGCAGTTTTCCCTGTTTTCCACCACCCCACTCTTTTAATAATTGTATATAACTGTACT  
TGTTCTACTTGCTTGTCTTTAAACAGGGGCCCCCACAGTTCACTCTCACTGTTAGATTT  
TGCTTTTCCAGGTATCCCCAACCTGCAATAAACTCTTCCCTCTTCAG

SEQ ID NO: 26\_AA383293\_H

CCAGCAGCCAAGAGGGTAGTGGTGTACCGGAATGGGGACCCATTCTTCCCAGGCTCCCAG  
CTGGTGGTGACTCAACGCCGCTTCCCCACCATGGAGGCCTTCTCTGCGAGGTGACATCA  
GCTGTGCAGGCCCCACTGGCTGTGCGTGCCCTCTACACACCTTGTTCATGGCCACCCTGTC  
ACCAACCTGGCAGACTTGAAGAACAGAGGGCAGTATGTGGCCGCTGGATTGACGATTC

FIGURE 2S

CACAAGCTCCCCCTTACCAGGCTTTTTGTCTCAGTGTGTTTCAGGAATGGGGACCTGGTA  
AGTCCCCCATTTAGTCTGAAGCTGTCCCAGGCTGCCAGCCAGGACTGGGAACTGTGTTG  
AAGCTCCTGACTGAGAAGGTCAAGTTGCAGAGTGGGGCTGTGAGACTCTGCACCCTAGAG  
GGGCTCCCCTGTCTCAGCAGGGAAGGAGCTGGTAACTGGCCATTACTATGTGGCTGTGCGA  
GAGGATGAGTTCAAGGACCTTCCCTATCCAGCTCTGTCCACAAGAGGGCTCCTGGCAGCA  
GGCAATGAAGCCCACCTGAGGAGTGGAGTGGGGACTGTGCTGGTTCCCCCAAGCCTCTT  
GGAAGGAAGGCTAAGAAGGAGACATGCCTAATCGTGACCCTGACCCTGAAATACCAGCAG  
TCAGAAACAAGCAGAGACGGGCAATCATTCCCATCAGGAGTTATAGGAGTATATGGAGCT  
CCCCACCGAAGGAAGGAGACAGCGGGGGCCCTGGAAGTAGCAGATGATGAAGACACTCAG  
ACAGAGGAGCCCTTGGATCAGAGGGCAGCACAGATAGTGAACAGGTTACTTGTCTGCAA  
GACTTTTTTGGTGATGACGATGTTTTTATTGTCATGTGGACCAGAAAAATTCGTTATGCC  
CAAGATGACTTTGTCTGGATCATAGTCGTGACGGCTCCTGAGAGAGCACCAGGCGGGC  
TTTGAGAAGCTCCGACGACCCGAGGAGAAGAGAAGGAGGCAGAGAAGGAGAAAAAGCCA  
TGTATGTCTGGAGGCAGAAGGATGACTCTCAGAGATGACCAACCTGCAAAGCTAGAAAAG  
GAGCCCCAAGACGAGGCCAGAAGAGAACAAGCCAGAGCGGCCAGCGGTGGAAGCCACGG  
CCCATGGGCATCATTGCCGCCAATGTGGAAGCAATTATGAGACTGGCCGGGTATTGGG  
GATGGGAACCTTTGCTGTCGTGAAGGAGTGCAGACACCGCGAGACCAGGCAGGCCTATGCG  
ATGAAGATCATTGACAAGTCCAGACTCAAGGGCAAGGAGGACATGGTGGACAGTGAGATC  
TTGATCATCCAGAGCCTCTCTCACCCCAACATCGTGAAATTGCATGAAGTCTACGAAACA  
GACATGGAAATCTACCTGATCCTGGAGTACGTGCAGGGAGGAGACCTTTTTGACGCCATC  
ATAGAAAGTGTGAAGTTCCCGGAGCCCGATGCTGCCCTCATGATCATGGACTTATGCAA  
GCCCTCGTCCACATGCACGACAAGAGCATTGTCCACCGGGACCTCAAGCCGGAAAACCTT  
TTGGTTCAGCGAAATGAGGACAAATCTACTACCTTGAAATTGGCTGATTTTGGACTTGCA  
AAGCATGTGGTGAGACCTATATTTACTGTGTGTGGGACCCCAACTTACGTAGCTCCCGAA  
ATTCTTTCTGAGAAAGGTTATGGACTGGAGGTGGACATGTGGGCTGCTGGCGTGATCCTC  
TATATCCTGCTGTGTGGCTTTCCCCCATTCGCGAGCCCTGAXXGAGGGGACCAGGACGAG  
CTCTTTAACATCATCCAGCTGGGCCACTTTGAGTTCCTCCCCCTTACTGGGACAATATC  
TCTGATGCTGCTAAAGATCTGGTGAGCCGGTTGCTGGTGGTAGACCCCAAAAAGCGCTAC  
ACAGCTCATCAGGTTCTTCAGCACCCCTGGATCGAAACAGCTGGCAAGACCAATACAGTG  
AAACGACAGAAGCAGGTGTCCCCCAGCAGCGATGGTCACTTCCGGAGCCAGCACAAGAGG  
GTTGTGGAGCAGGTATCATAGTCACCACCTTGGGAATCTGTCCAGCCCCCAGTTCTGCTC  
AAGGACAGAGAAAAGGATAGAAGTTTGAGAGAAAAACAATGAAAGAGGCTTCTTCACATA  
ATTGGTGAATCAGAGGGAGAGACACTGAGTATATTTTAAAGCATATTAAAAAAATTAAGT  
CAATGTTAAATGTCACAACATATTTTTAGATTTGTATATTTAAAGCCTTTAATACATTTT  
TGGGGGGTAAGCATTGTTCATCAGTGAGGAATTTTGGTAATAATGATGTGTTTTGCTTCCC  
CTTTGTAACCAAGTTTATTCTGTACTACAGGAGTGGTGCTTACCAGGGTCTAAACTCCCC  
CTGTGAGATTAATAAGGTGCATTG

SEQ ID NO: 28\_AA197883\_M

ATGCCAACCGCGCCGGTCTGCGCCCGCCGCCGCCAGCGACCCCGCCCCGCGGCA  
CCCAGTCGCCCTGCGCCTCCCATTCGCGGCCACCGAGGCCCATGTGACCATTCTCTGAAA  
TGCTTAAGCTCGAAGATCTCTGAGAGAAAGCTGCCAGGCCCCCTGGTTACCTGCGGGACGA  
GGACCTCTGGAGAAGCCAGTTCTGGGGCCACGTGGTGCCGTCATGCCGCTGTTTCAGCCCT  
CAGAGCAGCCTCCACTCAGTCCGCGCAGAGCACAGCCCACTGAAGCCCAGGGTGGTGACG  
GTGGTGAAGCTGGGTGGGCAGCCCCCTCCGTAAGGCCACCCTGCTCCTCAACCGGCGCTCA  
GTGCAGACCTTTGAGCAGCTCCTATCAGACATCTCCGAAGCCTTGGGCTTCCACGCTGG  
AAGAACGACCGTGTGCGGAAGCTGTTACCCTCAAGGGCAGGGAGGTGAAGAGTGTGTCT  
GACTTCTTCCGGGAGGGTGATGCTTTTCATAGCTATGGGCAAAGAGCCGCTGACATTGAAG  
AGTATCCAGTTGGCCATGGAGGAGCTGTATCCTAAGAACCGGGCTTTGCCCTGGCCCCCT  
CACAGTAGAGTCCCCCTCCCAAGGCTGAGAAGCAGACTTCCCAGCAAGCTTCTGAAAGGA

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number  
**WO 00/73469 A3**

(51) International Patent Classification<sup>7</sup>: **C12N 15/54**,  
9/12, 15/11, 5/12, C07K 16/40, A61K 38/00, G01N 33/68

(74) Agent: **FOLEY & LARDNER**: Suite 500, 3000 K Street,  
N.W., Washington, D.C. 20007-8696 (US).

(21) International Application Number: PCT/US00/14842

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,  
DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,  
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL,  
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ,  
UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 26 May 2000 (26.05.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/136,503 28 May 1999 (28.05.1999) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **SUGEN,  
INC.** [US/US]; 230 East Grand Avenue, South San Fran-  
cisco, CA 94080 (US).

**Published:**

— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **PLOWMAN, Gre-  
gory, D.** [US/US]; 4 Honeysuckle Lane, San Carlos, CA  
94070 (US). **MARTINEZ, Ricardo** [US/US]; 984 Cartier  
Lane, Foster City, CA 94404 (US). **WHYTE, David**  
[US/US]; 2623 Barclay Way, Belmont, CA 94002 (US).  
**SUDERSANAM, Sucha** [US/US]; 20 Corte Patencio,  
Greenbrae, CA 94904 (US).

(88) Date of publication of the international search report:  
29 November 2001

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

WO 00/73469 A3

(54) Title: PROTEIN KINASES

(57) Abstract: The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions.

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/US 00/14842

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12N15/54 C12N9/12 C12N15/11 C12N5/12 C07K16/40  
A61K38/00 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBL, MEDLINE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! accession number W65887, 12 June 1996 (1996-06-12) MARRA M. ET AL.: "The WashU-HHMI mouse EST project." XP002157499 abstract DOC. AGAINST INV. 1 (SEQ.IDs. 122, 4)	2,6,7, 11,12
E	WO 00 58473 A (CURAGEN CORP ;LEACH MARTIN (US); SHIMKETS RICHARD A (US)) 5 October 2000 (2000-10-05) SEQ.IDs. 4435 and 4436 DOC. AGAINST INV. 1 (SEQ.IDs. 122, 4) SEQ.IDs. 5049, 5050, 5571, 5572 DOC. AGAINST INV. 67 (SEQ.IDs. 188, 70) SEQ.IDs. 3009 and 3010 DOC. AGAINST INV. 76 (SEQ.IDs. 197, 79) --- -/-	1,2,4-7, 11,12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

22 June 2001

Date of mailing of the international search report

18. 07. 2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

# INTERNATIONAL SEARCH REPORT

Int ional Application No

PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>RUIZ-PEREZ V. L. ET AL.: "Mutations in a new gene in Ellis-van Creveld syndrome and Weyers acrodermal dysostosis." NATURE GENETICS, vol. 24, no. 3, March 2000 (2000-03), pages 283-286, XP002157498 ISSN: 1061-4036 page 284, left-hand column, line 6 - line 8 figure 1A page 286, right-hand column, last paragraph &amp; DATABASE EMBL 'Online! Accession Number Q9NY57, 1 October 2000 (2000-10-01) PUIZ-PEREZ V. V. ET AL.: "Serine/threonine protein kinase." abstract DOC. AGAINST INV. 1 (SEQ.IDs. 122, 4)</p>	1-12
X	<p>DATABASE EMBL 'Online! Accession Number AA305176, 18 April 1997 (1997-04-18) ADAMS M. D. ET AL.: "EST176172 colon carcinoma cell line II Homo sapiens cDNA 5'-end." XP002165842 abstract DOC. AGAINST INV. 3 (SEQ.IDs. 124, 6)</p>	6,7
X	<p>DATABASE EMBL 'Online! Accession Number AA116841, 16 November 1996 (1996-11-16) MARRA M. ET AL.: "Mus musculus cDNA clone IMAGE:538568 5' similar to TR:G406058 protein kinase." XP002165843 abstract DOC. AGAINST INV. 4 (SEQ.IDs. 125, 7)</p>	1,2,4,6, 7,10-13, 15
P,X	<p>WO 00 06728 A (INCYTE PHARMA INC ;PATTERSON CHANDRA (US); AZIMZAI YALDA (US); COR) 10 February 2000 (2000-02-10)  SEQ.ID.1 and 32 DOC. AGAINST INV. 4 (SEQ.IDs. 125, 7)</p>	2,4-7,9, 11-14, 26,27, 35,36
X	<p>WO 98 58052 A (INCYTE PHARMA INC ;CORLEY NEIL C (US); BANDMAN OLGA (US); GOLI SUR) 23 December 1998 (1998-12-23) SEQ.IDs. 4 and 11 DOC. AGAINST INV. 5 (SEQ.IDs. 126, 8)</p>	1-14, 26-30, 35-38
	<p>--- -/--</p>	

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 00 55332 A (INCYTE PHARMA INC ;AZIMZAI YALDA (US); YUE HENRY (US); AU YOUNG JA) 21 September 2000 (2000-09-21) SEQ.IDs. 7 and 21 DOC. AGAINST INV. 6 (SEQ.IDs. 127, 9) SEQ.IDs. 2 and 16 DOC. AGAINST INV. 26 (SEQ.IDs. 147, 29) ---	1-15, 26-30, 35-38
X	DATABASE EMBL 'Online! Accession Number AA593989, 24 September 1997 (1997-09-24) STRAUSBERG R.: "Homo sapiens clone IMAGE:1084047 3' similar to TR:G20878 serine/threonine protein kinase." XP002165844 abstract DOC. AGAINST INV. 6 (SEQ.IDs. 127, 9) ---	1,2,4,6, 7,10-13, 15
X	DATABASE EMBL 'Online! Accession Number AL050147, 20 May 1999 (1999-05-20) WAMBUTT R. ET AL.: "Homo sapiens mRNA." XP002165845 abstract DOC. AGAINST INV. 6 (SEQ.IDs. 127, 9) ---	6,7
X	HAYASHI A. ET AL.: "PKCnu, a new member of the protein kinase C family, composes a fourth subfamily with PKCmu." BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1450, no. 1, 6 May 1999 (1999-05-06), pages 99-106, XP000992627 ISSN: 0006-3002 the whole document DOC. AGAINST INV. 8 (SEQ.IDs. 129, 11) ---	1-15, 35-38
X	DATABASE EMBL 'Online! Accession Number AA763046, 28 January 1998 (1998-01-28) MARRA M. ET AL.: "Mus musculus cDNA clone similar to TR:P70268 protein kinase." XP002165846 abstract DOC. AGAINST INV. 9 (SEQ.IDs. 130, 12) ---	2,6,7, 11,12
	--- -/--	

## INTERNATIONAL SEARCH REPORT

Int .lional Application No

PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	OISHI K. ET AL.: "Identification and characterization of PKNbeta, a novel isoform of protein kinase PKN: Expression and arachidonic acid dependency are different from those of PKNalpha." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 261, no. 3, 11 August 1999 (1999-08-11), pages 808-814, XP002165839 ISSN: 0006-291X figure 1 DOC. AGAINST INV. 9 (SEQ.IDs. 130, 12)	1-15,26, 27,35,37
X	DATABASE EMBL 'Online! Accession Number H19102, 2 July 1995 (1995-07-02) HILLIER L. ET AL.: "Homo sapiens cDNA clone IMAGE:171993 5' similar to SP:F31E3.2 CE01267 protein kinase." XP002165847 abstract DOC. AGAINST INV. 11 (SEQ.IDs. 132, 14)	2,6,7, 11,12
X	WO 97 33909 A (CORIXA CORP) 18 September 1997 (1997-09-18)  SEQ.IDs.6 and 16 DOC. AGAINST INV. 12 (SEQ.IDs. 133, 15)	2,6,7,9, 11,12, 26,27, 35-38
X	DATABASE EMBL 'Online! Accession Number AA463334, 13 June 1997 (1997-06-13) HILLIER L. ET AL.: "Homo sapiens cDNA clone IMAGE:811660 5' similar to SW:COT1_NEUCR P38679 serine/threonine-protein kinase COT-1." XP002165848 abstract DOC. AGAINST INV. 12 (SEQ.IDs. 133, 15)	1,2,4,6, 7,10-13, 15
P,X	WO 99 57144 A (INCYTE PHARMA INC ;PATTERSON CHANDRA (US); AZIMZAI YALDA (US); RED) 11 November 1999 (1999-11-11)  SEQ.IDs. 52 and 117 DOC. AGAINST INV. 12 (SEQ.IDs. 133, 15)  -/--	2,6,7,9, 11,12, 26,27, 29,30, 35-38

## INTERNATIONAL SEARCH REPORT

 Int. Application No  
 PCT/US 00/14842

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	ZHANG H. ET AL.: "Cloning, characterization, and chromosome mapping of RPS6KC1, a novel putative member of the ribosome protein S6 kinase family, to chromosome 12q12-q13.1." GENOMICS, vol. 61, no. 3, 1 November 1999 (1999-11-01), pages 314-318, XP002165840 ISSN: 0888-7543 the whole document DOC. AGAINST INV. 12 (SEQ.IDs. 133, 15) ---	1-15,35
X	DATABASE EMBL 'Online! Accession Number AC006530, 8 February 1999 (1999-02-08) ROWEN L. ET AL.: "Sequencing of human chromosome 14." XP002165849 abstract DOC. AGAINST INV. 14 (SEQ.IDs. 135, 17) ---	1,2,4-7, 10-15
X	DATABASE EMBL 'Online! Accession Number AI215680, 23 October 1998 (1998-10-23) STRAUSBERG R.: "Homo sapiens cDNA clone IMAGE:1884219." XP002165850 abstract DOC. AGAINST INV. 14 (SEQ.IDs. 135, 17) ---	6,7
X	WO 98 11234 A (HAWKINS PHILLIP R ; INCYTE PHARMA INC (US); AU YOUNG JANICE (US); G) 19 March 1998 (1998-03-19) SEQ.IDs. 5 and 6 DOC. AGAINST INV. 15 (SEQ.IDs. 136, 18) DOC. AGAINST INV. 16 (SEQ.IDs. 137, 19) ---	1-15, 26-30, 35-38
X	EP 0 861 896 A (DADE BEHRING MARBURG GMBH) 2 September 1998 (1998-09-02) --- SEQ.IDs. 1 and 2 DOC. AGAINST INV. 15 (SEQ.IDs. 136, 18) DOC. AGAINST INV. 16 (SEQ.IDs. 137, 19) ---	1-15, 26-28, 35-38
P,X	DATABASE EMBL 'Online! Accession Number AF205855, 23 December 1999 (1999-12-23) SHIGAIEV A. ET AL.: "Mus musculus serum and glucocorticoid-dependent protein kinase (Sgk) mRNA." XP002165851 abstract DOC. AGAINST INV. 16 (SEQ.IDs. 137, 19) ---	1,2,4,6, 7,10-13, 15
	--- -/--	

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 00 35946 A (UNIV DUNDEE ;COHEN PHILIP (GB); DEAK MARIA (GB); KOBAYASHI TAKAYAS) 22 June 2000 (2000-06-22) figure 11 DOC. AGAINST INV. 17 (SEQ.IDs. 138, 20) DOC. AGAINST INV. 113 (SEQ.IDs. 234, 116) ---	1-14, 26, 27, 29, 30
X	DATABASE EMBL 'Online! Accession Number Z98752, 23 August 1997 (1997-08-23) RAMSAY H.: "Human DNA sequence from clone RP1-138B7 on chromosome 20q13.12." XP002165852 abstract DOC. AGAINST INV. 17 (SEQ.IDs. 138, 20) ---	1-14
X	WO 98 31802 A (GENETICS INST) 23 July 1998 (1998-07-23) SEQ.IDs. 13 and 14 DOC. AGAINST INV. 21 (SEQ.IDs. 142, 24) ---	6, 7, 11, 12
X	DATABASE EMBL 'Online! Accession Number AI061003, 23 July 1998 (1998-07-23) MARRA M. ET AL.: "Mus musculus cDNA clone IMAGE:1379597 5' similar to TR:008875 calcium calmodulin dependent kinase CPG16." XP002165853 abstract DOC. AGAINST INV. 22 (SEQ.IDs. 143, 25) ---	1, 2, 4, 6, 7, 10-13, 25
X	DATABASE EMBL 'Online! Accession Number AA383293, 18 April 1997 (1997-04-18) ADAMS M. D. ET AL.: "Homo sapiens cDNA 5'-end similar to serine/threonine kinase p78." XP002165854 abstract DOC. AGAINST INV. 23 (SEQ.IDs. 144, 26) ---	1, 2, 4, 6, 7, 10-13, 16
X	DATABASE EMBL 'Online! Accession number AA197883, 29 January 1997 (1997-01-29) MARRA M. ET AL.: "Mus musculus cDNA clone IMAGE:654045 5' similar to TR:G406113 protein kinase I." XP002165855 abstract DOC. AGAINST INV. 24 (SEQ.IDs. 145, 27) ---	1, 2, 4, 6, 7, 10-13

-/--

## INTERNATIONAL SEARCH REPORT

Int .tional Application No

PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 50395 A (HELIX RESEARCH INST ;MURAMATSU MASAOKI (JP); TOKUMITSU HIROSHI (JP) 7 October 1999 (1999-10-07) page 41 -page 51 DOC. AGAINST INV. 24 (SEQ.IDs. 145, 27) ---	1-4,6-13
X	SANJO H. ET AL: "DRAKS, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 44, 30 October 1998 (1998-10-30), pages 29066-29071, XP002165841 ISSN: 0021-9258 figure 1 DOC. AGAINST INV. 26 (SEQ.IDs. 147, 29) ---	1-14,16, 35,37
P,X	WO 99 33961 A (AKIRA SHIZUO ;KAWAI TARO (JP); ASAHI CHEMICAL IND (JP)) 8 July 1999 (1999-07-08)  SEQ.IDs. 5 and 6 DOC. AGAINST INV. 26 (SEQ.IDs. 147, 29) SEQ.IDs. 29 and 30 DOC. AGAINST INV. 40 (SEQ.IDs. 161, 43) ---	1-14,16, 26,27, 29,30, 35,37
X	NAGASE T. ET AL.: "PREDICTION OF THE CODING SEQUENCE OF UNIDENTIFIED HUMAN GENES. XIII. THE COMPLETE SEQUENCE OF 100 NEW CDNA CLONES FROM BRAIN WHICH CODE FOR LARGE PROTEINS IN VITRO" DNA RESEARCH, vol. 6, 26 February 1999 (1999-02-26), pages 63-70, XP000952912 ISSN: 1340-2838 the whole document -& DATABASE EMBL 'Online! Accession Number AB023153, 9 April 1999 (1999-04-09) NAGASE T. ET AL.: "Homo sapiens mRNA for KIAA0936 protein." XP002166242 abstract DOC. AGAINST INV. 54 (SEQ.IDs. 175, 57) -& DATABASE EMBL 'Online! Accession Number AB023216, 9 April 1999 (1999-04-09) NAGASE T. ET AL.: "Homo sapiens mRNA for KIAA0999 protein." XP002166243 abstract DOC. AGAINST INV. 28 (SEQ.IDs. 149, 31) ---	1,2,4-7, 10-14, 16,19
	--- -/--	

## INTERNATIONAL SEARCH REPORT

Int .tional Application No

PCT/US 00/14842

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 98 01756 A (UNIV WASHINGTON) 15 January 1998 (1998-01-15)</p> <p>SEQ.IDs. 1 and 2 DOC. AGAINST INV. 30 (SEQ.IDs. 151, 33)</p>	1-14, 16, 26, 27, 35, 36
X	<p>DATABASE EMBL 'Online! Accession Number W90839, 9 July 1996 (1996-07-09) MARRA M. ET AL.: "Mus musculus cDNA clone IMAGE:420441 5' similar to gb:M80359 putative serine/threonine protein kinase." XP002165856 abstract DOC. AGAINST INV. 31 (SEQ.IDs. 152, 34)</p>	1, 2, 4, 6, 7, 10-13, 16
X	<p>NAGASE T. ET AL.: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES. IV. THE CODING SEQUENCES OF 40 NEW GENES (KIAA0121-KIAA0160) DEDUCED BY ANALYSIS OF CDNA CLONES FROM HUMAN CELL LINE KG-1" DNA RESEARCH, vol. 2, no. 4, 31 August 1995 (1995-08-31), pages 167-174, XP000676653 ISSN: 1340-2838 the whole document -&amp; DATABASE EMBL 'Online! Accession Number D50925, 1 August 1996 (1996-08-01) NAGASE T. ET AL.: "Human mRNA for KIAA0135 gene." XP002166244 abstract DOC. AGAINST INV. 32 (SEQ.IDs. 153, 35) DOC. AGAINST INV. 33 (SEQ.IDs. 154, 36)</p>	1, 2, 4-7, 10-14, 16
X	<p>DATABASE EMBL 'Online! Accession Number U79240, 14 December 1996 (1996-12-14) YU W. ET AL.: "Human serine/threonine kinase mRNA." XP002165857 abstract DOC. AGAINST INV. 33 (SEQ.IDs. 154, 36)</p>	1, 2, 4-7, 10-14

-/--

# INTERNATIONAL SEARCH REPORT

Int ional Application No

PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online!  Accession Number AI036899,  29 June 1998 (1998-06-29)  MARRA M. ET AL.: "Mus musculus cDNA clone  IMAGE:1746011 5' similar to TR:Q99763  serine/threonine protein kinase."  XP002165858  abstract  DOC. AGAINST INV. 33 (SEQ.IDs. 154, 36)</p> <p style="text-align: center;">---</p>	1,2,4,6, 7,10-13
X	<p>DATABASE EMBL 'Online!  Accession Number AI469033,  17 March 1999 (1999-03-17)  STRAUSBERG R.: "Homo sapiens cDNA clone  IMAGE:2137322."  XP002165859  abstract  DOC. AGAINST INV. 35 (SEQ.IDs. 156, 38)</p> <p style="text-align: center;">---</p>	6,7
X	<p>DATABASE EMBL 'Online!  Accession Number AC007225,  7 April 1999 (1999-04-07)  BRUCE D. ET AL.: "Homo sapiens chromosome  16 clone RPCI-11_480G7."  XP002166245  abstract  DOC. AGAINST INV. 37 (SEQ.IDs. 158, 40)</p> <p style="text-align: center;">---</p>	6,7
P,X	<p>WO 99 49062 A (FAN WUFANG ;GENE LOGIC INC  (US); PRASHAR YATINDRA (US))  30 September 1999 (1999-09-30)  SEQ.IDs. 1 and 2  DOC. AGAINST INV. 37 (SEQ.IDs. 158, 40)  DOC. AGAINST INV. 55 (SEQ.IDs. 176, 58)</p> <p style="text-align: center;">---</p>	1-14, 26-30, 35-38
X	<p>DATABASE EMBL 'Online!  Accession Number AI596766,  26 April 1999 (1999-04-26)  MARRA M. ET AL.: "Mus musculus cDNA clone  IMAGE:949322 5' similar to WP:ZC373.4  CE02377 myosin-light-chain kinase domain."  XP002166246  abstract  DOC. AGAINST INV. 38 (SEQ.IDs. 159, 41)  DOC. AGAINST INV. 39 (SEQ.IDs. 160, 42)</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1,2,4,6, 7,10-13, 16

## INTERNATIONAL SEARCH REPORT

Int ional Application No

PCT/US 00/14842

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>NAGASE T. ET AL.: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES. XVI. THE COMPLETE SEQUENCES OF 150 NEW CDNA CLONES FROM BRAIN WHICH CODE FOR LARGE PROTEINS IN VITRO"</p> <p>DNA RESEARCH, vol. 7, 28 February 2000 (2000-02-28), pages 65-73, XP000923011 KIAA1297</p> <p>-&amp; DATABASE EMBL 'Online! Accession Number AB037718, 14 March 2000 (2000-03-14)</p> <p>OHARA O. ET AL.: "Homo sapiens mRNA for KIAA1297 protein." XP002166247</p> <p>abstract</p> <p>DOC. AGAINST INV. 38 (SEQ.IDs. 159, 41) DOC. AGAINST INV. 39 (SEQ.IDs. 160, 42)</p> <p>-&amp; DATABASE EMBL 'Online! Accession Number AB037759, 14 March 2000 (2000-03-14)</p> <p>OHARA O. ET AL.: "Homo sapiens mRNA for KIAA1338 protein." XP002167889</p> <p>abstract</p> <p>DOC. AGAINST INV. 67 (SEQ.IDs. 188, 70)</p> <p>-&amp; DATABASE EMBL 'Online! Accession Number AB037790, 14 March 2000 (2000-03-14)</p> <p>OHARA O. ET AL.: "Homo sapiens mRNA for KIAA1369 protein." XP002167890</p> <p>abstract</p> <p>DOC. AGAINST INV. 68 (SEQ.IDs. 189, 71)</p> <p>-&amp; DATABASE EMBL 'Online! Accession Number AB037781, 14 March 2000 (2000-03-14)</p> <p>NAGASE T. ET AL.: "Homo sapiens mRNA for KIAA1360 protein, partial cds." XP002168226</p> <p>abstract</p> <p>DOC. AGAINST INV. 82 (SEQ.IDs. 203, 85)</p> <p>---</p>	<p>1,2,4-7, 10-14, 16,25</p>
X	<p>KAWAI T. ET AL.: "Duet is a novel serine/threonine kinase with Dbl-Homology (DH) and Pleckstrin-Homology (PH) domains" GENE, vol. 227, no. 2, 18 February 1999 (1999-02-18), pages 249-255, XP004158739 ISSN: 0378-1119 the whole document</p> <p>DOC. AGAINST INV. 40 (SEQ.IDs. 161, 43)</p> <p>---</p> <p>-/--</p>	<p>1-14,29, 30,35-38</p>

## INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 00/14842

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online!  Accession Number AA454060,  11 June 1997 (1997-06-11)  HILLIER L. ET AL.: "Homo sapiens cDNA  clone IMAGE:795492 5' similar to TR:G49075  calmodulin-binding protein."  XP002166248  abstract  DOC. AGAINST INV. 41 (SEQ.IDs. 162, 44)</p>	6,7
X	<p>DATABASE EMBL 'Online!  Accession Number AI385971,  29 January 1999 (1999-01-29)  MARRA M. ET AL.: "Mus musculus cDNA clone  IMAGE:514336 5' similar to WP:R90.1  CE06325 protein kinase."  XP002166249  abstract  DOC. AGAINST INV. 43 (SEQ.IDs. 164, 46)</p>	1,2,4,6, 7,10-13, 16
X	<p>DATABASE EMBL 'Online!  Accession Number AA436054,  1 June 1997 (1997-06-01)  HILLIER L. ET AL.: "Homo sapiens cDNA  clone IMAGE:730582 5' similar to gb:X66363  serine/threonine-protein kinase pcta-1"  XP002166250  abstract  DOC. AGAINST INV. 44 (SEQ.IDs. 165, 47)</p>	1,2,4-7, 10-14,16
X	<p>DATABASE EMBL 'Online!  Accession Number AA061797,  24 September 1996 (1996-09-24)  MARRA M. ET AL.: "Mus musculus cDNA clone  IMAGE:513953 5' similar to gb:X66358  serine/threonine-protein kinase."  XP002166251  abstract  DOC. AGAINST INV. 45 (SEQ.IDs. 166, 48)  DOC. AGAINST INV. 46 (SEQ.IDs. 167, 49)</p>	1,2,4,6, 7,10-13, 17
A	<p>WO 98 35015 A (GERHOLD DAVID L ;MERCK &amp; CO  INC (US)) 13 August 1998 (1998-08-13)  SEQ.IDs.2 and 3  DOC. AGAINST INV. 50 (SEQ.IDs. 171, 53)  DOC. AGAINST INV. 114 (SEQ.IDs. 235, 117)</p>	1-30, 35-38
-/--		

# INTERNATIONAL SEARCH REPORT

Int ional Application No

PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NAYLER O. ET AL.: "Characterization and comparison of four serine- and arginine-rich (SR) protein kinases." BIOCHEMICAL JOURNAL, vol. 326, no. 3, 1997, pages 693-700, XP002166240 ISSN: 0264-6021 the whole document DOC. AGAINST INV. 51 (SEQ.IDs. 172, 54) ---	1-4, 6-13, 18, 26, 27
P, X	WO 99 38981 A (AKERBLOM INGRID E ; INCYTE PHARMA INC (US); CORLEY NEIL C (US); BAN) 5 August 1999 (1999-08-05) SEQ.IDs. 3 and 9 DOC. AGAINST INV. 51 (SEQ.IDs. 172, 54) SEQ.IDs. 6 and 12 DOC. AGAINST INV. 95 (SEQ.IDs. 216, 43) ---	1-14, 18, 26-30, 35-38
X	DATABASE EMBL 'Online! Accession Number AA839940, 2 March 1998 (1998-03-02) MARRA M. ET AL.: "Mus musculus cDNA clone IMAGE:1259911 5' similar to SW:KMLC_RAT P20689 myosin light chain kinase." XP002167891 abstract DOC. AGAINST INV. 55 (SEQ.IDs. 176, 58) ---	1, 2, 4, 6, 7, 10-13, 18
X	DATABASE EMBL 'Online! Accession Number AL031055, 10 July 1998 (1998-07-10) RAMSAY H.: "Human DNA sequence from clone RP1-28H20 on chromosome 20q13.1." XP002167892 abstract DOC. AGAINST INV. 56 (SEQ.IDs. 177, 59) ---	1, 2, 4-7, 10-14, 18
P, X	DATABASE EMBL 'Online! Accession Number AL137662, 27 January 2000 (2000-01-27) KOEHRER K. ET AL.: "Homo sapiens mRNA" XP002167893 abstract DOC. AGAINST INV. 57 (SEQ.IDs. 178, 60) ---	2, 6, 7, 11, 12
	--- -/--	

# INTERNATIONAL SEARCH REPORT

Int. ional Application No  
PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>NAGASE T. ET AL.: "Prediction of the coding sequences of unidentified human genes. VII. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro"</p> <p>DNA RESEARCH, vol. 4, no. 4, 28 April 1997 (1997-04-28), pages 141-150, XP002102085 ISSN: 1340-2838 the whole document -&amp; DATABASE EMBL 'Online! Accession Number AB002342, 1 July 1997 (1997-07-01)</p> <p>NAGASE T. ET AL.: "Human mRNA for KIAA0344 gene." XP002167894 abstract DOC. AGAINST INV. 59 (SEQ.IDs. 180, 62)</p>	2,6,7, 11,12
X	<p>WO 98 36054 A (HOOPER JOHN DAVID ;AMRAD OPERATIONS PTY LTD (AU); ANTALIS TONI MAR) 20 August 1998 (1998-08-20) SEQ.IDs. 9 and 10 DOC. AGAINST INV. 60 (SEQ.IDs. 181, 63)</p>	1-14, 26-30, 35-38
X	<p>ANDERSON K. A. ET AL.: "Components of a calmodulin-dependent protein kinase cascade. Molecular cloning, functional characterization and cellular localization of Ca2+/calmodulin-dependent protein kinase kinase beta."</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 48, 27 November 1998 (1998-11-27), pages 31880-31889, XP002167887 ISSN: 0021-9258 the whole document -&amp; DATABASE EMBL 'Online! Accession Number AF140507, 21 May 1999 (1999-05-21)</p> <p>ANDERSON K. A. ET AL.: "Homo sapiens Ca2+/calmodulin-dependent protein kinase beta, complete cds." XP002167895 abstract DOC. AGAINST INV. 62 (SEQ.IDs. 183, 65)</p>	1-14,23, 26,27
P,X	<p>WO 99 58558 A (INCYTE PHARMA INC ;PATTERSON CHANDRA (US); YUE HENRY (US); BANDMAN) 18 November 1999 (1999-11-18) SEQ.IDs. 2 and 15 DOC. AGAINST INV. 62 (SEQ.IDs. 183, 65)</p>	2,6,7,9, 11,12, 26-28

-/--

# INTERNATIONAL SEARCH REPORT

Int lional Application No  
PCT/US 00/14842

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! Accession Number AC004685, 15 May 1998 (1998-05-15) ADAMS M. D. AND LOFTUS B. J.: "Homo sapiens chromosome 16 BAC clone CIT987SK-A-233A8." XP002167896 abstract DOC. AGAINST INV. 63 (SEQ.IDs. 184, 66) ---	1,2,4-7
P,X	US 6 013 455 A (AZIMZAI YALDA ET AL) 11 January 2000 (2000-01-11)  SEQ.IDs. 2 and 11 DOC. AGAINST INV. 63 (SEQ.IDs. 184, 66) ---	1-14, 26-30, 35-38
X	EP 0 870 825 A (SMITHKLINE BEECHAM CORP) 14 October 1998 (1998-10-14)  figure 2 DOC. AGAINST INV. 65 (SEQ.IDs. 186, 68) DOC. AGAINST INV. 66 (SEQ.IDs. 187, 69) ---	1-14, 25-30, 35-38
X	DATABASE EMBL 'Online! Accession Number AA589241, 18 September 1997 (1997-09-18) MARRA M. ET AL.: "Mus musculus cDNA clone IMAGE:992145 5' similar to WP:F49E11.1 CE05897 serine/threonine protein kinase." XP002167897 abstract DOC. AGAINST INV. 66 (SEQ.IDs. 187, 69) ---	1,2,4,6, 7,10-13, 25
P,X	BERLANGA J. J. ET AL.: "Characterization of a mammalian homolog of the GCN2 eukaryotic initiation factor 2alpha kinase." EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 265, no. 2, October 1999 (1999-10), pages 754-762, XP002167888 ISSN: 0014-2956 the whole document DOC. AGAINST INV. 67 (SEQ.IDs. 188, 70) ---	1-14, 25-27,35
X	WO 94 05794 A (MASSACHUSETTS INST TECHNOLOGY) 17 March 1994 (1994-03-17)  page 13, paragraph 2 examples 1,2 DOC. AGAINST INV. 68 (SEQ.IDs. 189, 71) ---	1-14, 26-28, 35-38
	--- -/--	

# INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MELLOR H. ET AL.: "CLONING AND CHARACTERIZATION OF CDNA ENCODING RAT HEMIN-SENSITIVE INITIATION FACTOR-2ALPHA (EIF-2ALPHA) KINASE" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 14, 8 April 1994 (1994-04-08), pages 10201-10204, XP002920790 ISSN: 0021-9258 the whole document DOC. AGAINST INV. 68 (SEQ.IDs. 189, 71)	1-4,6-13
X	DATABASE EMBL 'Online! Accession Number AA387681, 25 June 1997 (1997-06-25) MARRA M. ET AL.: "Mus musculus cDNA clone." XP002167898 abstract DOC. AGAINST INV. 70 (SEQ.IDs. 191, 73)	6,7
P,X	WO 00 09678 A (TULARIK INC) 24 February 2000 (2000-02-24)  the whole document DOC. AGAINST INV. 71 (SEQ.IDs. 192, 74)	1-14,20, 26,27, 29,30, 35-38
X	DATABASE EMBL 'Online! Accession Number AF046653, 6 April 1998 (1998-04-06) ZAMBROWICZ B. P. ET AL.: "Mus musculus genomic clone OST10140." XP002167969 abstract DOC. AGAINST INV. 76 (SEQ.IDs. 197, 79)	1-4, 6-13,25
P,X	DATABASE EMBL 'Online! Accession Number AF238255, 12 April 2000 (2000-04-12) LIU T. C. ET AL.: "Homo sapiens mixed lineage kinase mRNA." XP002167970 abstract -& LIU T.-C. ET AL.: "Cloning and expression of ZAK, a mixed lineage kinase-like protein containing a leucine-zipper and a sterile-alpha motif." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 274, 11 August 2000 (2000-08-11), pages 811-816, XP002167968 the whole document DOC. AGAINST INV. 77 (SEQ.IDs. 198, 80)	1-14

-/--

# INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 00 14212 A (ACTON SUSAN ;MILLENNIUM PHARM INC (US)) 16 March 2000 (2000-03-16)  figure 2 DOC. AGAINST INV. 77 (SEQ.IDs. 198, 80) figure 3 DOC. AGAINST INV. 106 (SEQ.IDs. 227, 109) ---	1-14, 25-30, 35-38
X	DATABASE EMBL 'Online! Accession Number AA270784, 28 March 1997 (1997-03-28) MARRA M. ET AL.: "Mus musculus cDNA clone IMAGE:736476." XP002167971 abstract DOC. AGAINST INV. 80 (SEQ.IDs. 201, 83) ---	6,7
P, X	PAZDERNIK N. J. ET AL.: "MOUSE RECEPTOR INTERACTING PROTEIN 3 DOES NOT CONTAIN A CASPASE-RECRUITING OR A DEATH DOMAIN BUT INDUCES APOPTOSIS AND ACTIVATES NF-(KAPPA)B" MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 10, October 1999 (1999-10), pages 6500-6508, XP000939146 the whole document DOC. AGAINST INV. 80 (SEQ.IDs. 201, 83) ---	1-4, 6-13,22
X	DATABASE EMBL 'Online! Accession Number AL031297, 13 August 1998 (1998-08-13) COBLEY V.: "Human DNA sequence from clone 97P20 on chromosomelq23.2-24.3." XP002168227 abstract DOC. AGAINST INV. 81 (SEQ.IDs. 202, 84) ---	1-14
X	WO 99 04265 A (SAHIN UGUR ;TURECI OZLEM (DE); PFREUNDSCUH MICHAEL (DE); GOUT IVA) 28 January 1999 (1999-01-28) SEQ.IDs. 431 and 435 DOC. AGAINST INV. 82 (SEQ.IDs. 203, 85) ---	2,6,7, 11,12
X	DATABASE EMBL 'Online! Accession Number AA195964, 28 January 1997 (1997-01-28) HILLIER L. ET AL.: "Homo sapiens cDNA clone IMAGE:628136" XP002168228 abstract DOC. AGAINST INV. 84 (SEQ.IDs. 205, 87) ---	6,7
	---	

-/---

## INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>DATABASE EMBL 'Online!  Accession Number AK000342,  22 February 2000 (2000-02-22)  SUGANO S. ET AL.: "Homo sapiens cDNA  FLJ20335 fis, clone HEP11429."  XP002168229  abstract  DOC. AGAINST INV. 84 (SEQ.IDs. 205, 87)</p>	1-14
X	<p>DATABASE EMBL 'Online!  Accession Number AF027406,  6 January 1999 (1999-01-06)  BRENNER V. ET AL.: "Homo sapiens  muscle-specific serine kinase 1 (MSSK1)  mRNA."  XP002168230  abstract  DOC. AGAINST INV. 85 (SEQ.IDs. 206, 88)</p>	1-14
X	<p>DATABASE EMBL 'Online!  Accession Number AF043288,  6 January 1999 (1999-01-06)  BRENNER V. ET AL.: "Mus musculus  muscle-specific serine kinase 1 mRNA."  XP002168231  abstract  DOC. AGAINST INV. 85 (SEQ.IDs. 206, 88)</p>	1-4,6-13
P,X	<p>WO 00 22143 A (INCYTE PHARMA INC ;AZIMZAI  YALDA (US); CORLEY NEIL C (US); YUE HEN)  20 April 2000 (2000-04-20)  SEQ.IDs. 1 and 10  DOC. AGAINST INV. 85 (SEQ.IDs. 206, 88)  SEQ.IDs. 7 and 16  DOC. AGAINST INV. 104 (SEQ.IDs. 225, 107)</p>	1-4, 6-13, 26-28
X	<p>DATABASE EMBL 'Online!  Accession Number AI553938,  25 March 1999 (1999-03-25)  STAUSBERG R.: "Homo sapiens cDNA clone  IMAGE:2090493 3' similar to TR:015367  TSK_1."  XP002168388  abstract  DOC. AGAINST INV. 86 (SEQ.IDs. 207, 89)  DOC. AGAINST INV. 87 (SEQ.IDs. 208, 90)  DOC. AGAINST INV. 91 (SEQ.IDs. 212, 94)</p>	1,2,4-7, 10-14,25

-/--

## INTERNATIONAL SEARCH REPORT

Int. ional Application No

PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! Accession Number AV040939, 14 May 1999 (1999-05-14) CARNINCI P. ET AL.: "Mus musculus adult male testis cDNA, partial sequence." XP002168389 abstract DOC. AGAINST INV. 87 (SEQ.IDs. 208, 90)	6,7
X	DATABASE EMBL 'Online! Accession Number AA399596, 29 April 1997 (1997-04-29) HILLIER L. ET AL.: "Homo sapiens cDNA clone IMAGE:729913 5' similar to TR:G404634 Serine/threonine kinase." XP002168766 abstract DOC. AGAINST INV. 88 (SEQ.IDs. 209, 91)	1,2,4-7, 10-14,25
X	KUENG P. ET AL: "A novel family of serine/threonine kinases participating in spermiogenesis." JOURNAL OF CELL BIOLOGY, vol. 139, no. 7, 29 December 1997 (1997-12-29), pages 1851-1859, XP002168387 ISSN: 0021-9525 the whole document DOC. AGAINST INV. 89 (SEQ.IDs. 210, 92)	1-14, 26-28, 35-38
X	DATABASE EMBL 'Online! Accession Number AI652441, 5 May 1999 (1999-05-05) STRAUSBERG R.: "Homo sapiens cDNA clone IMAGE:2307063 3' similar to TR:P97417 serine/threonine kinase" XP002168390 abstract DOC. AGAINST INV. 89 (SEQ.IDs. 210, 92)	1,2,4-7, 10-14
X	DATABASE EMBL 'Online! Accession Number L77564, 16 June 1996 (1996-06-16) GONG W. ET AL.: "Homo sapiens DGS-G mRNA, 3'-end." XP002168391 abstract DOC. AGAINST INV. 89 (SEQ.IDs. 210, 92)	1,2,4-7, 10-14

-/--

## INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 00/14842

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online!  Accession Number AA905446,  9 April 1998 (1998-04-09)  STRAUSBERG R.: "Homo sapiens cDNA clone  IMAGE:1506197 3' similar to TR:P97417  serine threonine kinase."  XP002168767  abstract  DOC. AGAINST INV. 91 (SEQ.IDs. 212, 9)  DOC. AGAINST INV. 86 (SEQ.IDs. 207, 89)  ---</p>	1,2,4-7, 10-14,25
X	<p>DATABASE EMBL 'Online!  Accession Number AI538521,  24 March 1999 (1999-03-24)  STRAUSBERG R.: "Homo sapiens cDNA clone  IMAGE:2074994 3' similar to SW:UN51_CAEEL  Q23023 serine/threonine protein kinase  UNC-51"  XP002168768  abstract  DOC. AGAINST INV. 92 (SEQ.IDs. 213, 95)  DOC. AGAINST INV. 93 (SEQ.IDs. 214, 96)  ---</p>	1,2,4-7, 10-14,25
X	<p>DATABASE EMBL 'Online!  Accession Number AA498104,  3 July 1997 (1997-07-03)  MARRA M. ET AL.: "Mus musculus cDNA clone  IMAGE:918101."  XP002168769  abstract  DOC. AGAINST INV. 93 (SEQ.IDs. 214, 96)  ---</p>	6,7
X	<p>DATABASE EMBL 'Online!  Accession Number AA215311,  5 February 1997 (1997-02-05)  STRAUSBERG R.: "Homo sapiens cDNA clone  IMAGE:63368 5' similar to TR:E237261  calmodulin-domain protein kinase."  XP002168770  abstract  DOC. AGAINST INV. 94 (SEQ.IDs. 215, 97)  ---</p>	1,2,4-7, 10-14
P,X	<p>WO 99 32609 A (KAROLINSKA INNOVATIONS AB  ;ZAPHIROPOULOS PETER G (SE); TOFTGAARD R)  1 July 1999 (1999-07-01)  SEQ.IDs. 1 and 2  DOC. AGAINST INV. 95 (SEQ.IDs. 216, 98)  ---</p> <p style="text-align: center;">-/--</p>	1-14,18, 26-28, 35-38

# INTERNATIONAL SEARCH REPORT

Int. ional Application No

PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online!  Accession Number AA018361,  10 August 1996 (1996-08-10)  HILLIER L. ET AL.: "Homo sapiens cDNA  clone IMAGE:361543 5' similar to  SW:ASK1_ARATH P43291 serine/threonine  kinase ASK2."  XP002169144  abstract  DOC. AGAINST INV. 95 (SEQ.IDs. 216, 98)</p>	1,2,4-7, 10-14,18
X	<p>DATABASE EMBL 'Online!  Accession Number AI651075,  5 May 1999 (1999-05-05)  STRAUSBERG R.: "Homo sapiens cDNA clone  IMAGE:2304078 3' similar to TR:060679  serum inducible kinase."  XP002169145  abstract  DOC. AGAINST INV. 97 (SEQ.IDs. 218, 100)</p>	1,2,4-7, 10-14,25
X	<p>DATABASE EMBL 'Online!  Accession Number W08549,  27 April 1996 (1996-04-27)  MARRA M. ET AL.: "Mus musculus cDNA clone  IMAGE:332593."  XP002169146  abstract  DOC. AGAINST INV. 98 (SEQ.IDs. 219, 101)</p>	6,7
X	<p>DATABASE EMBL 'Online!  Accession Number AC002355,  24 July 1997 (1997-07-24)  HAWKINS T. L. ET AL.: "Homo sapiens  chromosome 9 clone 107G20 map 9q34"  XP002169147  abstract  DOC. AGAINST INV. 99 (SEQ.IDs. 220, 102)</p>	1-7
X	<p>DATABASE EMBL 'Online!  Accession Number AI606679,  26 April 1999 (1999-04-26)  MARRA M. ET AL.: "Mus musculus cDNA clone  IMAGE:516008."  XP002169148  abstract  DOC. AGAINST INV.100 (SEQ.IDs. 221, 103)</p>	6,7

-/--

## INTERNATIONAL SEARCH REPORT

Int .ional Application No

PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! Accession Number AA493011, 2 July 1997 (1997-07-02) MARRA. M. ET AL.: "Mus musculus cDNA clone IMAGE:917574." XP002169149 abstract DOC. AGAINST INV.100 (SEQ.IDs. 221, 103) ---	6,7
X	DATABASE EMBL 'Online! Accession Number AA396601, 28 April 1997 (1997-04-28) MARRA M. ET AL.: "Mus musculus cDNA clone IMAGE:570118." XP002169150 abstract DOC. AGAINST INV.102 (SEQ.IDs. 223, 105) ---	6,7
E	EP 1 033 401 A (GENSET SA) 6 September 2000 (2000-09-06) SEQ.ID.6560 DOC. AGAINST INV.102 (SEQ.IDs. 223, 105) ---	2,6,7, 11,12
X	DATABASE EMBL 'Online! Accession Number AA276191, 3 April 1997 (1997-04-03) MARRA M. ET AL.: " Mus musculus cDNA clone IMAGE:776192 5' similar t SW:KRB1_VACCC P20505 30 KD prtein kinase homolog." XP002169151 abstract DOC. AGAINST INV.104 (SEQ.IDs. 225, 107) ---	1-4,6-13
X	DATABASE EMBL 'Online! Accession Number AA399022, 29 April 1997 (1997-04-29) HILLIER L. ET AL.: "Homo sapiens cDNA clone IMAGE:729929." XP002169312 abstract DOC. AGAINST INV.106 (SEQ.IDs. 227, 109) ---	6,7
X	WO 97 47750 A (IMMUNEX CORP) 18 December 1997 (1997-12-18)  the whole document DOC. AGAINST INV.108 (SEQ.IDs. 229, 111) ---	1-14, 25-30, 35-38
	--- -/--	

# INTERNATIONAL SEARCH REPORT

Int. l. Application No  
PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! Accession Number AI298668, 4 December 1998 (1998-12-04) STRAUSBERG R.: "Homo sapiens cDNA clone IMAGE:1895716 3' similar to SW:NEK1_Mouse P51945 serine/threonine-protien kinase NEK1." XP002169313 abstract DOC. AGAINST INV.108 (SEQ.IDs. 229, 111)</p>	1,2,4-7, 10-14,25
X	<p>WANG X. S. ET AL.: "MAPKKK6, a novel mitogen-activated protein kinase kinase kinase, that associates with MAPKKK5." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 253, no. 1, 9 December 1998 (1998-12-09), pages 33-37, XP002169311 ISSN: 0006-291X the whole document DOC. AGAINST INV.109 (SEQ.IDs. 230, 112)</p>	1-14,25
X	<p>DATABASE EMBL 'Online! Accession Number AI638161, 29 April 1999 (1999-04-29) STRAUSBERG R.: "Homo sapiens cDNA cloneIMAGE:2239185 3' similar to SW:PAK3_Human 075914 serine/threonine-protein kinase." XP002169314 abstract DOC. AGAINST INV.110 (SEQ.IDs. 231, 113)</p>	1,2,4-7, 10-14
P,X	<p>NAGASE T. ET AL.: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES. XV. THE COMPLETE SEQUENCES OF 100 NEW CDNA CLONES FROM BRAIN WHICH CODE FOR LARGE PROTEINS IN VITRO" DNA RESEARCH, vol. 6, 29 October 1999 (1999-10-29), pages 337-345, XP000865804 ISSN: 1340-2838 -&amp; DATABASE EMBL 'Online! Accession Number AB033090, 11 November 1999 (1999-11-11) OHARA O. ET AL.: "Homo sapiens mRNA for KIAA1264 protein." XP002169637 abstract DOC. AGAINST INV.110 (SEQ.IDs. 231, 113)</p>	1-14

-/--

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/14842

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online!  Accession Number H29272,  19 July 1995 (1995-07-19)  HILLIER L. ET AL.: "Homo sapiens cDNA  clone IMAGE:49948."  XP002169315  abstract  DOC. AGAINST INV.111 (SEQ.IDs. 232, 114)</p>	6,7
P,X	<p>WO 99 64589 A (ZENECA LTD)  16 December 1999 (1999-12-16)</p> <p>the whole document  DOC. AGAINST INV.111 (SEQ.IDs. 232, 114)  DOC. AGAINST INV.112 (SEQ.IDs. 233, 115)</p>	1-14,23, 26-30, 35-38
X	<p>DATABASE EMBL 'Online!  Accession Number AA098024,  27 October 1996 (1996-10-27)  MARRA M. ET AL.: "Mus musculus cDNA clone  IMAGE:550913 5' similar to SW:DROME P18475  tyrosine-protein kinase receptor torso  precursor."  XP002169442  abstract  DOC. AGAINST INV.112 (SEQ.IDs. 233, 115)</p>	1-4, 6-13,23
X	<p>DATABASE EMBL 'Online!  Accession Number Z98752,  23 August 1997 (1997-08-23)  RAMSAY H.: "Human DNA sequence from clone  RP1-138B7 on chromosome 20q13.12."  XP002169443  nts. 43893 - 62413  DOC. AGAINST INV.113 (SEQ.IDs. 234, 116)</p>	1-14
X	<p>DATABASE EMBL 'Online!  Accession Number AF035013,  4 January 1999 (1999-01-04)  JIANG Y. AND ZHAO K.: "Homo sapiens cell  cycle related kinase mRNA, complete cds."  XP002169444  abstract  DOC. AGAINST INV.114 (SEQ.IDs. 235, 117)</p>	1-14,24

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 00/14842

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 31-34  
because they do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
~~see FURTHER INFORMATION sheet PCT/ISA/010~~
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically Claims Nos.: 1-16 (partially), 17 (completely), 18 and 19 (partially), 20 and 22 (completely), 23-38 (partially)
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: Invention 1: Claims 1-14,26-38 (all partially)

A nucleic acid molecule encoding a kinase polypeptide as represented by SEQ.ID.122 or a domain thereof; a vector and a recombinant cell comprising said nucleic acid molecule; a nucleic acid probe for the detection of said nucleic acid molecule; a polypeptide as represented by SEQ.ID.122 or a fragment thereof; an antibody or antibody fragment having specific binding affinity to said polypeptide; a hybridoma which produces said antibody; methods for identifying a substance that modulates the kinase activity of said polypeptide; methods for treating a disease or disorder by administering such a substance; and methods for the detection of a kinase polypeptide as represented by SEQ.ID.122.

2. Claims: Inventions 2-78: Claims 1-20,  
23-38 (all partially and as far as applicable)

A nucleic acid molecule encoding a kinase with a polypeptide sequence selected from SEQ.IDs.123-199, wherein invention 2 is limited to SEQ.ID. 123, invention 3 is limited to SEQ.ID. 124, ....., and invention 78 is limited to SEQ.ID.199, or a domain thereof; a vector and a recombinant cell comprising said nucleic acid molecule; a nucleic acid probe for the detection of said nucleic acid molecule; a polypeptide as represented by a polypeptide sequence selected from SEQ.IDs.123-199 or a fragment thereof; an antibody or antibody fragment having specific binding affinity to said polypeptide; a hybridoma which produces said antibody; methods for identifying a substance that modulates the kinase activity of said polypeptide; methods for treating a disease or disorder by administering such a substance; and methods for the detection of a kinase polypeptide represented by a polypeptide sequence selected from SEQ.IDs.123-199.

3. Claims: Invention 79: Claim 21 (completely) and Claims 1-14,26-38 (all partially)

A nucleic acid molecule encoding a kinase polypeptide as represented by SEQ.ID.200 or a domain thereof; a vector and a recombinant cell comprising said nucleic acid molecule; a nucleic acid probe for the detection of said nucleic acid molecule; a polypeptide as represented by SEQ.ID.200 or a fragment thereof; an antibody or antibody fragment having

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

specific binding affinity to said polypeptide; a hybridoma which produces said antibody; methods for identifying a substance that modulates the kinase activity of said polypeptide; methods for treating a disease or disorder by administering such a substance; and methods for the detection of a kinase polypeptide as represented by SEQ.ID.200.

4. Claims: Invention 80: Claim 22 (completely) and Claims 1-14, 26-38 (all partially)

A nucleic acid molecule encoding a kinase polypeptide as represented by SEQ.ID.201 or a domain thereof; a vector and a recombinant cell comprising said nucleic acid molecule; a nucleic acid probe for the detection of said nucleic acid molecule; a polypeptide as represented by SEQ.ID.201 or a fragment thereof; an antibody or antibody fragment having specific binding affinity to said polypeptide; a hybridoma which produces said antibody; methods for identifying a substance that modulates the kinase activity of said polypeptide; methods for treating a disease or disorder by administering such a substance; and methods for the detection of a kinase polypeptide as represented by SEQ.ID.201.

5. Claims: Inventions 81-121: Claims 1-20, 23-38 (all partially and as far as applicable)

A nucleic acid molecule encoding a kinase with a polypeptide sequence selected from SEQ.IDs.202-242, wherein invention 81 is limited to SEQ.ID. 202, invention 82 is limited to SEQ.ID. 203, ....., and invention 121 is limited to SEQ.ID.242, or a domain thereof; a vector and a recombinant cell comprising said nucleic acid molecule; a nucleic acid probe for the detection of said nucleic acid molecule; a polypeptide as represented by a polypeptide sequence selected from SEQ.IDs.202-242 or a fragment thereof; an antibody or antibody fragment having specific binding affinity to said polypeptide; a hybridoma which produces said antibody; methods for identifying a substance that modulates the kinase activity of said polypeptide; methods for treating a disease or disorder by administering such a substance; and methods for the detection of a kinase polypeptide represented by a polypeptide sequence selected from SEQ.IDs.202-242.

6. Claims: Inventions 122-136: Claims 15-20, 23-25 (all partially) and claims 1-14, 26-38 (if applicable)

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A nucleic acid molecule encoding a kinase polypeptide as represented by a 'gene name' selected from 'AA980090', 'AA045601', 'AA297313', 'N23936', '5R72-18-1', '5R79-54-1', '5R65-16-1', 'AA065538', 'H17727', 'W08549', 'AA430250', 'AA139478', 'R87679', 'W65887', 'AA948538', '5R69-23-3', and '5R69-26-2', wherein invention 122 is limited to 'AA980090', invention 123 is limited to 'AA045601', ..... and invention 136 is limited to '5R69-26-2', or a domain thereof; a vector and a recombinant cell comprising said nucleic acid molecule; a nucleic acid probe for the detection of said nucleic acid molecule; a polypeptide encoded by said nucleic acid molecule or a fragment thereof; an antibody or antibody fragment having specific binding affinity to said polypeptide; a hybridoma which produces said antibody; methods for identifying a substance that modulates the kinase activity of said polypeptide; methods for treating a disease or disorder by administering such a substance; and methods for the detection of a said polypeptide.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 31-34

The search was based on the sequence listing furnished in computer readable form, the numbering of which differs from the numbering in the figures.

Claims 31-34 refer to a 'substance that modulates the activity of a kinase' without giving a true technical characterization. Moreover, no such specific compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/14842

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0058473 A	05-10-2000	AU 3774500 A	16-10-2000
WO 0006728 A	10-02-2000	AU 5134999 A EP 1100904 A	21-02-2000 23-05-2001
WO 9858052 A	23-12-1998	US 5885803 A AU 8154798 A EP 1007692 A US 6207148 B	23-03-1999 04-01-1999 14-06-2000 27-03-2001
WO 0055332 A	21-09-2000	AU 3899600 A AU 5034200 A WO 0071679 A	04-10-2000 12-12-2000 30-11-2000
WO 9733909 A	18-09-1997	AU 728186 B AU 2329597 A BR 9708082 A CA 2249742 A EP 0914335 A NO 984229 A US 6034218 A	04-01-2001 01-10-1997 27-07-1999 18-09-1997 12-05-1999 13-11-1998 07-03-2000
WO 9957144 A	11-11-1999	AU 3885999 A EP 1075518 A	23-11-1999 14-02-2001
WO 9811234 A	19-03-1998	US 5773699 A US 5863780 A AU 4261197 A EP 0927257 A US 6045792 A US 6232077 B	30-06-1998 26-01-1999 02-04-1998 07-07-1999 04-04-2000 15-05-2001
EP 0861896 A	02-09-1998	DE 19708173 A CA 2224404 A JP 10248566 A	03-09-1998 28-08-1998 22-09-1998
WO 0035946 A	22-06-2000	NONE	
WO 9831802 A	23-07-1998	AU 6031398 A EP 0972026 A	07-08-1998 19-01-2000
WO 9950395 A	07-10-1999	NONE	
WO 9933961 A	08-07-1999	AU 1691499 A	19-07-1999
WO 9801756 A	15-01-1998	US 5863729 A AU 3651597 A	26-01-1999 02-02-1998
WO 9949062 A	30-09-1999	AU 3208999 A EP 1073756 A	18-10-1999 07-02-2001
WO 9835015 A	13-08-1998	EP 0972011 A US 5968800 A US 6030788 A	19-01-2000 19-10-1999 29-02-2000
WO 9938981 A	05-08-1999	US 5962232 A AU 2113899 A EP 1051497 A	05-10-1999 16-08-1999 15-11-2000

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/14842

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9836054 A	20-08-1998	AU 5973498 A	08-09-1998
WO 9958558 A	18-11-1999	AU 4077099 A EP 1078057 A	29-11-1999 28-02-2001
US 6013455 A	11-01-2000	AU 1315900 A WO 0022143 A	01-05-2000 20-04-2000
EP 0870825 A	14-10-1998	US 5965420 A CA 2231046 A JP 11000179 A US 6165766 A	12-10-1999 05-09-1998 06-01-1999 26-12-2000
WO 9405794 A	17-03-1994	EP 0658204 A US 5690930 A	21-06-1995 25-11-1997
WO 0009678 A	24-02-2000	AU 5491599 A	06-03-2000
WO 0014212 A	16-03-2000	US 6183962 B AU 5817799 A US 6043040 A US 6146841 A US 6180358 B US 6153417 A US 6146832 A US 6190874 B US 6121030 A US 6200770 B US 6214597 B	06-02-2001 27-03-2000 28-03-2000 14-11-2000 30-01-2001 28-11-2000 14-11-2000 20-02-2001 19-09-2000 13-03-2001 10-04-2001
WO 9904265 A	28-01-1999	US 6218521 B US 6043084 A AU 8571598 A EP 0996857 A	17-04-2001 28-03-2000 10-02-1999 03-05-2000
WO 0022143 A	20-04-2000	US 6013455 A AU 1315900 A	11-01-2000 01-05-2000
WO 9932609 A	01-07-1999	AU 1991799 A AU 1991899 A EP 1037920 A WO 9932517 A	12-07-1999 12-07-1999 27-09-2000 01-07-1999
EP 1033401 A	06-09-2000	NONE	
WO 9747750 A	18-12-1997	AU 718792 B AU 3284297 A EP 0914451 A JP 2000512147 T NO 985742 A	20-04-2000 07-01-1998 12-05-1999 19-09-2000 10-02-1999
WO 9964589 A	16-12-1999	AU 4278299 A EP 1084245 A	30-12-1999 21-03-2001